[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fq9GuvbgCJoMhHgpNi1xb_3Js9kjoZvUF1UCu1Wq1oao":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":87,"rows":94},"University of Virginia",[4],657,false,138,34,280135,92,424,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Type 1 Diabetes Mellitus",27,{"name":18,"count":19},"Polycystic Ovary Syndrome",23,{"name":21,"count":22},"Diabetes Mellitus, Type 1",22,{"name":24,"count":25},"Type 1 Diabetes",15,{"name":27,"count":28},"Obesity",14,{"name":30,"count":31},"Breast Cancer",12,{"name":33,"count":34},"Hyperandrogenism",10,{"name":36,"count":37},"Hyperandrogenemia",9,[39,44,49,54,59,64,68,72,77,82],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03331302","Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy","2020-06-30","Hyperpolarized Xenon-129 MRI",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04662658","Hyperpolarized Xenon-129 MR Imaging of the Lung","2022-12","Hyperpolarized Xenon -129 MRI",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03161223","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma","2023-02","Durvalumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT03962465","Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed\u002FRefractory B-cell ALL","2023-07-15","Inotuzumab ozogamicin",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT03002389","Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics","2023-12-31","Anoro Ellipta",{"nctId":65,"briefTitle":66,"date":62,"intervention":67},"NCT03697395","Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant","Lung transplant recipient with MRI imaging",{"nctId":69,"briefTitle":70,"date":62,"intervention":71},"NCT05514847","Low Dose Aspirin for Preterm Preeclampsia Preventionmg\u002Fday Dose in High-risk Patients","Aspirin 81Mg Ec Tab",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT03272334","Her2-BATS and Pembrolizumab in Metastatic Breast Cancer","2024-11-30","HER2 BATs with Pembrolizumab",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06161675","Feasibility of Delivering VergeRx at FQHCs","2025-01-31","Nicotine Replacement Therapy Patch",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06428682","Role of TXA in Patients Undergoing Breast Free Flap Reconstruction","2025-05-13","Tranexamic acid",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,152,191,231,256,283,305,331,356,374,403,421,446,464,482,506,568,606,632,658,685,703,721,772,794,825,884,915,938,956,983,1001,1019,1044,1062,1080,1102,1126,1146,1176,1204,1227,1253,1277,1302,1320,1338,1356,1377,1395,1413,1431,1449,1476,1494,1521,1539,1557,1577,1602,1627,1651,1677,1705,1723,1741,1759,1777,1795,1813,1838,1862,1887,1913,1936,1954,2005,2064,2092,2116,2138,2161,2179,2201,2219,2242,2266,2300,2318,2336,2354,2375,2393,2422,2448,2466,2492,2510,2534,2559,2577,2602,2629,2647,2674,2692,2717,2742,2766,2784,2808,2833,2868,2902,2938,2963,2981,3006,3033,3051,3069,3087,3105,3132,3150,3168,3196,3214,3238,3263,3287,3311,3334,3352,3370,3388,3450,3476,3507,3543,3573,3595,3613,3652,3676,3701,3719,3737,3755,3773,3791,3815,3841,3859,3877,3904,3928,3946,3970,3988,4013,4036,4060,4083,4101,4123,4141,4164,4188,4206,4224,4242,4267,4291,4314,4342,4360,4378,4396,4422,4447,4465,4489,4515,4533,4561,4584,4607,4641,4675,4697,4723,4741,4759,4777,4795,4813,4838,4862,4885,4912,4938,4956,4980,5005,5023,5041,5065,5091,5109,5132,5157,5180,5204,5222,5245,5263,5295,5317,5338,5364,5382,5400,5418,5436,5459,5483,5506,5529,5552,5574,5592,5610,5628,5652,5718,5748,5794,5840,5878,5921,5947,5986,6017,6057,6089,6123,6154,6184,6208,6234,6257,6275,6298,6323,6341,6359,6383,6401,6423,6449,6467,6485,6514,6532,6553,6571,6594,6619,6641,6663,6687,6713,6731,6749,6767,6789,6807,6830,6855,6877,6898,6921,6944,6962,6988,7006,7029,7052,7076,7094,7112,7136,7161,7179,7206,7224,7242,7266,7284,7308],{"intervention":96,"totalTrials":97,"cells":98},"Insulin",3,{"EARLY_PHASE1":99,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":150},{"trials":100,"activeCount":109},[101,115],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT04133922","Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes","WITHDRAWN",[88],"2023-10","2024-10","2019-10-14",0,[24,111],"Insulin Sensitivity\u002FResistance",[113,96,114],"GLP-1","Dextrose 20 % in Water",{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"completion":120,"start":121,"enrollment":25,"conditions":122,"interventions":125},"NCT03520569","Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults","COMPLETED",[88],"2021-04-01","2019-02-04",[123,124],"Vascular Stiffness","Insulin Sensitivity",[126,96,127],"Octreotide","Dextrose 20% solution",{"trials":129,"activeCount":109},[],{"trials":131,"activeCount":109},[],{"trials":133,"activeCount":109},[],{"trials":135,"activeCount":149,"soonestReadout":141},[136],{"nctId":137,"briefTitle":138,"status":139,"phases":140,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":147},"NCT06781775","GDM: Insulin with or Without Metformin?","RECRUITING",[92],"2026-05-01","2027-05-01","2024-12-12",130,[146],"Gestational Diabetes",[148,96],"Metformin + Insulin",1,{"trials":151,"activeCount":109},[],{"intervention":153,"totalTrials":154,"cells":155},"Liraglutide",2,{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":189},{"trials":157,"activeCount":109},[],{"trials":159,"activeCount":109},[],{"trials":161,"activeCount":109},[],{"trials":163,"activeCount":109},[],{"trials":165,"activeCount":149,"soonestReadout":182},[166,178],{"nctId":167,"briefTitle":168,"status":169,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":177},"NCT03883412","Effect of Exercise and\u002For Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)","UNKNOWN",[92],"2025-06","2025-12","2019-02-28",60,[176],"Type2 Diabetes",[153],{"nctId":179,"briefTitle":180,"status":139,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT04575844","Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome",[92],"2027-04-30","2020-11-01",80,[186],"Metabolic Syndrome",[153,188],"Liraglutide + Exercise training",{"trials":190,"activeCount":109},[],{"intervention":192,"totalTrials":154,"cells":193},"Bupivacaine",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":213,"NA":229},{"trials":195,"activeCount":109},[],{"trials":197,"activeCount":109},[],{"trials":199,"activeCount":109},[],{"trials":201,"activeCount":109},[202],{"nctId":203,"briefTitle":204,"status":118,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":184,"conditions":209,"interventions":211},"NCT04974385","Liposomal Bupivacaine Versus Non-liposomal Bupivacaine for Total Shoulder Arthroplasty",[91],"2022-04-30","2022-05-04","2021-08-04",[210],"Analgesia",[212,192],"Liposomal bupivacaine",{"trials":214,"activeCount":149,"soonestReadout":220},[215],{"nctId":216,"briefTitle":217,"status":218,"phases":219,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":228},"NCT07146685","Effect of Local Anesthetic Concentration on Rebound Pain: A Randomized Control Study","NOT_YET_RECRUITING",[92],"2028-01-01","2029-01-01","2026-01-01",168,[225,226,227],"Rebound Pain","Shoulder Arthroplasty","Interscalene Block",[192],{"trials":230,"activeCount":109},[],{"intervention":232,"totalTrials":149,"cells":233},"Dupilumab Injectable Product",{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":254},{"trials":235,"activeCount":109},[],{"trials":237,"activeCount":109},[],{"trials":239,"activeCount":109},[],{"trials":241,"activeCount":109},[],{"trials":243,"activeCount":149,"soonestReadout":248},[244],{"nctId":245,"briefTitle":246,"status":139,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":174,"conditions":251,"interventions":253},"NCT04380038","Viral Infection in Asthma (VIA) Study",[92],"2026-06-30","2026-12-31","2022-05-01",[252],"Asthma",[232],{"trials":255,"activeCount":109},[],{"intervention":257,"totalTrials":149,"cells":258},"GLP-1RA",{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":265,"PHASE4":267,"NA":281},{"trials":260,"activeCount":109},[],{"trials":262,"activeCount":109},[],{"trials":264,"activeCount":109},[],{"trials":266,"activeCount":109},[],{"trials":268,"activeCount":149,"soonestReadout":273},[269],{"nctId":270,"briefTitle":271,"status":139,"phases":272,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":280},"NCT07178145","Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction",[92],"2029-09","2029-12","2025-11-20",192,[278,279],"Heart Failure Preserved Ejection Fraction","Epicardial Adipose Tissue",[257],{"trials":282,"activeCount":109},[],{"intervention":86,"totalTrials":149,"cells":284},{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":293,"NA":303},{"trials":286,"activeCount":109},[],{"trials":288,"activeCount":109},[],{"trials":290,"activeCount":109},[],{"trials":292,"activeCount":109},[],{"trials":294,"activeCount":149,"soonestReadout":85},[295],{"nctId":83,"briefTitle":84,"status":139,"phases":296,"primaryCompletion":85,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},[92],"2026-05-13","2024-05-13",100,[30,301],"Blood Loss, Surgical",[86],{"trials":304,"activeCount":109},[],{"intervention":306,"totalTrials":149,"cells":307},"Nitro-Bid 2 % Topical Ointment",{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":314,"PHASE4":316,"NA":329},{"trials":309,"activeCount":109},[],{"trials":311,"activeCount":109},[],{"trials":313,"activeCount":109},[],{"trials":315,"activeCount":109},[],{"trials":317,"activeCount":149,"soonestReadout":322},[318],{"nctId":319,"briefTitle":320,"status":139,"phases":321,"primaryCompletion":322,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":328},"NCT06428669","Effect of Nitropaste in Chest Masculinizing Surgery",[92],"2025-08","2025-11","2022-08-15",256,[327],"Gender Dysphoria",[306],{"trials":330,"activeCount":109},[],{"intervention":71,"totalTrials":149,"cells":332},{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":339,"PHASE4":341,"NA":354},{"trials":334,"activeCount":109},[],{"trials":336,"activeCount":109},[],{"trials":338,"activeCount":109},[],{"trials":340,"activeCount":109},[],{"trials":342,"activeCount":149,"soonestReadout":62},[343],{"nctId":69,"briefTitle":70,"status":344,"phases":345,"primaryCompletion":62,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":352},"ACTIVE_NOT_RECRUITING",[92],"2025-12-31","2022-10-01",150,[350,351],"Preeclampsia","Pregnancy Related",[71,353],"Aspirin 162Mg Ec Tab",{"trials":355,"activeCount":109},[],{"intervention":353,"totalTrials":149,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":372},{"trials":359,"activeCount":109},[],{"trials":361,"activeCount":109},[],{"trials":363,"activeCount":109},[],{"trials":365,"activeCount":109},[],{"trials":367,"activeCount":149,"soonestReadout":62},[368],{"nctId":69,"briefTitle":70,"status":344,"phases":369,"primaryCompletion":62,"completion":346,"start":347,"enrollment":348,"conditions":370,"interventions":371},[92],[350,351],[71,353],{"trials":373,"activeCount":109},[],{"intervention":375,"totalTrials":149,"cells":376},"Colchicine 0.6 mg",{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":401},{"trials":378,"activeCount":109},[],{"trials":380,"activeCount":109},[],{"trials":382,"activeCount":109},[],{"trials":384,"activeCount":109},[],{"trials":386,"activeCount":149,"soonestReadout":391},[387],{"nctId":388,"briefTitle":389,"status":139,"phases":390,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":399},"NCT06286423","Colchicine in Acutely Decompensated HFREF",[92],"2026-06","2028-06","2024-06",30,[396,397,398],"Heart Failure","Decompensated Heart Failure","Heart Failure With Reduced Ejection Fraction",[375,400],"Control\u002FPlacebo group",{"trials":402,"activeCount":109},[],{"intervention":400,"totalTrials":149,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":413,"NA":419},{"trials":406,"activeCount":109},[],{"trials":408,"activeCount":109},[],{"trials":410,"activeCount":109},[],{"trials":412,"activeCount":109},[],{"trials":414,"activeCount":149,"soonestReadout":391},[415],{"nctId":388,"briefTitle":389,"status":139,"phases":416,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":417,"interventions":418},[92],[396,397,398],[375,400],{"trials":420,"activeCount":109},[],{"intervention":422,"totalTrials":149,"cells":423},"Dupilumab Prefilled Syringe",{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":444},{"trials":425,"activeCount":109},[],{"trials":427,"activeCount":109},[],{"trials":429,"activeCount":109},[],{"trials":431,"activeCount":109},[],{"trials":433,"activeCount":149,"soonestReadout":248},[434],{"nctId":435,"briefTitle":436,"status":139,"phases":437,"primaryCompletion":248,"completion":249,"start":438,"enrollment":439,"conditions":440,"interventions":443},"NCT05094570","Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP",[92],"2022-09-01",20,[441,442],"Nasal Polyps","Staphylococcus Aureus",[422],{"trials":445,"activeCount":109},[],{"intervention":148,"totalTrials":149,"cells":447},{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":454,"PHASE4":456,"NA":462},{"trials":449,"activeCount":109},[],{"trials":451,"activeCount":109},[],{"trials":453,"activeCount":109},[],{"trials":455,"activeCount":109},[],{"trials":457,"activeCount":149,"soonestReadout":141},[458],{"nctId":137,"briefTitle":138,"status":139,"phases":459,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":460,"interventions":461},[92],[146],[148,96],{"trials":463,"activeCount":109},[],{"intervention":188,"totalTrials":149,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":480},{"trials":467,"activeCount":109},[],{"trials":469,"activeCount":109},[],{"trials":471,"activeCount":109},[],{"trials":473,"activeCount":109},[],{"trials":475,"activeCount":149,"soonestReadout":182},[476],{"nctId":179,"briefTitle":180,"status":139,"phases":477,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":478,"interventions":479},[92],[186],[153,188],{"trials":481,"activeCount":109},[],{"intervention":483,"totalTrials":149,"cells":484},"Metformin Hydrochloride",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":504},{"trials":486,"activeCount":109},[],{"trials":488,"activeCount":109},[],{"trials":490,"activeCount":109},[],{"trials":492,"activeCount":109},[],{"trials":494,"activeCount":149,"soonestReadout":499},[495],{"nctId":496,"briefTitle":497,"status":344,"phases":498,"primaryCompletion":499,"completion":499,"start":80,"enrollment":28,"conditions":500,"interventions":503},"NCT06638671","Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity",[92],"2026-07-01",[501,502],"Exercise Capacity","Metformin",[483],{"trials":505,"activeCount":109},[],{"intervention":507,"totalTrials":508,"cells":509},"Capecitabine",4,{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":537,"PHASE3":549,"PHASE4":564,"NA":566},{"trials":511,"activeCount":109},[],{"trials":513,"activeCount":109},[514,525],{"nctId":515,"briefTitle":516,"status":118,"phases":517,"start":518,"enrollment":519,"conditions":520,"interventions":522},"NCT00114153","Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer",[89],"2003-06",48,[521],"Head and Neck Cancer",[523,524],"capecitabine","carboplatin",{"nctId":526,"briefTitle":527,"status":118,"phases":528,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT03473639","A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy",[89],"2021-09-02","2022-11-01","2019-01-29",13,[534,30],"Metastatic Breast Cancer",[536,507],"Entinostat",{"trials":538,"activeCount":109},[539],{"nctId":540,"briefTitle":541,"status":169,"phases":542,"primaryCompletion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT01333332","Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer",[90],"2012-08","2010-08",35,[547],"Pancreatic Cancer",[507],{"trials":550,"activeCount":149,"soonestReadout":555},[551],{"nctId":552,"briefTitle":553,"status":139,"phases":554,"primaryCompletion":555,"completion":274,"start":556,"enrollment":557,"conditions":558,"interventions":562},"NCT05288777","Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer",[90,91],"2028-12","2022-07-11",45,[30,559,560,561],"Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III",[563,507],"T-DM1",{"trials":565,"activeCount":109},[],{"trials":567,"activeCount":109},[],{"intervention":569,"totalTrials":154,"cells":570},"Levetiracetam",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":602,"NA":604},{"trials":572,"activeCount":109},[],{"trials":574,"activeCount":109},[],{"trials":576,"activeCount":109},[],{"trials":578,"activeCount":149,"soonestReadout":596},[579,592],{"nctId":580,"briefTitle":581,"status":118,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":589},"NCT01960075","Established Status Epilepticus Treatment Trial",[91],"2019-02","2019-05","2015-10",478,[588],"Benzodiazepine Refractory Status Epilepticus",[590,569,591],"Fosphenytoin","Valproic acid",{"nctId":593,"briefTitle":594,"status":139,"phases":595,"primaryCompletion":596,"completion":274,"start":597,"enrollment":598,"conditions":599,"interventions":601},"NCT06907173","Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)",[91],"2029-06","2026-03-06",770,[600],"Status Epilepticus",[569,569,569],{"trials":603,"activeCount":109},[],{"trials":605,"activeCount":109},[],{"intervention":607,"totalTrials":149,"cells":608},"Tirzepatide",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":628,"NA":630},{"trials":610,"activeCount":109},[],{"trials":612,"activeCount":109},[],{"trials":614,"activeCount":109},[],{"trials":616,"activeCount":149,"soonestReadout":621},[617],{"nctId":618,"briefTitle":619,"status":218,"phases":620,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":627},"NCT07298915","The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)",[91],"2026-12","2027-06","2026-08",24,[626],"Obesity & Overweight",[607],{"trials":629,"activeCount":109},[],{"trials":631,"activeCount":109},[],{"intervention":633,"totalTrials":149,"cells":634},"Tamoxifen, Letrozole, Anastrozole, or Exemestane",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":654,"NA":656},{"trials":636,"activeCount":109},[],{"trials":638,"activeCount":109},[],{"trials":640,"activeCount":109},[],{"trials":642,"activeCount":149,"soonestReadout":647},[643],{"nctId":644,"briefTitle":645,"status":139,"phases":646,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":651,"interventions":653},"NCT06507618","Pre-Operative Window of ET to Inform RT Decisions (POWER II)",[91],"2029-06-30","2034-03-01","2024-07-19",354,[652],"Breast Cancer Female",[633],{"trials":655,"activeCount":109},[],{"trials":657,"activeCount":109},[],{"intervention":659,"totalTrials":149,"cells":660},"Hydrocortisone administration",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":681,"NA":683},{"trials":662,"activeCount":109},[],{"trials":664,"activeCount":109},[],{"trials":666,"activeCount":109},[],{"trials":668,"activeCount":149,"soonestReadout":673},[669],{"nctId":670,"briefTitle":671,"status":218,"phases":672,"primaryCompletion":673,"completion":273,"start":674,"enrollment":675,"conditions":676,"interventions":679},"NCT07332325","STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis",[91],"2029-03","2026-10",344,[677,678],"Sepsis","Tuberculosis",[659,680],"Expanded antimicrobial therapy",{"trials":682,"activeCount":109},[],{"trials":684,"activeCount":109},[],{"intervention":680,"totalTrials":149,"cells":686},{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":699,"NA":701},{"trials":688,"activeCount":109},[],{"trials":690,"activeCount":109},[],{"trials":692,"activeCount":109},[],{"trials":694,"activeCount":149,"soonestReadout":673},[695],{"nctId":670,"briefTitle":671,"status":218,"phases":696,"primaryCompletion":673,"completion":273,"start":674,"enrollment":675,"conditions":697,"interventions":698},[91],[677,678],[659,680],{"trials":700,"activeCount":109},[],{"trials":702,"activeCount":109},[],{"intervention":563,"totalTrials":149,"cells":704},{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":717,"NA":719},{"trials":706,"activeCount":109},[],{"trials":708,"activeCount":109},[],{"trials":710,"activeCount":109},[],{"trials":712,"activeCount":149,"soonestReadout":555},[713],{"nctId":552,"briefTitle":553,"status":139,"phases":714,"primaryCompletion":555,"completion":274,"start":556,"enrollment":557,"conditions":715,"interventions":716},[90,91],[30,559,560,561],[563,507],{"trials":718,"activeCount":109},[],{"trials":720,"activeCount":109},[],{"intervention":722,"totalTrials":97,"cells":723},"Pralatrexate",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":742,"PHASE3":766,"PHASE4":768,"NA":770},{"trials":725,"activeCount":109},[],{"trials":727,"activeCount":149,"soonestReadout":732},[728],{"nctId":729,"briefTitle":730,"status":344,"phases":731,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":739},"NCT03240211","Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL",[89],"2025-07-24","2026-05-25","2022-02-02",37,[737,738],"PTCL","CTCL",[740,722,741],"Pembrolizumab","Decitabine",{"trials":743,"activeCount":154,"soonestReadout":52},[744,753],{"nctId":50,"briefTitle":51,"status":139,"phases":745,"primaryCompletion":52,"completion":52,"start":746,"enrollment":747,"conditions":748,"interventions":750},[89,90],"2018-05-30",148,[749],"Lymphoma, T-Cell",[53,722,751,752],"Romidepsin","5-Azacitidine",{"nctId":754,"briefTitle":755,"status":139,"phases":756,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":761,"interventions":762},"NCT04747236","Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL",[90],"2028-06-02","2030-06-02","2021-02-19",50,[737],[763,751,764,722,765],"Azacytidine","Belinostat","Gemcitabine",{"trials":767,"activeCount":109},[],{"trials":769,"activeCount":109},[],{"trials":771,"activeCount":109},[],{"intervention":751,"totalTrials":154,"cells":773},{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":788,"PHASE4":790,"NA":792},{"trials":775,"activeCount":109},[],{"trials":777,"activeCount":109},[],{"trials":779,"activeCount":154,"soonestReadout":52},[780,784],{"nctId":50,"briefTitle":51,"status":139,"phases":781,"primaryCompletion":52,"completion":52,"start":746,"enrollment":747,"conditions":782,"interventions":783},[89,90],[749],[53,722,751,752],{"nctId":754,"briefTitle":755,"status":139,"phases":785,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":786,"interventions":787},[90],[737],[763,751,764,722,765],{"trials":789,"activeCount":109},[],{"trials":791,"activeCount":109},[],{"trials":793,"activeCount":109},[],{"intervention":740,"totalTrials":154,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":804,"PHASE3":819,"PHASE4":821,"NA":823},{"trials":797,"activeCount":109},[],{"trials":799,"activeCount":149,"soonestReadout":732},[800],{"nctId":729,"briefTitle":730,"status":344,"phases":801,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":802,"interventions":803},[89],[737,738],[740,722,741],{"trials":805,"activeCount":149,"soonestReadout":810},[806],{"nctId":807,"briefTitle":808,"status":344,"phases":809,"primaryCompletion":810,"completion":810,"start":811,"enrollment":624,"conditions":812,"interventions":814},"NCT05404945","Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above",[90],"2027-10-03","2022-07-26",[813],"Classical Hodgkin Lymphoma",[740,815,816,817,818],"Doxorubicin","Vinblastine","Dacarbazine","Brentuximab vedotin",{"trials":820,"activeCount":109},[],{"trials":822,"activeCount":109},[],{"trials":824,"activeCount":109},[],{"intervention":826,"totalTrials":508,"cells":827},"Alanyl-glutamine",{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":857,"PHASE4":880,"NA":882},{"trials":829,"activeCount":109},[],{"trials":831,"activeCount":109},[],{"trials":833,"activeCount":149,"soonestReadout":249},[834,847],{"nctId":835,"briefTitle":836,"status":139,"phases":837,"primaryCompletion":249,"completion":838,"start":839,"enrollment":840,"conditions":841,"interventions":846},"NCT04305769","Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)",[90],"2027-06-30","2021-06-01",260,[842,843,844,845],"Clostridioides Difficile Infection","Clostridium Difficile Infection","Clostridium Difficile Diarrhea","Clostridia Difficile Colitis",[826],{"nctId":848,"briefTitle":849,"status":850,"phases":851,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":855,"interventions":856},"NCT02053350","Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection","TERMINATED",[90],"2017-04-05","2015-04",7,[843],[826],{"trials":858,"activeCount":109},[859,871],{"nctId":860,"briefTitle":861,"status":104,"phases":862,"completion":863,"start":864,"enrollment":865,"conditions":866,"interventions":868},"NCT00338221","Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition",[91],"2005-04","2004-08",108,[867],"Diarrhea, Malnutrition",[869,870],"alanyl-glutamine","glycine",{"nctId":872,"briefTitle":873,"status":104,"phases":874,"completion":875,"start":864,"enrollment":865,"conditions":876,"interventions":878},"NCT00133562","HIAS II - Study of Nutritional Supplementation in Hospitalized Children With Persistent Diarrhea or Malnutrition",[91],"2006-05",[867,877],"Other Nutritional Deficiencies",[826,879],"Glycine",{"trials":881,"activeCount":109},[],{"trials":883,"activeCount":109},[],{"intervention":815,"totalTrials":154,"cells":885},{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":887,"activeCount":109},[],{"trials":889,"activeCount":109},[],{"trials":891,"activeCount":149,"soonestReadout":810},[892,905],{"nctId":893,"briefTitle":894,"status":104,"phases":895,"primaryCompletion":896,"completion":896,"start":897,"enrollment":109,"conditions":898,"interventions":900},"NCT04038489","COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer",[90],"2023-04-30","2019-10-18",[30,899],"Estrogen Receptor-positive Breast Cancer",[901,902,815,903,904],"Aspirin","Tamoxifen Pill","Cyclophosphamide","Paclitaxel",{"nctId":807,"briefTitle":808,"status":344,"phases":906,"primaryCompletion":810,"completion":810,"start":811,"enrollment":624,"conditions":907,"interventions":908},[90],[813],[740,815,816,817,818],{"trials":910,"activeCount":109},[],{"trials":912,"activeCount":109},[],{"trials":914,"activeCount":109},[],{"intervention":63,"totalTrials":149,"cells":916},{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":918,"activeCount":109},[],{"trials":920,"activeCount":109},[],{"trials":922,"activeCount":149,"soonestReadout":62},[923],{"nctId":60,"briefTitle":61,"status":344,"phases":924,"primaryCompletion":62,"completion":925,"start":926,"enrollment":927,"conditions":928,"interventions":930},[90],"2028-01-31","2017-11-05",95,[929],"Chronic Obstructive Pulmonary Disease",[63,931],"Arnuity Ellipta",{"trials":933,"activeCount":109},[],{"trials":935,"activeCount":109},[],{"trials":937,"activeCount":109},[],{"intervention":931,"totalTrials":149,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":941,"activeCount":109},[],{"trials":943,"activeCount":109},[],{"trials":945,"activeCount":149,"soonestReadout":62},[946],{"nctId":60,"briefTitle":61,"status":344,"phases":947,"primaryCompletion":62,"completion":925,"start":926,"enrollment":927,"conditions":948,"interventions":949},[90],[929],[63,931],{"trials":951,"activeCount":109},[],{"trials":953,"activeCount":109},[],{"trials":955,"activeCount":109},[],{"intervention":957,"totalTrials":149,"cells":958},"Trimethoprim-sulfamethoxazole",{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":960,"activeCount":109},[],{"trials":962,"activeCount":109},[],{"trials":964,"activeCount":149,"soonestReadout":969},[965],{"nctId":966,"briefTitle":967,"status":139,"phases":968,"primaryCompletion":969,"completion":970,"start":971,"enrollment":174,"conditions":972,"interventions":974},"NCT07451171","Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children",[90],"2026-08-02","2026-09-01","2026-04-18",[973],"Small Intestine Bacterial Overgrowth",[957,975,976],"Metronidazole","Amoxicillin-Clavulanate",{"trials":978,"activeCount":109},[],{"trials":980,"activeCount":109},[],{"trials":982,"activeCount":109},[],{"intervention":975,"totalTrials":149,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":986,"activeCount":109},[],{"trials":988,"activeCount":109},[],{"trials":990,"activeCount":149,"soonestReadout":969},[991],{"nctId":966,"briefTitle":967,"status":139,"phases":992,"primaryCompletion":969,"completion":970,"start":971,"enrollment":174,"conditions":993,"interventions":994},[90],[973],[957,975,976],{"trials":996,"activeCount":109},[],{"trials":998,"activeCount":109},[],{"trials":1000,"activeCount":109},[],{"intervention":976,"totalTrials":149,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1013,"PHASE4":1015,"NA":1017},{"trials":1004,"activeCount":109},[],{"trials":1006,"activeCount":109},[],{"trials":1008,"activeCount":149,"soonestReadout":969},[1009],{"nctId":966,"briefTitle":967,"status":139,"phases":1010,"primaryCompletion":969,"completion":970,"start":971,"enrollment":174,"conditions":1011,"interventions":1012},[90],[973],[957,975,976],{"trials":1014,"activeCount":109},[],{"trials":1016,"activeCount":109},[],{"trials":1018,"activeCount":109},[],{"intervention":1020,"totalTrials":149,"cells":1021},"EGFR BATs after standard of care chemo",{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1038,"PHASE4":1040,"NA":1042},{"trials":1023,"activeCount":109},[],{"trials":1025,"activeCount":109},[],{"trials":1027,"activeCount":149,"soonestReadout":171},[1028],{"nctId":1029,"briefTitle":1030,"status":344,"phases":1031,"primaryCompletion":171,"completion":1032,"start":1033,"enrollment":22,"conditions":1034,"interventions":1037},"NCT03269526","BATs Treatment for Pancreatic Cancer, Phase Ib\u002FII",[89,90],"2025-06-01","2017-07-28",[1035,1036],"Locally Advanced Pancreatic Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma",[1020],{"trials":1039,"activeCount":109},[],{"trials":1041,"activeCount":109},[],{"trials":1043,"activeCount":109},[],{"intervention":53,"totalTrials":149,"cells":1045},{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1047,"activeCount":109},[],{"trials":1049,"activeCount":109},[],{"trials":1051,"activeCount":149,"soonestReadout":52},[1052],{"nctId":50,"briefTitle":51,"status":139,"phases":1053,"primaryCompletion":52,"completion":52,"start":746,"enrollment":747,"conditions":1054,"interventions":1055},[89,90],[749],[53,722,751,752],{"trials":1057,"activeCount":109},[],{"trials":1059,"activeCount":109},[],{"trials":1061,"activeCount":109},[],{"intervention":752,"totalTrials":149,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1074,"PHASE4":1076,"NA":1078},{"trials":1065,"activeCount":109},[],{"trials":1067,"activeCount":109},[],{"trials":1069,"activeCount":149,"soonestReadout":52},[1070],{"nctId":50,"briefTitle":51,"status":139,"phases":1071,"primaryCompletion":52,"completion":52,"start":746,"enrollment":747,"conditions":1072,"interventions":1073},[89,90],[749],[53,722,751,752],{"trials":1075,"activeCount":109},[],{"trials":1077,"activeCount":109},[],{"trials":1079,"activeCount":109},[],{"intervention":67,"totalTrials":149,"cells":1081},{"EARLY_PHASE1":1082,"PHASE1":1084,"PHASE2":1086,"PHASE3":1096,"PHASE4":1098,"NA":1100},{"trials":1083,"activeCount":109},[],{"trials":1085,"activeCount":109},[],{"trials":1087,"activeCount":149,"soonestReadout":62},[1088],{"nctId":65,"briefTitle":66,"status":344,"phases":1089,"primaryCompletion":62,"completion":1090,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1095},[90],"2038-12-31","2019-04-01",1200,[1094],"Chronic Rejection of Lung Transplant",[67],{"trials":1097,"activeCount":109},[],{"trials":1099,"activeCount":109},[],{"trials":1101,"activeCount":109},[],{"intervention":1103,"totalTrials":149,"cells":1104},"Memantine Hydrochloride",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1106,"activeCount":109},[],{"trials":1108,"activeCount":109},[],{"trials":1110,"activeCount":149,"soonestReadout":621},[1111],{"nctId":1112,"briefTitle":1113,"status":344,"phases":1114,"primaryCompletion":621,"completion":621,"start":1115,"enrollment":1116,"conditions":1117,"interventions":1119},"NCT05063851","The Use of Memantine for Prevention of Alzheimer's Disease",[90],"2021-10-11",32,[1118],"Alzheimer Disease",[1103],{"trials":1121,"activeCount":109},[],{"trials":1123,"activeCount":109},[],{"trials":1125,"activeCount":109},[],{"intervention":76,"totalTrials":149,"cells":1127},{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1140,"PHASE4":1142,"NA":1144},{"trials":1129,"activeCount":109},[],{"trials":1131,"activeCount":109},[],{"trials":1133,"activeCount":149,"soonestReadout":75},[1134],{"nctId":73,"briefTitle":74,"status":344,"phases":1135,"primaryCompletion":75,"completion":1136,"start":1137,"enrollment":22,"conditions":1138,"interventions":1139},[89,90],"2031-01","2017-12-29",[534],[76],{"trials":1141,"activeCount":109},[],{"trials":1143,"activeCount":109},[],{"trials":1145,"activeCount":109},[],{"intervention":1147,"totalTrials":149,"cells":1148},"GLP-1 receptor agonist",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1170,"PHASE4":1172,"NA":1174},{"trials":1150,"activeCount":109},[],{"trials":1152,"activeCount":109},[],{"trials":1154,"activeCount":149,"soonestReadout":1159},[1155],{"nctId":1156,"briefTitle":1157,"status":139,"phases":1158,"primaryCompletion":1159,"completion":1160,"start":1161,"enrollment":1162,"conditions":1163,"interventions":1169},"NCT06903923","Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy",[90],"2030-02-28","2030-04-30","2025-07-31",120,[1164,1165,1166,1167,1168,27],"Obesity in Children","Bone Strength","GLP - 1","Lifestyle Modification","Bone Density",[1147],{"trials":1171,"activeCount":109},[],{"trials":1173,"activeCount":109},[],{"trials":1175,"activeCount":109},[],{"intervention":1177,"totalTrials":149,"cells":1178},"CIR-0602K",{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1180,"activeCount":109},[],{"trials":1182,"activeCount":109},[],{"trials":1184,"activeCount":149,"soonestReadout":1189},[1185],{"nctId":1186,"briefTitle":1187,"status":139,"phases":1188,"primaryCompletion":1189,"completion":1189,"start":1190,"enrollment":1191,"conditions":1192,"interventions":1197},"NCT07186660","Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes",[90],"2028-09","2026-02-22",40,[1193,1194,96,1195,1196],"Type 1 Diabetes (T1D)","Glycemic Control for Diabetes Mellitus","Ketones","Cardiovascular Health",[1177],{"trials":1199,"activeCount":109},[],{"trials":1201,"activeCount":109},[],{"trials":1203,"activeCount":109},[],{"intervention":1205,"totalTrials":149,"cells":1206},"magnesium and riboflavin supplement",{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1208,"activeCount":109},[],{"trials":1210,"activeCount":109},[],{"trials":1212,"activeCount":149,"soonestReadout":346},[1213],{"nctId":1214,"briefTitle":1215,"status":139,"phases":1216,"primaryCompletion":346,"completion":346,"start":1217,"enrollment":865,"conditions":1218,"interventions":1220},"NCT06260072","Magnesium and Riboflavin Treatment for Post-Concussion Headache",[90],"2020-02-10",[1219],"Concussion, Intermediate",[1205],{"trials":1222,"activeCount":109},[],{"trials":1224,"activeCount":109},[],{"trials":1226,"activeCount":109},[],{"intervention":1228,"totalTrials":149,"cells":1229},"Cardioprotection",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1231,"activeCount":109},[],{"trials":1233,"activeCount":109},[],{"trials":1235,"activeCount":149,"soonestReadout":1240},[1236],{"nctId":1237,"briefTitle":1238,"status":139,"phases":1239,"primaryCompletion":1240,"completion":1189,"start":1241,"enrollment":1242,"conditions":1243,"interventions":1246},"NCT04977180","Cardioprotection in AML",[90],"2028-03","2022-03-04",70,[1244,1245],"AML","Acute Myeloid Leukemia",[1228],{"trials":1248,"activeCount":109},[],{"trials":1250,"activeCount":109},[],{"trials":1252,"activeCount":109},[],{"intervention":1254,"totalTrials":149,"cells":1255},"HER2 FPBMC",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1271,"PHASE4":1273,"NA":1275},{"trials":1257,"activeCount":109},[],{"trials":1259,"activeCount":109},[],{"trials":1261,"activeCount":149,"soonestReadout":596},[1262],{"nctId":1263,"briefTitle":1264,"status":218,"phases":1265,"primaryCompletion":596,"completion":1266,"start":1267,"enrollment":19,"conditions":1268,"interventions":1270},"NCT07441889","HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)",[89,90],"2032-06","2026-04",[30,1269],"Prostate Cancer",[1254],{"trials":1272,"activeCount":109},[],{"trials":1274,"activeCount":109},[],{"trials":1276,"activeCount":109},[],{"intervention":1278,"totalTrials":149,"cells":1279},"Cannabidiol",{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1281,"activeCount":109},[],{"trials":1283,"activeCount":109},[],{"trials":1285,"activeCount":149,"soonestReadout":1290},[1286],{"nctId":1287,"briefTitle":1288,"status":218,"phases":1289,"primaryCompletion":1290,"completion":1291,"start":1292,"enrollment":439,"conditions":1293,"interventions":1295},"NCT06108349","Topical Cannabidiol for Treating Carpal Tunnel Syndrome",[90],"2026-12-01","2027-01-01","2025-07-01",[1294],"Carpal Tunnel Syndrome",[1278],{"trials":1297,"activeCount":109},[],{"trials":1299,"activeCount":109},[],{"trials":1301,"activeCount":109},[],{"intervention":816,"totalTrials":149,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1305,"activeCount":109},[],{"trials":1307,"activeCount":109},[],{"trials":1309,"activeCount":149,"soonestReadout":810},[1310],{"nctId":807,"briefTitle":808,"status":344,"phases":1311,"primaryCompletion":810,"completion":810,"start":811,"enrollment":624,"conditions":1312,"interventions":1313},[90],[813],[740,815,816,817,818],{"trials":1315,"activeCount":109},[],{"trials":1317,"activeCount":109},[],{"trials":1319,"activeCount":109},[],{"intervention":817,"totalTrials":149,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1323,"activeCount":109},[],{"trials":1325,"activeCount":109},[],{"trials":1327,"activeCount":149,"soonestReadout":810},[1328],{"nctId":807,"briefTitle":808,"status":344,"phases":1329,"primaryCompletion":810,"completion":810,"start":811,"enrollment":624,"conditions":1330,"interventions":1331},[90],[813],[740,815,816,817,818],{"trials":1333,"activeCount":109},[],{"trials":1335,"activeCount":109},[],{"trials":1337,"activeCount":109},[],{"intervention":818,"totalTrials":149,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1350,"PHASE4":1352,"NA":1354},{"trials":1341,"activeCount":109},[],{"trials":1343,"activeCount":109},[],{"trials":1345,"activeCount":149,"soonestReadout":810},[1346],{"nctId":807,"briefTitle":808,"status":344,"phases":1347,"primaryCompletion":810,"completion":810,"start":811,"enrollment":624,"conditions":1348,"interventions":1349},[90],[813],[740,815,816,817,818],{"trials":1351,"activeCount":109},[],{"trials":1353,"activeCount":109},[],{"trials":1355,"activeCount":109},[],{"intervention":43,"totalTrials":149,"cells":1357},{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1371,"PHASE4":1373,"NA":1375},{"trials":1359,"activeCount":109},[],{"trials":1361,"activeCount":109},[],{"trials":1363,"activeCount":149,"soonestReadout":42},[1364],{"nctId":40,"briefTitle":41,"status":139,"phases":1365,"primaryCompletion":42,"completion":1366,"start":1367,"enrollment":394,"conditions":1368,"interventions":1369},[89,90],"2020-12-31","2018-09-01",[929],[43,1370],"Radioactive Xenon-133 scintigraphy",{"trials":1372,"activeCount":109},[],{"trials":1374,"activeCount":109},[],{"trials":1376,"activeCount":109},[],{"intervention":1370,"totalTrials":149,"cells":1378},{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1380,"activeCount":109},[],{"trials":1382,"activeCount":109},[],{"trials":1384,"activeCount":149,"soonestReadout":42},[1385],{"nctId":40,"briefTitle":41,"status":139,"phases":1386,"primaryCompletion":42,"completion":1366,"start":1367,"enrollment":394,"conditions":1387,"interventions":1388},[89,90],[929],[43,1370],{"trials":1390,"activeCount":109},[],{"trials":1392,"activeCount":109},[],{"trials":1394,"activeCount":109},[],{"intervention":763,"totalTrials":149,"cells":1396},{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1401,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1398,"activeCount":109},[],{"trials":1400,"activeCount":109},[],{"trials":1402,"activeCount":149,"soonestReadout":757},[1403],{"nctId":754,"briefTitle":755,"status":139,"phases":1404,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":1405,"interventions":1406},[90],[737],[763,751,764,722,765],{"trials":1408,"activeCount":109},[],{"trials":1410,"activeCount":109},[],{"trials":1412,"activeCount":109},[],{"intervention":764,"totalTrials":149,"cells":1414},{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1425,"PHASE4":1427,"NA":1429},{"trials":1416,"activeCount":109},[],{"trials":1418,"activeCount":109},[],{"trials":1420,"activeCount":149,"soonestReadout":757},[1421],{"nctId":754,"briefTitle":755,"status":139,"phases":1422,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":1423,"interventions":1424},[90],[737],[763,751,764,722,765],{"trials":1426,"activeCount":109},[],{"trials":1428,"activeCount":109},[],{"trials":1430,"activeCount":109},[],{"intervention":765,"totalTrials":149,"cells":1432},{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1443,"PHASE4":1445,"NA":1447},{"trials":1434,"activeCount":109},[],{"trials":1436,"activeCount":109},[],{"trials":1438,"activeCount":149,"soonestReadout":757},[1439],{"nctId":754,"briefTitle":755,"status":139,"phases":1440,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":1441,"interventions":1442},[90],[737],[763,751,764,722,765],{"trials":1444,"activeCount":109},[],{"trials":1446,"activeCount":109},[],{"trials":1448,"activeCount":109},[],{"intervention":1450,"totalTrials":149,"cells":1451},"Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine",{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1470,"PHASE4":1472,"NA":1474},{"trials":1453,"activeCount":109},[],{"trials":1455,"activeCount":109},[],{"trials":1457,"activeCount":149,"soonestReadout":1462},[1458],{"nctId":1459,"briefTitle":1460,"status":139,"phases":1461,"primaryCompletion":1462,"completion":1463,"start":1464,"enrollment":519,"conditions":1465,"interventions":1468},"NCT07094711","Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)",[90],"2028-09-30","2028-12-30","2026-04-27",[1466,1467],"Mycobacterium Avium-intracellulare Infection","Mycobacterium Infections, Nontuberculous",[1450,1469],"preservative-free saline",{"trials":1471,"activeCount":109},[],{"trials":1473,"activeCount":109},[],{"trials":1475,"activeCount":109},[],{"intervention":1469,"totalTrials":149,"cells":1477},{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1488,"PHASE4":1490,"NA":1492},{"trials":1479,"activeCount":109},[],{"trials":1481,"activeCount":109},[],{"trials":1483,"activeCount":149,"soonestReadout":1462},[1484],{"nctId":1459,"briefTitle":1460,"status":139,"phases":1485,"primaryCompletion":1462,"completion":1463,"start":1464,"enrollment":519,"conditions":1486,"interventions":1487},[90],[1466,1467],[1450,1469],{"trials":1489,"activeCount":109},[],{"trials":1491,"activeCount":109},[],{"trials":1493,"activeCount":109},[],{"intervention":1495,"totalTrials":149,"cells":1496},"transdermal 17β-E2 with cyclic progestin",{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1515,"PHASE4":1517,"NA":1519},{"trials":1498,"activeCount":109},[],{"trials":1500,"activeCount":109},[],{"trials":1502,"activeCount":149,"soonestReadout":1507},[1503],{"nctId":1504,"briefTitle":1505,"status":139,"phases":1506,"primaryCompletion":1507,"completion":1508,"start":1509,"enrollment":348,"conditions":1510,"interventions":1512},"NCT07010146","Role of Estrogen on Skeletal Outcomes in FHA",[90],"2029-12-31","2030-05-31","2025-10-01",[1165,1168,1511],"FHA (Functional Hypothalamic Amenorrhea)",[1495,1513,1514],"oral 17β-E2 with cyclic progestin","transdermal EE+LNG",{"trials":1516,"activeCount":109},[],{"trials":1518,"activeCount":109},[],{"trials":1520,"activeCount":109},[],{"intervention":1513,"totalTrials":149,"cells":1522},{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1533,"PHASE4":1535,"NA":1537},{"trials":1524,"activeCount":109},[],{"trials":1526,"activeCount":109},[],{"trials":1528,"activeCount":149,"soonestReadout":1507},[1529],{"nctId":1504,"briefTitle":1505,"status":139,"phases":1530,"primaryCompletion":1507,"completion":1508,"start":1509,"enrollment":348,"conditions":1531,"interventions":1532},[90],[1165,1168,1511],[1495,1513,1514],{"trials":1534,"activeCount":109},[],{"trials":1536,"activeCount":109},[],{"trials":1538,"activeCount":109},[],{"intervention":1514,"totalTrials":149,"cells":1540},{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1551,"PHASE4":1553,"NA":1555},{"trials":1542,"activeCount":109},[],{"trials":1544,"activeCount":109},[],{"trials":1546,"activeCount":149,"soonestReadout":1507},[1547],{"nctId":1504,"briefTitle":1505,"status":139,"phases":1548,"primaryCompletion":1507,"completion":1508,"start":1509,"enrollment":348,"conditions":1549,"interventions":1550},[90],[1165,1168,1511],[1495,1513,1514],{"trials":1552,"activeCount":109},[],{"trials":1554,"activeCount":109},[],{"trials":1556,"activeCount":109},[],{"intervention":48,"totalTrials":149,"cells":1558},{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1563,"PHASE3":1571,"PHASE4":1573,"NA":1575},{"trials":1560,"activeCount":109},[],{"trials":1562,"activeCount":109},[],{"trials":1564,"activeCount":149,"soonestReadout":47},[1565],{"nctId":45,"briefTitle":46,"status":139,"phases":1566,"primaryCompletion":47,"completion":172,"start":1567,"enrollment":624,"conditions":1568,"interventions":1570},[89,90],"2020-11-05",[1569],"E-Cig Use",[48],{"trials":1572,"activeCount":109},[],{"trials":1574,"activeCount":109},[],{"trials":1576,"activeCount":109},[],{"intervention":1578,"totalTrials":149,"cells":1579},"Androgen Deprivation Therapy",{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1596,"PHASE4":1598,"NA":1600},{"trials":1581,"activeCount":109},[],{"trials":1583,"activeCount":109},[],{"trials":1585,"activeCount":149,"soonestReadout":1590},[1586],{"nctId":1587,"briefTitle":1588,"status":344,"phases":1589,"primaryCompletion":1590,"completion":1591,"start":1592,"enrollment":174,"conditions":1593,"interventions":1595},"NCT04465500","EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer",[90],"2028-01-30","2029-01-30","2025-01-30",[1269,1594],"Prostate Adenocarcinoma",[1578],{"trials":1597,"activeCount":109},[],{"trials":1599,"activeCount":109},[],{"trials":1601,"activeCount":109},[],{"intervention":1603,"totalTrials":149,"cells":1604},"EGFR FPBMC",{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1606,"activeCount":109},[],{"trials":1608,"activeCount":109},[],{"trials":1610,"activeCount":149,"soonestReadout":1615},[1611],{"nctId":1612,"briefTitle":1613,"status":139,"phases":1614,"primaryCompletion":1615,"completion":1616,"start":1617,"enrollment":19,"conditions":1618,"interventions":1620},"NCT06479239","Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer",[89,90],"2027-12","2031-06","2024-11-06",[1619,547],"Pancreas Cancer",[1603],{"trials":1622,"activeCount":109},[],{"trials":1624,"activeCount":109},[],{"trials":1626,"activeCount":109},[],{"intervention":1628,"totalTrials":149,"cells":1629},"Hyperpolarized Xenon129",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1645,"PHASE4":1647,"NA":1649},{"trials":1631,"activeCount":109},[],{"trials":1633,"activeCount":109},[],{"trials":1635,"activeCount":149,"soonestReadout":1640},[1636],{"nctId":1637,"briefTitle":1638,"status":139,"phases":1639,"primaryCompletion":1640,"completion":1641,"start":1091,"enrollment":174,"conditions":1642,"interventions":1644},"NCT07046910","Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection",[90],"2029-03-30","2029-03-31",[1643],"Lung Transplant Rejection",[1628],{"trials":1646,"activeCount":109},[],{"trials":1648,"activeCount":109},[],{"trials":1650,"activeCount":109},[],{"intervention":1652,"totalTrials":149,"cells":1653},"Brezavvy 20Mg Oral",{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1669,"PHASE3":1671,"PHASE4":1673,"NA":1675},{"trials":1655,"activeCount":109},[],{"trials":1657,"activeCount":149,"soonestReadout":1662},[1658],{"nctId":1659,"briefTitle":1660,"status":139,"phases":1661,"primaryCompletion":1662,"completion":674,"start":1663,"enrollment":348,"conditions":1664,"interventions":1668},"NCT06600178","Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)",[89],"2026-03","2025-06-27",[1665,1666,1667],"Angina Patients With Non-obstructive Coronary Artery Disease","Coronary Microvascular Disease","Coronary Microvascular Dysfunction (CMD)",[1652],{"trials":1670,"activeCount":109},[],{"trials":1672,"activeCount":109},[],{"trials":1674,"activeCount":109},[],{"trials":1676,"activeCount":109},[],{"intervention":58,"totalTrials":149,"cells":1678},{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1697,"PHASE3":1699,"PHASE4":1701,"NA":1703},{"trials":1680,"activeCount":109},[],{"trials":1682,"activeCount":149,"soonestReadout":57},[1683],{"nctId":55,"briefTitle":56,"status":344,"phases":1684,"primaryCompletion":57,"completion":1685,"start":1686,"enrollment":1687,"conditions":1688,"interventions":1690},[89],"2026-07","2022-07-22",36,[1689],"B-cell Acute Lymphoblastic Leukemia",[58,1691,1692,1693,1694,1695,1696],"Prednisone Pill","Daunorubicin","Vincristine","Cytarabine","Methotrexate","Pegaspargase",{"trials":1698,"activeCount":109},[],{"trials":1700,"activeCount":109},[],{"trials":1702,"activeCount":109},[],{"trials":1704,"activeCount":109},[],{"intervention":1691,"totalTrials":149,"cells":1706},{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1715,"PHASE3":1717,"PHASE4":1719,"NA":1721},{"trials":1708,"activeCount":109},[],{"trials":1710,"activeCount":149,"soonestReadout":57},[1711],{"nctId":55,"briefTitle":56,"status":344,"phases":1712,"primaryCompletion":57,"completion":1685,"start":1686,"enrollment":1687,"conditions":1713,"interventions":1714},[89],[1689],[58,1691,1692,1693,1694,1695,1696],{"trials":1716,"activeCount":109},[],{"trials":1718,"activeCount":109},[],{"trials":1720,"activeCount":109},[],{"trials":1722,"activeCount":109},[],{"intervention":1692,"totalTrials":149,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1733,"PHASE3":1735,"PHASE4":1737,"NA":1739},{"trials":1726,"activeCount":109},[],{"trials":1728,"activeCount":149,"soonestReadout":57},[1729],{"nctId":55,"briefTitle":56,"status":344,"phases":1730,"primaryCompletion":57,"completion":1685,"start":1686,"enrollment":1687,"conditions":1731,"interventions":1732},[89],[1689],[58,1691,1692,1693,1694,1695,1696],{"trials":1734,"activeCount":109},[],{"trials":1736,"activeCount":109},[],{"trials":1738,"activeCount":109},[],{"trials":1740,"activeCount":109},[],{"intervention":1693,"totalTrials":149,"cells":1742},{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1751,"PHASE3":1753,"PHASE4":1755,"NA":1757},{"trials":1744,"activeCount":109},[],{"trials":1746,"activeCount":149,"soonestReadout":57},[1747],{"nctId":55,"briefTitle":56,"status":344,"phases":1748,"primaryCompletion":57,"completion":1685,"start":1686,"enrollment":1687,"conditions":1749,"interventions":1750},[89],[1689],[58,1691,1692,1693,1694,1695,1696],{"trials":1752,"activeCount":109},[],{"trials":1754,"activeCount":109},[],{"trials":1756,"activeCount":109},[],{"trials":1758,"activeCount":109},[],{"intervention":1694,"totalTrials":149,"cells":1760},{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1769,"PHASE3":1771,"PHASE4":1773,"NA":1775},{"trials":1762,"activeCount":109},[],{"trials":1764,"activeCount":149,"soonestReadout":57},[1765],{"nctId":55,"briefTitle":56,"status":344,"phases":1766,"primaryCompletion":57,"completion":1685,"start":1686,"enrollment":1687,"conditions":1767,"interventions":1768},[89],[1689],[58,1691,1692,1693,1694,1695,1696],{"trials":1770,"activeCount":109},[],{"trials":1772,"activeCount":109},[],{"trials":1774,"activeCount":109},[],{"trials":1776,"activeCount":109},[],{"intervention":1695,"totalTrials":149,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1787,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1780,"activeCount":109},[],{"trials":1782,"activeCount":149,"soonestReadout":57},[1783],{"nctId":55,"briefTitle":56,"status":344,"phases":1784,"primaryCompletion":57,"completion":1685,"start":1686,"enrollment":1687,"conditions":1785,"interventions":1786},[89],[1689],[58,1691,1692,1693,1694,1695,1696],{"trials":1788,"activeCount":109},[],{"trials":1790,"activeCount":109},[],{"trials":1792,"activeCount":109},[],{"trials":1794,"activeCount":109},[],{"intervention":1696,"totalTrials":149,"cells":1796},{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1805,"PHASE3":1807,"PHASE4":1809,"NA":1811},{"trials":1798,"activeCount":109},[],{"trials":1800,"activeCount":149,"soonestReadout":57},[1801],{"nctId":55,"briefTitle":56,"status":344,"phases":1802,"primaryCompletion":57,"completion":1685,"start":1686,"enrollment":1687,"conditions":1803,"interventions":1804},[89],[1689],[58,1691,1692,1693,1694,1695,1696],{"trials":1806,"activeCount":109},[],{"trials":1808,"activeCount":109},[],{"trials":1810,"activeCount":109},[],{"trials":1812,"activeCount":109},[],{"intervention":1814,"totalTrials":149,"cells":1815},"Dapagliflozin 10mg Tab",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1830,"PHASE3":1832,"PHASE4":1834,"NA":1836},{"trials":1817,"activeCount":109},[],{"trials":1819,"activeCount":149,"soonestReadout":1824},[1820],{"nctId":1821,"briefTitle":1822,"status":139,"phases":1823,"primaryCompletion":1824,"completion":1825,"start":1826,"enrollment":1191,"conditions":1827,"interventions":1829},"NCT05762952","Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease",[89],"2025-08-05","2026-03-31","2023-06-06",[1828],"Myocardial Ischemia",[1814],{"trials":1831,"activeCount":109},[],{"trials":1833,"activeCount":109},[],{"trials":1835,"activeCount":109},[],{"trials":1837,"activeCount":109},[],{"intervention":1839,"totalTrials":149,"cells":1840},"Recombinant von Willebrand Factor",{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1854,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1842,"activeCount":109},[],{"trials":1844,"activeCount":149,"soonestReadout":249},[1845],{"nctId":1846,"briefTitle":1847,"status":139,"phases":1848,"primaryCompletion":249,"completion":1849,"start":1850,"enrollment":31,"conditions":1851,"interventions":1853},"NCT06118372","Recombinant vWF Concentrate and ECMO",[89],"2027-02-28","2024-10-03",[1852],"Bleeding Disorder",[1839],{"trials":1855,"activeCount":109},[],{"trials":1857,"activeCount":109},[],{"trials":1859,"activeCount":109},[],{"trials":1861,"activeCount":109},[],{"intervention":1863,"totalTrials":149,"cells":1864},"Azithromycin",{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1879,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1866,"activeCount":109},[],{"trials":1868,"activeCount":149,"soonestReadout":1873},[1869],{"nctId":1870,"briefTitle":1871,"status":218,"phases":1872,"primaryCompletion":1873,"completion":1874,"start":1875,"enrollment":348,"conditions":1876,"interventions":1878},"NCT07615842","Assessing the Impact of Unnecessary Antibiotic Treatment on the Development of Appropriate Adaptive Immune Responses in Malnourished Bangladeshi Infants",[89],"2027-06-01","2028-06-01","2026-06-01",[1877],"Antibiotic Resistance Prevention",[1863],{"trials":1880,"activeCount":109},[],{"trials":1882,"activeCount":109},[],{"trials":1884,"activeCount":109},[],{"trials":1886,"activeCount":109},[],{"intervention":1888,"totalTrials":149,"cells":1889},"CD33 FPBMC",{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1905,"PHASE3":1907,"PHASE4":1909,"NA":1911},{"trials":1891,"activeCount":109},[],{"trials":1893,"activeCount":149,"soonestReadout":1898},[1894],{"nctId":1895,"briefTitle":1896,"status":139,"phases":1897,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":19,"conditions":1901,"interventions":1904},"NCT07270978","Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS",[89],"2028-08","2031-07","2026-03-26",[1245,1902,1903],"Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasm",[1888],{"trials":1906,"activeCount":109},[],{"trials":1908,"activeCount":109},[],{"trials":1910,"activeCount":109},[],{"trials":1912,"activeCount":109},[],{"intervention":1914,"totalTrials":149,"cells":1915},"anti-EGFR bispecific-armed T cells",{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1917,"activeCount":109},[],{"trials":1919,"activeCount":149,"soonestReadout":1615},[1920],{"nctId":1921,"briefTitle":1922,"status":139,"phases":1923,"primaryCompletion":1615,"completion":555,"start":1924,"enrollment":31,"conditions":1925,"interventions":1927},"NCT07343986","Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma",[89],"2026-03-23",[1926],"Glioblastoma (GBM)",[1914],{"trials":1929,"activeCount":109},[],{"trials":1931,"activeCount":109},[],{"trials":1933,"activeCount":109},[],{"trials":1935,"activeCount":109},[],{"intervention":741,"totalTrials":149,"cells":1937},{"EARLY_PHASE1":1938,"PHASE1":1940,"PHASE2":1946,"PHASE3":1948,"PHASE4":1950,"NA":1952},{"trials":1939,"activeCount":109},[],{"trials":1941,"activeCount":149,"soonestReadout":732},[1942],{"nctId":729,"briefTitle":730,"status":344,"phases":1943,"primaryCompletion":732,"completion":733,"start":734,"enrollment":735,"conditions":1944,"interventions":1945},[89],[737,738],[740,722,741],{"trials":1947,"activeCount":109},[],{"trials":1949,"activeCount":109},[],{"trials":1951,"activeCount":109},[],{"trials":1953,"activeCount":109},[],{"intervention":1955,"totalTrials":97,"cells":1956},"Methadone",{"EARLY_PHASE1":1957,"PHASE1":1984,"PHASE2":1986,"PHASE3":1988,"PHASE4":2001,"NA":2003},{"trials":1958,"activeCount":154,"soonestReadout":1963},[1959,1969],{"nctId":1960,"briefTitle":1961,"status":139,"phases":1962,"primaryCompletion":1963,"completion":1963,"start":1964,"enrollment":1191,"conditions":1965,"interventions":1967},"NCT06387303","Pain Control and Quality of Recovery After Intravenous Methadone Versus Intrathecal Morphine in Major Abdominal Surgery",[88],"2026-05-11","2024-08-06",[1966],"Pain, Postoperative",[1955,1968],"Morphine",{"nctId":1970,"briefTitle":1971,"status":139,"phases":1972,"primaryCompletion":1973,"completion":1973,"start":1974,"enrollment":1191,"conditions":1975,"interventions":1982},"NCT06810336","Pain Control and Quality of Recovery After Intravenous Methadone Versus Intravenous Remifentanil in Craniotomy Surgery",[88],"2027-09-10","2025-03-10",[1976,1977,1978,1979,1980,1981],"Brain Injury","Brain Tumors","Craniotomy Surgery","Pain","Postoperative","Postoperative Care",[1983,1955],"Remifentanil",{"trials":1985,"activeCount":109},[],{"trials":1987,"activeCount":109},[],{"trials":1989,"activeCount":109},[1990],{"nctId":1991,"briefTitle":1992,"status":118,"phases":1993,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":1996,"conditions":1997,"interventions":1999},"NCT01205256","IRB-HSR# 14145 R,S Methadone: Analgesia and Pharmacokinetics in Adolescents Undergoing Scoliosis Correction",[91],"2010-04","2009-03",11,[1998],"Scoliosis",[2000],"methadone",{"trials":2002,"activeCount":109},[],{"trials":2004,"activeCount":109},[],{"intervention":2006,"totalTrials":2007,"cells":2008},"Spironolactone",5,{"EARLY_PHASE1":2009,"PHASE1":2038,"PHASE2":2040,"PHASE3":2042,"PHASE4":2044,"NA":2046},{"trials":2010,"activeCount":154,"soonestReadout":1509},[2011,2021,2028],{"nctId":2012,"briefTitle":2013,"status":139,"phases":2014,"primaryCompletion":1509,"completion":2015,"start":2016,"enrollment":1116,"conditions":2017,"interventions":2019},"NCT03068910","Hyperandrogenemia and Altered Day-night LH Pulse Patterns",[88],"2025-12-01","2016-07-21",[33,18,2018],"Puberty",[2020,2006],"Micronized progesterone",{"nctId":2022,"briefTitle":2023,"status":139,"phases":2024,"primaryCompletion":1509,"completion":2015,"start":2025,"enrollment":1116,"conditions":2026,"interventions":2027},"NCT04723862","Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?",[88],"2021-11-12",[33,18,2018],[2006],{"nctId":2029,"briefTitle":2030,"status":169,"phases":2031,"primaryCompletion":2032,"completion":2032,"start":2033,"enrollment":624,"conditions":2034,"interventions":2037},"NCT04075149","Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess?",[88],"2024-09-01","2019-12-18",[18,2035,2036],"Puberty Disorders","Ovulation Disorder",[2006],{"trials":2039,"activeCount":109},[],{"trials":2041,"activeCount":109},[],{"trials":2043,"activeCount":109},[],{"trials":2045,"activeCount":109},[],{"trials":2047,"activeCount":109},[2048,2056],{"nctId":2049,"briefTitle":2050,"status":118,"phases":2051,"primaryCompletion":2052,"completion":2052,"start":2053,"enrollment":1116,"conditions":2054,"interventions":2055},"NCT03174288","The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes",[93],"2019-05-22","2015-08",[24],[2006],{"nctId":2057,"briefTitle":2058,"status":169,"phases":2059,"primaryCompletion":2060,"completion":2060,"start":2061,"enrollment":439,"conditions":2062,"interventions":2063},"NCT01422759","Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess",[93],"2024-12","2016-12-09",[27,36,18],[2006],{"intervention":2020,"totalTrials":154,"cells":2065},{"EARLY_PHASE1":2066,"PHASE1":2082,"PHASE2":2084,"PHASE3":2086,"PHASE4":2088,"NA":2090},{"trials":2067,"activeCount":149,"soonestReadout":1509},[2068,2072],{"nctId":2012,"briefTitle":2013,"status":139,"phases":2069,"primaryCompletion":1509,"completion":2015,"start":2016,"enrollment":1116,"conditions":2070,"interventions":2071},[88],[33,18,2018],[2020,2006],{"nctId":2073,"briefTitle":2074,"status":169,"phases":2075,"primaryCompletion":1509,"completion":1509,"start":2076,"enrollment":34,"conditions":2077,"interventions":2079},"NCT04597099","Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion",[88],"2022-10-26",[2078,18],"PCOS",[2020,2080,2081],"Flutamide","Estradiol patch",{"trials":2083,"activeCount":109},[],{"trials":2085,"activeCount":109},[],{"trials":2087,"activeCount":109},[],{"trials":2089,"activeCount":109},[],{"trials":2091,"activeCount":109},[],{"intervention":2093,"totalTrials":149,"cells":2094},"Dapansutrile",{"EARLY_PHASE1":2095,"PHASE1":2106,"PHASE2":2108,"PHASE3":2110,"PHASE4":2112,"NA":2114},{"trials":2096,"activeCount":149,"soonestReadout":2101},[2097],{"nctId":2098,"briefTitle":2099,"status":218,"phases":2100,"primaryCompletion":2101,"completion":1591,"start":2102,"enrollment":174,"conditions":2103,"interventions":2105},"NCT05880355","Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI",[88],"2028-12-31","2026-04-01",[2104],"Myocardial Infarction",[2093],{"trials":2107,"activeCount":109},[],{"trials":2109,"activeCount":109},[],{"trials":2111,"activeCount":109},[],{"trials":2113,"activeCount":109},[],{"trials":2115,"activeCount":109},[],{"intervention":2117,"totalTrials":149,"cells":2118},"Micronized progesterone suspension",{"EARLY_PHASE1":2119,"PHASE1":2128,"PHASE2":2130,"PHASE3":2132,"PHASE4":2134,"NA":2136},{"trials":2120,"activeCount":149,"soonestReadout":1509},[2121],{"nctId":2122,"briefTitle":2123,"status":139,"phases":2124,"primaryCompletion":1509,"completion":2015,"start":2125,"enrollment":1687,"conditions":2126,"interventions":2127},"NCT00929006","Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism",[88],"2008-06",[2018,33],[2117],{"trials":2129,"activeCount":109},[],{"trials":2131,"activeCount":109},[],{"trials":2133,"activeCount":109},[],{"trials":2135,"activeCount":109},[],{"trials":2137,"activeCount":109},[],{"intervention":2139,"totalTrials":149,"cells":2140},"PolyICLC",{"EARLY_PHASE1":2141,"PHASE1":2151,"PHASE2":2153,"PHASE3":2155,"PHASE4":2157,"NA":2159},{"trials":2142,"activeCount":149,"soonestReadout":623},[2143],{"nctId":2144,"briefTitle":2145,"status":139,"phases":2146,"primaryCompletion":623,"completion":623,"start":2147,"enrollment":1996,"conditions":2148,"interventions":2150},"NCT06472661","FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma",[88],"2024-09-27",[2149],"Advanced Melanoma",[2139],{"trials":2152,"activeCount":109},[],{"trials":2154,"activeCount":109},[],{"trials":2156,"activeCount":109},[],{"trials":2158,"activeCount":109},[],{"trials":2160,"activeCount":109},[],{"intervention":1968,"totalTrials":149,"cells":2162},{"EARLY_PHASE1":2163,"PHASE1":2169,"PHASE2":2171,"PHASE3":2173,"PHASE4":2175,"NA":2177},{"trials":2164,"activeCount":149,"soonestReadout":1963},[2165],{"nctId":1960,"briefTitle":1961,"status":139,"phases":2166,"primaryCompletion":1963,"completion":1963,"start":1964,"enrollment":1191,"conditions":2167,"interventions":2168},[88],[1966],[1955,1968],{"trials":2170,"activeCount":109},[],{"trials":2172,"activeCount":109},[],{"trials":2174,"activeCount":109},[],{"trials":2176,"activeCount":109},[],{"trials":2178,"activeCount":109},[],{"intervention":2180,"totalTrials":149,"cells":2181},"Estradiol",{"EARLY_PHASE1":2182,"PHASE1":2191,"PHASE2":2193,"PHASE3":2195,"PHASE4":2197,"NA":2199},{"trials":2183,"activeCount":149,"soonestReadout":1509},[2184],{"nctId":2185,"briefTitle":2186,"status":139,"phases":2187,"primaryCompletion":1509,"completion":2015,"start":2188,"enrollment":735,"conditions":2189,"interventions":2190},"NCT03401047","Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome",[88],"2017-11-30",[18],[2180],{"trials":2192,"activeCount":109},[],{"trials":2194,"activeCount":109},[],{"trials":2196,"activeCount":109},[],{"trials":2198,"activeCount":109},[],{"trials":2200,"activeCount":109},[],{"intervention":1983,"totalTrials":149,"cells":2202},{"EARLY_PHASE1":2203,"PHASE1":2209,"PHASE2":2211,"PHASE3":2213,"PHASE4":2215,"NA":2217},{"trials":2204,"activeCount":149,"soonestReadout":1973},[2205],{"nctId":1970,"briefTitle":1971,"status":139,"phases":2206,"primaryCompletion":1973,"completion":1973,"start":1974,"enrollment":1191,"conditions":2207,"interventions":2208},[88],[1976,1977,1978,1979,1980,1981],[1983,1955],{"trials":2210,"activeCount":109},[],{"trials":2212,"activeCount":109},[],{"trials":2214,"activeCount":109},[],{"trials":2216,"activeCount":109},[],{"trials":2218,"activeCount":109},[],{"intervention":2220,"totalTrials":149,"cells":2221},"Psilocybin 25 mg",{"EARLY_PHASE1":2222,"PHASE1":2232,"PHASE2":2234,"PHASE3":2236,"PHASE4":2238,"NA":2240},{"trials":2223,"activeCount":149,"soonestReadout":2228},[2224],{"nctId":2225,"briefTitle":2226,"status":139,"phases":2227,"primaryCompletion":2228,"completion":2228,"start":1662,"enrollment":31,"conditions":2229,"interventions":2231},"NCT06724289","Psilocybin for Prolonged Grief Disorder",[88],"2027-08",[2230],"Prolonged Grief Disorder",[2220],{"trials":2233,"activeCount":109},[],{"trials":2235,"activeCount":109},[],{"trials":2237,"activeCount":109},[],{"trials":2239,"activeCount":109},[],{"trials":2241,"activeCount":109},[],{"intervention":2243,"totalTrials":149,"cells":2244},"Hyperpolarized Xe129",{"EARLY_PHASE1":2245,"PHASE1":2256,"PHASE2":2258,"PHASE3":2260,"PHASE4":2262,"NA":2264},{"trials":2246,"activeCount":149,"soonestReadout":621},[2247],{"nctId":2248,"briefTitle":2249,"status":139,"phases":2250,"primaryCompletion":621,"completion":1615,"start":2251,"enrollment":2252,"conditions":2253,"interventions":2255},"NCT06853145","Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis",[88],"2025-05-01",6,[2254],"Idiopathic Pulmonary Fibrosis",[2243],{"trials":2257,"activeCount":109},[],{"trials":2259,"activeCount":109},[],{"trials":2261,"activeCount":109},[],{"trials":2263,"activeCount":109},[],{"trials":2265,"activeCount":109},[],{"intervention":2267,"totalTrials":149,"cells":2268},"4 weeks of Nicotine lozenge",{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2270,"activeCount":109},[],{"trials":2272,"activeCount":109},[],{"trials":2274,"activeCount":109},[],{"trials":2276,"activeCount":109},[],{"trials":2278,"activeCount":109},[],{"trials":2280,"activeCount":149,"soonestReadout":2285},[2281],{"nctId":2282,"briefTitle":2283,"status":139,"phases":2284,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2289,"interventions":2296},"NCT05660525","Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia",[93],"2027-05-31","2028-03-01","2024-03-06",768,[2290,2291,2292,2293,2294,2295],"Smoking Cessation","Smoking, Cigarette","Smoking Reduction","Smoking","Smoking, Tobacco","Quitting Smoking",[2267,2297,2298,2299],"8 weeks of Nicotine Replacement Therapy Patch","4 weeks of Nicotine Replacement Therapy Patch","8 Weeks Nicotine Lozenge",{"intervention":2297,"totalTrials":149,"cells":2301},{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2303,"activeCount":109},[],{"trials":2305,"activeCount":109},[],{"trials":2307,"activeCount":109},[],{"trials":2309,"activeCount":109},[],{"trials":2311,"activeCount":109},[],{"trials":2313,"activeCount":149,"soonestReadout":2285},[2314],{"nctId":2282,"briefTitle":2283,"status":139,"phases":2315,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2316,"interventions":2317},[93],[2290,2291,2292,2293,2294,2295],[2267,2297,2298,2299],{"intervention":2298,"totalTrials":149,"cells":2319},{"EARLY_PHASE1":2320,"PHASE1":2322,"PHASE2":2324,"PHASE3":2326,"PHASE4":2328,"NA":2330},{"trials":2321,"activeCount":109},[],{"trials":2323,"activeCount":109},[],{"trials":2325,"activeCount":109},[],{"trials":2327,"activeCount":109},[],{"trials":2329,"activeCount":109},[],{"trials":2331,"activeCount":149,"soonestReadout":2285},[2332],{"nctId":2282,"briefTitle":2283,"status":139,"phases":2333,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2334,"interventions":2335},[93],[2290,2291,2292,2293,2294,2295],[2267,2297,2298,2299],{"intervention":2299,"totalTrials":149,"cells":2337},{"EARLY_PHASE1":2338,"PHASE1":2340,"PHASE2":2342,"PHASE3":2344,"PHASE4":2346,"NA":2348},{"trials":2339,"activeCount":109},[],{"trials":2341,"activeCount":109},[],{"trials":2343,"activeCount":109},[],{"trials":2345,"activeCount":109},[],{"trials":2347,"activeCount":109},[],{"trials":2349,"activeCount":149,"soonestReadout":2285},[2350],{"nctId":2282,"briefTitle":2283,"status":139,"phases":2351,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2352,"interventions":2353},[93],[2290,2291,2292,2293,2294,2295],[2267,2297,2298,2299],{"intervention":81,"totalTrials":149,"cells":2355},{"EARLY_PHASE1":2356,"PHASE1":2358,"PHASE2":2360,"PHASE3":2362,"PHASE4":2364,"NA":2366},{"trials":2357,"activeCount":109},[],{"trials":2359,"activeCount":109},[],{"trials":2361,"activeCount":109},[],{"trials":2363,"activeCount":109},[],{"trials":2365,"activeCount":109},[],{"trials":2367,"activeCount":149,"soonestReadout":80},[2368],{"nctId":78,"briefTitle":79,"status":344,"phases":2369,"primaryCompletion":80,"completion":499,"start":2370,"enrollment":299,"conditions":2371,"interventions":2373},[93],"2024-09-23",[2372],"Tobacco Use Cessation",[81,2374],"Nicotine lozenge",{"intervention":2374,"totalTrials":149,"cells":2376},{"EARLY_PHASE1":2377,"PHASE1":2379,"PHASE2":2381,"PHASE3":2383,"PHASE4":2385,"NA":2387},{"trials":2378,"activeCount":109},[],{"trials":2380,"activeCount":109},[],{"trials":2382,"activeCount":109},[],{"trials":2384,"activeCount":109},[],{"trials":2386,"activeCount":109},[],{"trials":2388,"activeCount":149,"soonestReadout":80},[2389],{"nctId":78,"briefTitle":79,"status":344,"phases":2390,"primaryCompletion":80,"completion":499,"start":2370,"enrollment":299,"conditions":2391,"interventions":2392},[93],[2372],[81,2374],{"intervention":2394,"totalTrials":154,"cells":2395},"Liposomal Bupivacaine",{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2402,"PHASE4":2408,"NA":2420},{"trials":2397,"activeCount":109},[],{"trials":2399,"activeCount":109},[],{"trials":2401,"activeCount":109},[],{"trials":2403,"activeCount":109},[2404],{"nctId":203,"briefTitle":204,"status":118,"phases":2405,"primaryCompletion":206,"completion":207,"start":208,"enrollment":184,"conditions":2406,"interventions":2407},[91],[210],[212,192],{"trials":2409,"activeCount":109},[2410],{"nctId":2411,"briefTitle":2412,"status":118,"phases":2413,"primaryCompletion":2414,"completion":2415,"start":2416,"enrollment":25,"conditions":2417,"interventions":2419},"NCT03708198","Pharmacokinetics of Single-Dose Liposomal Bupivacaine in Surgeon Performed Intercostal Nerve Blocks",[92],"2019-10-11","2020-08-11","2018-06-11",[2418],"Thoracic",[2394],{"trials":2421,"activeCount":109},[],{"intervention":2423,"totalTrials":149,"cells":2424},"water-soluble therapy",{"EARLY_PHASE1":2425,"PHASE1":2427,"PHASE2":2429,"PHASE3":2431,"PHASE4":2433,"NA":2446},{"trials":2426,"activeCount":109},[],{"trials":2428,"activeCount":109},[],{"trials":2430,"activeCount":109},[],{"trials":2432,"activeCount":109},[],{"trials":2434,"activeCount":109},[2435],{"nctId":2436,"briefTitle":2437,"status":118,"phases":2438,"primaryCompletion":2439,"completion":2439,"start":2440,"enrollment":2441,"conditions":2442,"interventions":2444},"NCT01926392","Comparison of a Water-soluble Topical Antimicrobial to Silver Sulfadiazine in Partial Thickness Burns",[92],"2011-10","2011-04",8,[2443],"Burn",[2423,2445],"silver sulfadiazine",{"trials":2447,"activeCount":109},[],{"intervention":2445,"totalTrials":149,"cells":2449},{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2456,"PHASE4":2458,"NA":2464},{"trials":2451,"activeCount":109},[],{"trials":2453,"activeCount":109},[],{"trials":2455,"activeCount":109},[],{"trials":2457,"activeCount":109},[],{"trials":2459,"activeCount":109},[2460],{"nctId":2436,"briefTitle":2437,"status":118,"phases":2461,"primaryCompletion":2439,"completion":2439,"start":2440,"enrollment":2441,"conditions":2462,"interventions":2463},[92],[2443],[2423,2445],{"trials":2465,"activeCount":109},[],{"intervention":2467,"totalTrials":149,"cells":2468},"Metolazone Oral",{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2473,"PHASE3":2475,"PHASE4":2477,"NA":2490},{"trials":2470,"activeCount":109},[],{"trials":2472,"activeCount":109},[],{"trials":2474,"activeCount":109},[],{"trials":2476,"activeCount":109},[],{"trials":2478,"activeCount":109},[2479],{"nctId":2480,"briefTitle":2481,"status":850,"phases":2482,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":2007,"conditions":2485,"interventions":2488},"NCT03574857","Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance",[92],"2021-01-01","2018-06-01",[396,398,2486,2487],"Heart Failure Acute","Cardiovascular Diseases",[2467,2489],"Chlorothiazide",{"trials":2491,"activeCount":109},[],{"intervention":2489,"totalTrials":149,"cells":2493},{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2500,"PHASE4":2502,"NA":2508},{"trials":2495,"activeCount":109},[],{"trials":2497,"activeCount":109},[],{"trials":2499,"activeCount":109},[],{"trials":2501,"activeCount":109},[],{"trials":2503,"activeCount":109},[2504],{"nctId":2480,"briefTitle":2481,"status":850,"phases":2505,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":2007,"conditions":2506,"interventions":2507},[92],[396,398,2486,2487],[2467,2489],{"trials":2509,"activeCount":109},[],{"intervention":2511,"totalTrials":149,"cells":2512},"Capsaicin",{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2517,"PHASE3":2519,"PHASE4":2521,"NA":2532},{"trials":2514,"activeCount":109},[],{"trials":2516,"activeCount":109},[],{"trials":2518,"activeCount":109},[],{"trials":2520,"activeCount":109},[],{"trials":2522,"activeCount":109},[2523],{"nctId":2524,"briefTitle":2525,"status":118,"phases":2526,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":439,"conditions":2529,"interventions":2531},"NCT04283292","Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome",[92],"2022-03-18","2020-12-01",[2530],"Cannabinoid Hyperemesis Syndrome",[2511],{"trials":2533,"activeCount":109},[],{"intervention":2535,"totalTrials":149,"cells":2536},"beclomethasone",{"EARLY_PHASE1":2537,"PHASE1":2539,"PHASE2":2541,"PHASE3":2543,"PHASE4":2545,"NA":2557},{"trials":2538,"activeCount":109},[],{"trials":2540,"activeCount":109},[],{"trials":2542,"activeCount":109},[],{"trials":2544,"activeCount":109},[],{"trials":2546,"activeCount":109},[2547],{"nctId":2548,"briefTitle":2549,"status":118,"phases":2550,"primaryCompletion":2551,"completion":2551,"start":2552,"enrollment":2553,"conditions":2554,"interventions":2555},"NCT02577497","Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma",[92],"2018-07-06","2016-06",31,[252],[2535,2556],"fluticasone",{"trials":2558,"activeCount":109},[],{"intervention":2556,"totalTrials":149,"cells":2560},{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2567,"PHASE4":2569,"NA":2575},{"trials":2562,"activeCount":109},[],{"trials":2564,"activeCount":109},[],{"trials":2566,"activeCount":109},[],{"trials":2568,"activeCount":109},[],{"trials":2570,"activeCount":109},[2571],{"nctId":2548,"briefTitle":2549,"status":118,"phases":2572,"primaryCompletion":2551,"completion":2551,"start":2552,"enrollment":2553,"conditions":2573,"interventions":2574},[92],[252],[2535,2556],{"trials":2576,"activeCount":109},[],{"intervention":2578,"totalTrials":149,"cells":2579},"propofol",{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2586,"PHASE4":2588,"NA":2600},{"trials":2581,"activeCount":109},[],{"trials":2583,"activeCount":109},[],{"trials":2585,"activeCount":109},[],{"trials":2587,"activeCount":109},[],{"trials":2589,"activeCount":109},[2590],{"nctId":2591,"briefTitle":2592,"status":118,"phases":2593,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":2596,"conditions":2597,"interventions":2599},"NCT01150838","Propofol for Pediatric Tracheal Intubation With Deep Anesthesia During Sevoflurane Induction",[92],"2010-06","2008-07",106,[2598],"Anesthesia Intubation Complication",[2578],{"trials":2601,"activeCount":109},[],{"intervention":2603,"totalTrials":149,"cells":2604},"Fibrinogen",{"EARLY_PHASE1":2605,"PHASE1":2607,"PHASE2":2609,"PHASE3":2611,"PHASE4":2613,"NA":2627},{"trials":2606,"activeCount":109},[],{"trials":2608,"activeCount":109},[],{"trials":2610,"activeCount":109},[],{"trials":2612,"activeCount":109},[],{"trials":2614,"activeCount":109},[2615],{"nctId":2616,"briefTitle":2617,"status":118,"phases":2618,"primaryCompletion":2619,"completion":2620,"start":2621,"enrollment":2553,"conditions":2622,"interventions":2625},"NCT04376762","Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients",[92],"2023-03-01","2023-05-01","2021-10-26",[2623,2624],"Pediatric HD","Bleeding",[2603,2626],"Cryoprecipitate",{"trials":2628,"activeCount":109},[],{"intervention":2626,"totalTrials":149,"cells":2630},{"EARLY_PHASE1":2631,"PHASE1":2633,"PHASE2":2635,"PHASE3":2637,"PHASE4":2639,"NA":2645},{"trials":2632,"activeCount":109},[],{"trials":2634,"activeCount":109},[],{"trials":2636,"activeCount":109},[],{"trials":2638,"activeCount":109},[],{"trials":2640,"activeCount":109},[2641],{"nctId":2616,"briefTitle":2617,"status":118,"phases":2642,"primaryCompletion":2619,"completion":2620,"start":2621,"enrollment":2553,"conditions":2643,"interventions":2644},[92],[2623,2624],[2603,2626],{"trials":2646,"activeCount":109},[],{"intervention":2648,"totalTrials":149,"cells":2649},"Liposomal bupivacaine TAP block",{"EARLY_PHASE1":2650,"PHASE1":2652,"PHASE2":2654,"PHASE3":2656,"PHASE4":2658,"NA":2672},{"trials":2651,"activeCount":109},[],{"trials":2653,"activeCount":109},[],{"trials":2655,"activeCount":109},[],{"trials":2657,"activeCount":109},[],{"trials":2659,"activeCount":109},[2660],{"nctId":2661,"briefTitle":2662,"status":118,"phases":2663,"primaryCompletion":2664,"completion":2664,"start":2665,"enrollment":2666,"conditions":2667,"interventions":2670},"NCT04777591","Effectiveness of Exparel TAP Block in Breast Free Flap Reconstruction",[92],"2022-12-28","2021-03-01",117,[2668,2669],"Postoperative Pain","Breast Reconstruction",[2648,2671],"Bupivacain",{"trials":2673,"activeCount":109},[],{"intervention":2671,"totalTrials":149,"cells":2675},{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2680,"PHASE3":2682,"PHASE4":2684,"NA":2690},{"trials":2677,"activeCount":109},[],{"trials":2679,"activeCount":109},[],{"trials":2681,"activeCount":109},[],{"trials":2683,"activeCount":109},[],{"trials":2685,"activeCount":109},[2686],{"nctId":2661,"briefTitle":2662,"status":118,"phases":2687,"primaryCompletion":2664,"completion":2664,"start":2665,"enrollment":2666,"conditions":2688,"interventions":2689},[92],[2668,2669],[2648,2671],{"trials":2691,"activeCount":109},[],{"intervention":2693,"totalTrials":149,"cells":2694},"Dexmedetomidine",{"EARLY_PHASE1":2695,"PHASE1":2697,"PHASE2":2699,"PHASE3":2701,"PHASE4":2703,"NA":2715},{"trials":2696,"activeCount":109},[],{"trials":2698,"activeCount":109},[],{"trials":2700,"activeCount":109},[],{"trials":2702,"activeCount":109},[],{"trials":2704,"activeCount":109},[2705],{"nctId":2706,"briefTitle":2707,"status":118,"phases":2708,"primaryCompletion":2709,"completion":2709,"start":543,"enrollment":2710,"conditions":2711,"interventions":2714},"NCT01850017","Study of Dexmedetomidine in Spine Surgery",[92],"2015-05",142,[2712,2713],"Collapse of Thoracic Vertebra","Collapse of Lumbar Vertebrae",[2693],{"trials":2716,"activeCount":109},[],{"intervention":2718,"totalTrials":149,"cells":2719},"Alvimopan",{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2724,"PHASE3":2726,"PHASE4":2728,"NA":2740},{"trials":2721,"activeCount":109},[],{"trials":2723,"activeCount":109},[],{"trials":2725,"activeCount":109},[],{"trials":2727,"activeCount":109},[],{"trials":2729,"activeCount":109},[2730],{"nctId":2731,"briefTitle":2732,"status":118,"phases":2733,"primaryCompletion":2734,"completion":2734,"start":2735,"enrollment":2736,"conditions":2737,"interventions":2739},"NCT02789111","Trial of Alvimopan in Major Spine Surgery",[92],"2018-12-01","2016-06-01",49,[2738],"Constipation",[2718],{"trials":2741,"activeCount":109},[],{"intervention":2743,"totalTrials":149,"cells":2744},"Dextran 70",{"EARLY_PHASE1":2745,"PHASE1":2747,"PHASE2":2749,"PHASE3":2751,"PHASE4":2753,"NA":2764},{"trials":2746,"activeCount":109},[],{"trials":2748,"activeCount":109},[],{"trials":2750,"activeCount":109},[],{"trials":2752,"activeCount":109},[],{"trials":2754,"activeCount":109},[2755],{"nctId":2756,"briefTitle":2757,"status":850,"phases":2758,"primaryCompletion":1994,"completion":1994,"start":2759,"enrollment":2441,"conditions":2760,"interventions":2762},"NCT00570960","Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis",[92],"2007-06",[2761],"Spontaneous Bacterial Peritonitis",[2743,2763],"human albumin",{"trials":2765,"activeCount":109},[],{"intervention":2763,"totalTrials":149,"cells":2767},{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2772,"PHASE3":2774,"PHASE4":2776,"NA":2782},{"trials":2769,"activeCount":109},[],{"trials":2771,"activeCount":109},[],{"trials":2773,"activeCount":109},[],{"trials":2775,"activeCount":109},[],{"trials":2777,"activeCount":109},[2778],{"nctId":2756,"briefTitle":2757,"status":850,"phases":2779,"primaryCompletion":1994,"completion":1994,"start":2759,"enrollment":2441,"conditions":2780,"interventions":2781},[92],[2761],[2743,2763],{"trials":2783,"activeCount":109},[],{"intervention":2785,"totalTrials":149,"cells":2786},"Alirocumab",{"EARLY_PHASE1":2787,"PHASE1":2789,"PHASE2":2791,"PHASE3":2793,"PHASE4":2795,"NA":2806},{"trials":2788,"activeCount":109},[],{"trials":2790,"activeCount":109},[],{"trials":2792,"activeCount":109},[],{"trials":2794,"activeCount":109},[],{"trials":2796,"activeCount":109},[2797],{"nctId":2798,"briefTitle":2799,"status":118,"phases":2800,"primaryCompletion":2801,"completion":2801,"start":2802,"enrollment":1191,"conditions":2803,"interventions":2805},"NCT02959047","A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease",[92],"2023-05-08","2017-07-17",[2804],"Peripheral Arterial Disease",[2785],{"trials":2807,"activeCount":109},[],{"intervention":2809,"totalTrials":149,"cells":2810},"Linaclotide",{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2817,"PHASE4":2819,"NA":2831},{"trials":2812,"activeCount":109},[],{"trials":2814,"activeCount":109},[],{"trials":2816,"activeCount":109},[],{"trials":2818,"activeCount":109},[],{"trials":2820,"activeCount":109},[2821],{"nctId":2822,"briefTitle":2823,"status":118,"phases":2824,"primaryCompletion":2552,"completion":2552,"start":2825,"enrollment":394,"conditions":2826,"interventions":2830},"NCT02465385","Single-dose Linaclotide for Capsule Endoscopy Preparation",[92],"2015-02",[2827,2828,2829],"Crohn's","Ulcerative Colitis","Gastrointestinal Bleeding",[2809],{"trials":2832,"activeCount":109},[],{"intervention":870,"totalTrials":97,"cells":2834},{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2841,"PHASE4":2864,"NA":2866},{"trials":2836,"activeCount":109},[],{"trials":2838,"activeCount":109},[],{"trials":2840,"activeCount":109},[],{"trials":2842,"activeCount":109},[2843,2847,2851],{"nctId":860,"briefTitle":861,"status":104,"phases":2844,"completion":863,"start":864,"enrollment":865,"conditions":2845,"interventions":2846},[91],[867],[869,870],{"nctId":872,"briefTitle":873,"status":104,"phases":2848,"completion":875,"start":864,"enrollment":865,"conditions":2849,"interventions":2850},[91],[867,877],[826,879],{"nctId":2852,"briefTitle":2853,"status":169,"phases":2854,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":2857,"conditions":2858,"interventions":2860},"NCT00133406","Long-term Impact and Intervention for Diarrhea in Brazil",[91],"2011-12","2006-06",321,[2859],"Diarrheal Disorder",[2861,2862,870,2863],"Glutamine","Vitamin A","zinc",{"trials":2865,"activeCount":109},[],{"trials":2867,"activeCount":109},[],{"intervention":2869,"totalTrials":154,"cells":2870},"Lidocaine",{"EARLY_PHASE1":2871,"PHASE1":2873,"PHASE2":2875,"PHASE3":2886,"PHASE4":2898,"NA":2900},{"trials":2872,"activeCount":109},[],{"trials":2874,"activeCount":109},[],{"trials":2876,"activeCount":109},[2877],{"nctId":2878,"briefTitle":2879,"status":118,"phases":2880,"primaryCompletion":2881,"completion":2881,"start":2882,"enrollment":2883,"conditions":2884,"interventions":2885},"NCT01204242","IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery:",[90],"2018-11-08","2009-08-01",78,[30],[2869],{"trials":2887,"activeCount":109},[2888],{"nctId":2889,"briefTitle":2890,"status":118,"phases":2891,"primaryCompletion":2892,"completion":2892,"start":863,"enrollment":557,"conditions":2893,"interventions":2895},"NCT00600158","Effects of Intravenous Local Anesthetic on Bowel Function After Colectomy",[91],"2006-07",[2894],"Postoperative Ileus",[2896,2897],"bupivacaine with hydromorphone","lidocaine",{"trials":2899,"activeCount":109},[],{"trials":2901,"activeCount":109},[],{"intervention":2903,"totalTrials":154,"cells":2904},"CBD",{"EARLY_PHASE1":2905,"PHASE1":2907,"PHASE2":2909,"PHASE3":2923,"PHASE4":2934,"NA":2936},{"trials":2906,"activeCount":109},[],{"trials":2908,"activeCount":109},[],{"trials":2910,"activeCount":109},[2911],{"nctId":2912,"briefTitle":2913,"status":118,"phases":2914,"primaryCompletion":2915,"completion":2916,"start":2917,"enrollment":2918,"conditions":2919,"interventions":2921},"NCT04611347","Is Topical CBD Effective in Treating Thumb Joint Arthritis",[90],"2021-01-21","2022-05-11","2020-07-28",18,[2903,2920],"Hand Osteoarthritis",[2903,2922],"Shea Butter",{"trials":2924,"activeCount":109},[2925],{"nctId":2926,"briefTitle":2927,"status":104,"phases":2928,"primaryCompletion":2929,"completion":47,"start":2930,"enrollment":109,"conditions":2931,"interventions":2933},"NCT05170451","Topical CBD for Musculoskeletal Pain",[90,91],"2022-06","2022-01",[2932],"Musculoskeletal Pain",[2903],{"trials":2935,"activeCount":109},[],{"trials":2937,"activeCount":109},[],{"intervention":2939,"totalTrials":149,"cells":2940},"standard",{"EARLY_PHASE1":2941,"PHASE1":2943,"PHASE2":2945,"PHASE3":2947,"PHASE4":2959,"NA":2961},{"trials":2942,"activeCount":109},[],{"trials":2944,"activeCount":109},[],{"trials":2946,"activeCount":109},[],{"trials":2948,"activeCount":109},[2949],{"nctId":2950,"briefTitle":2951,"status":118,"phases":2952,"primaryCompletion":585,"completion":585,"start":1995,"enrollment":2953,"conditions":2954,"interventions":2957},"NCT02717273","Surgical Site Infections After Liver Transplantation Based on Perioperative Antibiotics",[91],102,[2955,2956],"Liver Transplantation","Surgical Site Infection",[2939,2958],"extended",{"trials":2960,"activeCount":109},[],{"trials":2962,"activeCount":109},[],{"intervention":2958,"totalTrials":149,"cells":2964},{"EARLY_PHASE1":2965,"PHASE1":2967,"PHASE2":2969,"PHASE3":2971,"PHASE4":2977,"NA":2979},{"trials":2966,"activeCount":109},[],{"trials":2968,"activeCount":109},[],{"trials":2970,"activeCount":109},[],{"trials":2972,"activeCount":109},[2973],{"nctId":2950,"briefTitle":2951,"status":118,"phases":2974,"primaryCompletion":585,"completion":585,"start":1995,"enrollment":2953,"conditions":2975,"interventions":2976},[91],[2955,2956],[2939,2958],{"trials":2978,"activeCount":109},[],{"trials":2980,"activeCount":109},[],{"intervention":2982,"totalTrials":149,"cells":2983},"Omega 3 Fish Oil supplements",{"EARLY_PHASE1":2984,"PHASE1":2986,"PHASE2":2988,"PHASE3":2990,"PHASE4":3002,"NA":3004},{"trials":2985,"activeCount":109},[],{"trials":2987,"activeCount":109},[],{"trials":2989,"activeCount":109},[],{"trials":2991,"activeCount":109},[2992],{"nctId":2993,"briefTitle":2994,"status":118,"phases":2995,"primaryCompletion":544,"completion":544,"start":2996,"enrollment":2997,"conditions":2998,"interventions":3001},"NCT00681408","Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)",[90,91],"2007-03",41,[2999,3000],"Non-alcoholic Steatohepatitis","Fatty Liver",[2982],{"trials":3003,"activeCount":109},[],{"trials":3005,"activeCount":109},[],{"intervention":3007,"totalTrials":149,"cells":3008},"Low-Dose Topiramate",{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3013,"PHASE3":3015,"PHASE4":3029,"NA":3031},{"trials":3010,"activeCount":109},[],{"trials":3012,"activeCount":109},[],{"trials":3014,"activeCount":109},[],{"trials":3016,"activeCount":109},[3017],{"nctId":3018,"briefTitle":3019,"status":118,"phases":3020,"primaryCompletion":3021,"completion":3021,"start":3022,"enrollment":3023,"conditions":3024,"interventions":3027},"NCT01182766","New Treatment for Alcohol and Nicotine Dependence",[90,91],"2017-10-06","2011-11-01",236,[3025,3026],"Alcohol Dependence","Nicotine Dependence",[3007,3028],"High-Dose Topiramate",{"trials":3030,"activeCount":109},[],{"trials":3032,"activeCount":109},[],{"intervention":3028,"totalTrials":149,"cells":3034},{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3041,"PHASE4":3047,"NA":3049},{"trials":3036,"activeCount":109},[],{"trials":3038,"activeCount":109},[],{"trials":3040,"activeCount":109},[],{"trials":3042,"activeCount":109},[3043],{"nctId":3018,"briefTitle":3019,"status":118,"phases":3044,"primaryCompletion":3021,"completion":3021,"start":3022,"enrollment":3023,"conditions":3045,"interventions":3046},[90,91],[3025,3026],[3007,3028],{"trials":3048,"activeCount":109},[],{"trials":3050,"activeCount":109},[],{"intervention":2896,"totalTrials":149,"cells":3052},{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3057,"PHASE3":3059,"PHASE4":3065,"NA":3067},{"trials":3054,"activeCount":109},[],{"trials":3056,"activeCount":109},[],{"trials":3058,"activeCount":109},[],{"trials":3060,"activeCount":109},[3061],{"nctId":2889,"briefTitle":2890,"status":118,"phases":3062,"primaryCompletion":2892,"completion":2892,"start":863,"enrollment":557,"conditions":3063,"interventions":3064},[91],[2894],[2896,2897],{"trials":3066,"activeCount":109},[],{"trials":3068,"activeCount":109},[],{"intervention":590,"totalTrials":149,"cells":3070},{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3075,"PHASE3":3077,"PHASE4":3083,"NA":3085},{"trials":3072,"activeCount":109},[],{"trials":3074,"activeCount":109},[],{"trials":3076,"activeCount":109},[],{"trials":3078,"activeCount":109},[3079],{"nctId":580,"briefTitle":581,"status":118,"phases":3080,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":3081,"interventions":3082},[91],[588],[590,569,591],{"trials":3084,"activeCount":109},[],{"trials":3086,"activeCount":109},[],{"intervention":591,"totalTrials":149,"cells":3088},{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3093,"PHASE3":3095,"PHASE4":3101,"NA":3103},{"trials":3090,"activeCount":109},[],{"trials":3092,"activeCount":109},[],{"trials":3094,"activeCount":109},[],{"trials":3096,"activeCount":109},[3097],{"nctId":580,"briefTitle":581,"status":118,"phases":3098,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":3099,"interventions":3100},[91],[588],[590,569,591],{"trials":3102,"activeCount":109},[],{"trials":3104,"activeCount":109},[],{"intervention":3106,"totalTrials":149,"cells":3107},"tOPV",{"EARLY_PHASE1":3108,"PHASE1":3110,"PHASE2":3112,"PHASE3":3114,"PHASE4":3128,"NA":3130},{"trials":3109,"activeCount":109},[],{"trials":3111,"activeCount":109},[],{"trials":3113,"activeCount":109},[],{"trials":3115,"activeCount":109},[3116],{"nctId":3117,"briefTitle":3118,"status":169,"phases":3119,"primaryCompletion":3120,"completion":3121,"start":853,"enrollment":3122,"conditions":3123,"interventions":3125},"NCT02477046","Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh",[91],"2016-07","2017-06",810,[3124],"Vaccine Virus Shedding",[3106,3126,3127],"bOPV","IPV",{"trials":3129,"activeCount":109},[],{"trials":3131,"activeCount":109},[],{"intervention":3126,"totalTrials":149,"cells":3133},{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3138,"PHASE3":3140,"PHASE4":3146,"NA":3148},{"trials":3135,"activeCount":109},[],{"trials":3137,"activeCount":109},[],{"trials":3139,"activeCount":109},[],{"trials":3141,"activeCount":109},[3142],{"nctId":3117,"briefTitle":3118,"status":169,"phases":3143,"primaryCompletion":3120,"completion":3121,"start":853,"enrollment":3122,"conditions":3144,"interventions":3145},[91],[3124],[3106,3126,3127],{"trials":3147,"activeCount":109},[],{"trials":3149,"activeCount":109},[],{"intervention":3127,"totalTrials":149,"cells":3151},{"EARLY_PHASE1":3152,"PHASE1":3154,"PHASE2":3156,"PHASE3":3158,"PHASE4":3164,"NA":3166},{"trials":3153,"activeCount":109},[],{"trials":3155,"activeCount":109},[],{"trials":3157,"activeCount":109},[],{"trials":3159,"activeCount":109},[3160],{"nctId":3117,"briefTitle":3118,"status":169,"phases":3161,"primaryCompletion":3120,"completion":3121,"start":853,"enrollment":3122,"conditions":3162,"interventions":3163},[91],[3124],[3106,3126,3127],{"trials":3165,"activeCount":109},[],{"trials":3167,"activeCount":109},[],{"intervention":3169,"totalTrials":149,"cells":3170},"IV insulin to maintain target glucose concentration of 80-130 mg\u002FdL",{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3177,"PHASE4":3192,"NA":3194},{"trials":3172,"activeCount":109},[],{"trials":3174,"activeCount":109},[],{"trials":3176,"activeCount":109},[],{"trials":3178,"activeCount":109},[3179],{"nctId":3180,"briefTitle":3181,"status":118,"phases":3182,"primaryCompletion":3183,"completion":3183,"start":3184,"enrollment":3185,"conditions":3186,"interventions":3190},"NCT01369069","Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial",[91],"2018-11-19","2012-04",1151,[3187,3188,3189],"Acute Ischemic Stroke","Diabetes","Hyperglycemia",[3169,3191],"Standard Care control - sliding scale insulin to keep glucose less than 180 mg\u002FdL",{"trials":3193,"activeCount":109},[],{"trials":3195,"activeCount":109},[],{"intervention":3191,"totalTrials":149,"cells":3197},{"EARLY_PHASE1":3198,"PHASE1":3200,"PHASE2":3202,"PHASE3":3204,"PHASE4":3210,"NA":3212},{"trials":3199,"activeCount":109},[],{"trials":3201,"activeCount":109},[],{"trials":3203,"activeCount":109},[],{"trials":3205,"activeCount":109},[3206],{"nctId":3180,"briefTitle":3181,"status":118,"phases":3207,"primaryCompletion":3183,"completion":3183,"start":3184,"enrollment":3185,"conditions":3208,"interventions":3209},[91],[3187,3188,3189],[3169,3191],{"trials":3211,"activeCount":109},[],{"trials":3213,"activeCount":109},[],{"intervention":3215,"totalTrials":149,"cells":3216},"Tobramycin",{"EARLY_PHASE1":3217,"PHASE1":3219,"PHASE2":3221,"PHASE3":3223,"PHASE4":3234,"NA":3236},{"trials":3218,"activeCount":109},[],{"trials":3220,"activeCount":109},[],{"trials":3222,"activeCount":109},[],{"trials":3224,"activeCount":109},[3225],{"nctId":3226,"briefTitle":3227,"status":850,"phases":3228,"primaryCompletion":3229,"completion":3229,"start":3230,"enrollment":1996,"conditions":3231,"interventions":3233},"NCT03705962","Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open Fractures",[91],"2019-03-07","2015-07",[3232],"Fractures, Open",[3215],{"trials":3235,"activeCount":109},[],{"trials":3237,"activeCount":109},[],{"intervention":3239,"totalTrials":149,"cells":3240},"Ondansetron + Brief Behavioral Enhancement Treatment",{"EARLY_PHASE1":3241,"PHASE1":3243,"PHASE2":3245,"PHASE3":3247,"PHASE4":3259,"NA":3261},{"trials":3242,"activeCount":109},[],{"trials":3244,"activeCount":109},[],{"trials":3246,"activeCount":109},[],{"trials":3248,"activeCount":109},[3249],{"nctId":3250,"briefTitle":3251,"status":104,"phases":3252,"primaryCompletion":3253,"completion":3254,"start":3255,"enrollment":109,"conditions":3256,"interventions":3258},"NCT01591291","Pharmacogenetic Treatments for Alcoholism",[90,91],"2017-12","2018-02","2012-06",[3257],"Alcoholism",[3239],{"trials":3260,"activeCount":109},[],{"trials":3262,"activeCount":109},[],{"intervention":3264,"totalTrials":149,"cells":3265},"midodrine",{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3272,"PHASE4":3283,"NA":3285},{"trials":3267,"activeCount":109},[],{"trials":3269,"activeCount":109},[],{"trials":3271,"activeCount":109},[],{"trials":3273,"activeCount":109},[3274],{"nctId":3275,"briefTitle":3276,"status":104,"phases":3277,"primaryCompletion":3278,"completion":3278,"start":3279,"enrollment":109,"conditions":3280,"interventions":3282},"NCT02990546","Midodrine in the Recovery Phase of Septic Shock",[91],"2018-05-02","2017-03-01",[3281],"Septic Shock",[3264],{"trials":3284,"activeCount":109},[],{"trials":3286,"activeCount":109},[],{"intervention":3288,"totalTrials":149,"cells":3289},"rasagiline",{"EARLY_PHASE1":3290,"PHASE1":3292,"PHASE2":3294,"PHASE3":3296,"PHASE4":3307,"NA":3309},{"trials":3291,"activeCount":109},[],{"trials":3293,"activeCount":109},[],{"trials":3295,"activeCount":109},[],{"trials":3297,"activeCount":109},[3298],{"nctId":3299,"briefTitle":3300,"status":850,"phases":3301,"primaryCompletion":3255,"completion":543,"start":3302,"enrollment":3303,"conditions":3304,"interventions":3306},"NCT01192503","Safety and Efficacy of Rasagiline in Restless Legs Syndrome",[90,91],"2010-09",52,[3305],"Restless Legs Syndrome",[3288],{"trials":3308,"activeCount":109},[],{"trials":3310,"activeCount":109},[],{"intervention":3312,"totalTrials":149,"cells":3313},"Midodrine Hydrochloride",{"EARLY_PHASE1":3314,"PHASE1":3316,"PHASE2":3318,"PHASE3":3320,"PHASE4":3330,"NA":3332},{"trials":3315,"activeCount":109},[],{"trials":3317,"activeCount":109},[],{"trials":3319,"activeCount":109},[],{"trials":3321,"activeCount":109},[3322],{"nctId":3323,"briefTitle":3324,"status":850,"phases":3325,"primaryCompletion":3326,"completion":3326,"start":3327,"enrollment":34,"conditions":3328,"interventions":3329},"NCT03706053","Midodrine Use in Septic Shock",[91],"2022-02-11","2018-11-05",[3281],[3312],{"trials":3331,"activeCount":109},[],{"trials":3333,"activeCount":109},[],{"intervention":2861,"totalTrials":149,"cells":3335},{"EARLY_PHASE1":3336,"PHASE1":3338,"PHASE2":3340,"PHASE3":3342,"PHASE4":3348,"NA":3350},{"trials":3337,"activeCount":109},[],{"trials":3339,"activeCount":109},[],{"trials":3341,"activeCount":109},[],{"trials":3343,"activeCount":109},[3344],{"nctId":2852,"briefTitle":2853,"status":169,"phases":3345,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":2857,"conditions":3346,"interventions":3347},[91],[2859],[2861,2862,870,2863],{"trials":3349,"activeCount":109},[],{"trials":3351,"activeCount":109},[],{"intervention":2862,"totalTrials":149,"cells":3353},{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3358,"PHASE3":3360,"PHASE4":3366,"NA":3368},{"trials":3355,"activeCount":109},[],{"trials":3357,"activeCount":109},[],{"trials":3359,"activeCount":109},[],{"trials":3361,"activeCount":109},[3362],{"nctId":2852,"briefTitle":2853,"status":169,"phases":3363,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":2857,"conditions":3364,"interventions":3365},[91],[2859],[2861,2862,870,2863],{"trials":3367,"activeCount":109},[],{"trials":3369,"activeCount":109},[],{"intervention":2863,"totalTrials":149,"cells":3371},{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3376,"PHASE3":3378,"PHASE4":3384,"NA":3386},{"trials":3373,"activeCount":109},[],{"trials":3375,"activeCount":109},[],{"trials":3377,"activeCount":109},[],{"trials":3379,"activeCount":109},[3380],{"nctId":2852,"briefTitle":2853,"status":169,"phases":3381,"primaryCompletion":2855,"completion":2855,"start":2856,"enrollment":2857,"conditions":3382,"interventions":3383},[91],[2859],[2861,2862,870,2863],{"trials":3385,"activeCount":109},[],{"trials":3387,"activeCount":109},[],{"intervention":3389,"totalTrials":508,"cells":3390},"sargramostim",{"EARLY_PHASE1":3391,"PHASE1":3393,"PHASE2":3408,"PHASE3":3444,"PHASE4":3446,"NA":3448},{"trials":3392,"activeCount":109},[],{"trials":3394,"activeCount":109},[3395],{"nctId":3396,"briefTitle":3397,"status":118,"phases":3398,"primaryCompletion":3399,"completion":2759,"start":3400,"enrollment":37,"conditions":3401,"interventions":3404},"NCT00091273","Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer",[89],"2006-02","2004-06",[3402,3403],"Ovarian Cancer","Primary Peritoneal Cavity Cancer",[3405,3406,3389,3407],"incomplete Freund's adjuvant","ovarian cancer peptide vaccine","tetanus toxoid helper peptide",{"trials":3409,"activeCount":109},[3410,3423,3433],{"nctId":3411,"briefTitle":3412,"status":118,"phases":3413,"primaryCompletion":3414,"start":3415,"enrollment":1191,"conditions":3416,"interventions":3418},"NCT00003222","Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma",[90],"2003-09","1998-04",[3417],"Melanoma (Skin)",[3419,3420,3405,3389,3421,3422],"aldesleukin","gp100 antigen","tetanus peptide melanoma vaccine","tyrosinase peptide",{"nctId":3424,"briefTitle":3425,"status":118,"phases":3426,"primaryCompletion":3427,"start":3428,"enrollment":854,"conditions":3429,"interventions":3431},"NCT00089206","Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery",[90],"2005-11","2002-08",[3430,3417],"Intraocular Melanoma",[3405,3432,3389],"multi-epitope melanoma peptide vaccine",{"nctId":3434,"briefTitle":3435,"status":3436,"phases":3437,"primaryCompletion":3438,"start":3439,"enrollment":3440,"conditions":3441,"interventions":3442},"NCT00278122","Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery","SUSPENDED",[90],"2015-12","2005-07",42,[3417],[3389,3443],"paclitaxel",{"trials":3445,"activeCount":109},[],{"trials":3447,"activeCount":109},[],{"trials":3449,"activeCount":109},[],{"intervention":3405,"totalTrials":97,"cells":3451},{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3460,"PHASE3":3470,"PHASE4":3472,"NA":3474},{"trials":3453,"activeCount":109},[],{"trials":3455,"activeCount":109},[3456],{"nctId":3396,"briefTitle":3397,"status":118,"phases":3457,"primaryCompletion":3399,"completion":2759,"start":3400,"enrollment":37,"conditions":3458,"interventions":3459},[89],[3402,3403],[3405,3406,3389,3407],{"trials":3461,"activeCount":109},[3462,3466],{"nctId":3411,"briefTitle":3412,"status":118,"phases":3463,"primaryCompletion":3414,"start":3415,"enrollment":1191,"conditions":3464,"interventions":3465},[90],[3417],[3419,3420,3405,3389,3421,3422],{"nctId":3424,"briefTitle":3425,"status":118,"phases":3467,"primaryCompletion":3427,"start":3428,"enrollment":854,"conditions":3468,"interventions":3469},[90],[3430,3417],[3405,3432,3389],{"trials":3471,"activeCount":109},[],{"trials":3473,"activeCount":109},[],{"trials":3475,"activeCount":109},[],{"intervention":3477,"totalTrials":154,"cells":3478},"docetaxel",{"EARLY_PHASE1":3479,"PHASE1":3481,"PHASE2":3491,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3480,"activeCount":109},[],{"trials":3482,"activeCount":109},[3483],{"nctId":3484,"briefTitle":3485,"status":118,"phases":3486,"start":3487,"enrollment":624,"conditions":3488,"interventions":3490},"NCT00114205","Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion",[89],"2003-07",[3489],"Metastatic Cancer",[3477],{"trials":3492,"activeCount":109},[3493],{"nctId":3494,"briefTitle":3495,"status":118,"phases":3496,"primaryCompletion":2759,"start":3400,"enrollment":735,"conditions":3497,"interventions":3499},"NCT00114192","Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer",[90],[3498],"Lung Cancer",[3477,3500],"thalidomide",{"trials":3502,"activeCount":109},[],{"trials":3504,"activeCount":109},[],{"trials":3506,"activeCount":109},[],{"intervention":3508,"totalTrials":154,"cells":3509},"IFA",{"EARLY_PHASE1":3510,"PHASE1":3512,"PHASE2":3526,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3511,"activeCount":109},[],{"trials":3513,"activeCount":109},[3514],{"nctId":3515,"briefTitle":3516,"status":118,"phases":3517,"primaryCompletion":3518,"start":3519,"enrollment":22,"conditions":3520,"interventions":3521},"NCT00003224","Vaccine Therapy in Treating Patients With Metastatic Melanoma",[89],"2000-08","1996-02",[3417],[3522,3508,3523,3524,3525],"QS21","p946","p946\u002Ftet-p","Tet-p",{"trials":3527,"activeCount":109},[3528],{"nctId":3529,"briefTitle":3530,"status":118,"phases":3531,"primaryCompletion":875,"start":3487,"enrollment":3532,"conditions":3533,"interventions":3534},"NCT00089219","Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma",[89,90],39,[3430,3417],[3508,3535,3536],"6MHP","GM-CSF",{"trials":3538,"activeCount":109},[],{"trials":3540,"activeCount":109},[],{"trials":3542,"activeCount":109},[],{"intervention":3536,"totalTrials":154,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3549,"PHASE3":3567,"PHASE4":3569,"NA":3571},{"trials":3546,"activeCount":109},[],{"trials":3548,"activeCount":109},[],{"trials":3550,"activeCount":109},[3551,3563],{"nctId":3552,"briefTitle":3553,"status":169,"phases":3554,"primaryCompletion":3555,"completion":3555,"start":3556,"enrollment":1191,"conditions":3557,"interventions":3560},"NCT02173093","Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma",[89,90],"2019-12","2014-11",[3558,3559],"Disseminated Neuroblastoma","Recurrent Neuroblastoma",[3561,3562,3536],"IL-2","GD2Bi-aATC",{"nctId":3529,"briefTitle":3530,"status":118,"phases":3564,"primaryCompletion":875,"start":3487,"enrollment":3532,"conditions":3565,"interventions":3566},[89,90],[3430,3417],[3508,3535,3536],{"trials":3568,"activeCount":109},[],{"trials":3570,"activeCount":109},[],{"trials":3572,"activeCount":109},[],{"intervention":3443,"totalTrials":154,"cells":3574},{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3589,"PHASE4":3591,"NA":3593},{"trials":3576,"activeCount":109},[],{"trials":3578,"activeCount":109},[],{"trials":3580,"activeCount":109},[3581,3585],{"nctId":3434,"briefTitle":3435,"status":3436,"phases":3582,"primaryCompletion":3438,"start":3439,"enrollment":3440,"conditions":3583,"interventions":3584},[90],[3417],[3389,3443],{"nctId":893,"briefTitle":894,"status":104,"phases":3586,"primaryCompletion":896,"completion":896,"start":897,"enrollment":109,"conditions":3587,"interventions":3588},[90],[30,899],[901,902,815,903,904],{"trials":3590,"activeCount":109},[],{"trials":3592,"activeCount":109},[],{"trials":3594,"activeCount":109},[],{"intervention":3500,"totalTrials":149,"cells":3596},{"EARLY_PHASE1":3597,"PHASE1":3599,"PHASE2":3601,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3598,"activeCount":109},[],{"trials":3600,"activeCount":109},[],{"trials":3602,"activeCount":109},[3603],{"nctId":3494,"briefTitle":3495,"status":118,"phases":3604,"primaryCompletion":2759,"start":3400,"enrollment":735,"conditions":3605,"interventions":3606},[90],[3498],[3477,3500],{"trials":3608,"activeCount":109},[],{"trials":3610,"activeCount":109},[],{"trials":3612,"activeCount":109},[],{"intervention":3614,"totalTrials":149,"cells":3615},"Genistein",{"EARLY_PHASE1":3616,"PHASE1":3618,"PHASE2":3620,"PHASE3":3646,"PHASE4":3648,"NA":3650},{"trials":3617,"activeCount":109},[],{"trials":3619,"activeCount":109},[],{"trials":3621,"activeCount":109},[3622],{"nctId":3623,"briefTitle":3624,"status":850,"phases":3625,"primaryCompletion":3626,"completion":3626,"start":3627,"enrollment":508,"conditions":3628,"interventions":3645},"NCT02624388","Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)",[90],"2021-09","2016-08",[3629,3630,3631,3632,3633,3634,3635,3636,3637,3638,3639,3640,3641,3642,3643,3644],"Lymphoma","Childhood Lymphoma","Solid Tumor","Childhood Solid Tumor","Neuroblastoma","Ewing Sarcoma","Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Rhabdomyosarcoma","Soft Tissue Sarcoma","Medulloblastoma","Germ Cell Tumor","Wilms Tumor","Brain Neoplasms","Medulloblastoma, Childhood","Neuroectodermal Tumors, Primitive",[3614],{"trials":3647,"activeCount":109},[],{"trials":3649,"activeCount":109},[],{"trials":3651,"activeCount":109},[],{"intervention":3653,"totalTrials":149,"cells":3654},"Riboflavin",{"EARLY_PHASE1":3655,"PHASE1":3657,"PHASE2":3659,"PHASE3":3670,"PHASE4":3672,"NA":3674},{"trials":3656,"activeCount":109},[],{"trials":3658,"activeCount":109},[],{"trials":3660,"activeCount":109},[3661],{"nctId":3662,"briefTitle":3663,"status":169,"phases":3664,"primaryCompletion":3665,"completion":3555,"start":3627,"enrollment":3666,"conditions":3667,"interventions":3669},"NCT02772237","The Impact of Riboflavin on Sports-related Concussion",[90],"2018-12",500,[3668],"Sports-related Concussion",[3653],{"trials":3671,"activeCount":109},[],{"trials":3673,"activeCount":109},[],{"trials":3675,"activeCount":109},[],{"intervention":3677,"totalTrials":149,"cells":3678},"tenecteplase",{"EARLY_PHASE1":3679,"PHASE1":3681,"PHASE2":3683,"PHASE3":3695,"PHASE4":3697,"NA":3699},{"trials":3680,"activeCount":109},[],{"trials":3682,"activeCount":109},[],{"trials":3684,"activeCount":109},[3685],{"nctId":3686,"briefTitle":3687,"status":850,"phases":3688,"primaryCompletion":1995,"completion":3689,"start":3427,"enrollment":3690,"conditions":3691,"interventions":3693},"NCT00252239","Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)",[90],"2009-09",112,[3692],"Stroke",[3677,3694],"tissue plasminogen activator, tPA",{"trials":3696,"activeCount":109},[],{"trials":3698,"activeCount":109},[],{"trials":3700,"activeCount":109},[],{"intervention":3694,"totalTrials":149,"cells":3702},{"EARLY_PHASE1":3703,"PHASE1":3705,"PHASE2":3707,"PHASE3":3713,"PHASE4":3715,"NA":3717},{"trials":3704,"activeCount":109},[],{"trials":3706,"activeCount":109},[],{"trials":3708,"activeCount":109},[3709],{"nctId":3686,"briefTitle":3687,"status":850,"phases":3710,"primaryCompletion":1995,"completion":3689,"start":3427,"enrollment":3690,"conditions":3711,"interventions":3712},[90],[3692],[3677,3694],{"trials":3714,"activeCount":109},[],{"trials":3716,"activeCount":109},[],{"trials":3718,"activeCount":109},[],{"intervention":3419,"totalTrials":149,"cells":3720},{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3725,"PHASE3":3731,"PHASE4":3733,"NA":3735},{"trials":3722,"activeCount":109},[],{"trials":3724,"activeCount":109},[],{"trials":3726,"activeCount":109},[3727],{"nctId":3411,"briefTitle":3412,"status":118,"phases":3728,"primaryCompletion":3414,"start":3415,"enrollment":1191,"conditions":3729,"interventions":3730},[90],[3417],[3419,3420,3405,3389,3421,3422],{"trials":3732,"activeCount":109},[],{"trials":3734,"activeCount":109},[],{"trials":3736,"activeCount":109},[],{"intervention":3420,"totalTrials":149,"cells":3738},{"EARLY_PHASE1":3739,"PHASE1":3741,"PHASE2":3743,"PHASE3":3749,"PHASE4":3751,"NA":3753},{"trials":3740,"activeCount":109},[],{"trials":3742,"activeCount":109},[],{"trials":3744,"activeCount":109},[3745],{"nctId":3411,"briefTitle":3412,"status":118,"phases":3746,"primaryCompletion":3414,"start":3415,"enrollment":1191,"conditions":3747,"interventions":3748},[90],[3417],[3419,3420,3405,3389,3421,3422],{"trials":3750,"activeCount":109},[],{"trials":3752,"activeCount":109},[],{"trials":3754,"activeCount":109},[],{"intervention":3421,"totalTrials":149,"cells":3756},{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3761,"PHASE3":3767,"PHASE4":3769,"NA":3771},{"trials":3758,"activeCount":109},[],{"trials":3760,"activeCount":109},[],{"trials":3762,"activeCount":109},[3763],{"nctId":3411,"briefTitle":3412,"status":118,"phases":3764,"primaryCompletion":3414,"start":3415,"enrollment":1191,"conditions":3765,"interventions":3766},[90],[3417],[3419,3420,3405,3389,3421,3422],{"trials":3768,"activeCount":109},[],{"trials":3770,"activeCount":109},[],{"trials":3772,"activeCount":109},[],{"intervention":3422,"totalTrials":149,"cells":3774},{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3779,"PHASE3":3785,"PHASE4":3787,"NA":3789},{"trials":3776,"activeCount":109},[],{"trials":3778,"activeCount":109},[],{"trials":3780,"activeCount":109},[3781],{"nctId":3411,"briefTitle":3412,"status":118,"phases":3782,"primaryCompletion":3414,"start":3415,"enrollment":1191,"conditions":3783,"interventions":3784},[90],[3417],[3419,3420,3405,3389,3421,3422],{"trials":3786,"activeCount":109},[],{"trials":3788,"activeCount":109},[],{"trials":3790,"activeCount":109},[],{"intervention":3792,"totalTrials":149,"cells":3793},"IV glucose insulin and potassium, GIK",{"EARLY_PHASE1":3794,"PHASE1":3796,"PHASE2":3798,"PHASE3":3809,"PHASE4":3811,"NA":3813},{"trials":3795,"activeCount":109},[],{"trials":3797,"activeCount":109},[],{"trials":3799,"activeCount":109},[3800],{"nctId":3801,"briefTitle":3802,"status":118,"phases":3803,"primaryCompletion":3804,"completion":3805,"start":875,"enrollment":3806,"conditions":3807,"interventions":3808},"NCT00282867","Glucose Regulation in Acute Stroke Patients (GRASP) Study",[90],"2008-02","2009-02",74,[3692,3189],[3792],{"trials":3810,"activeCount":109},[],{"trials":3812,"activeCount":109},[],{"trials":3814,"activeCount":109},[],{"intervention":3816,"totalTrials":149,"cells":3817},"ticagrelor",{"EARLY_PHASE1":3818,"PHASE1":3820,"PHASE2":3822,"PHASE3":3835,"PHASE4":3837,"NA":3839},{"trials":3819,"activeCount":109},[],{"trials":3821,"activeCount":109},[],{"trials":3823,"activeCount":109},[3824],{"nctId":3825,"briefTitle":3826,"status":118,"phases":3827,"primaryCompletion":3828,"completion":3828,"start":3829,"enrollment":3830,"conditions":3831,"interventions":3834},"NCT02335099","Determine the Safety\u002FEfficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis",[89,90],"2019-06","2014-12",54,[3832,3833],"End Stage Renal Disease","Vascular Access Patency",[3816],{"trials":3836,"activeCount":109},[],{"trials":3838,"activeCount":109},[],{"trials":3840,"activeCount":109},[],{"intervention":3561,"totalTrials":149,"cells":3842},{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3853,"PHASE4":3855,"NA":3857},{"trials":3844,"activeCount":109},[],{"trials":3846,"activeCount":109},[],{"trials":3848,"activeCount":109},[3849],{"nctId":3552,"briefTitle":3553,"status":169,"phases":3850,"primaryCompletion":3555,"completion":3555,"start":3556,"enrollment":1191,"conditions":3851,"interventions":3852},[89,90],[3558,3559],[3561,3562,3536],{"trials":3854,"activeCount":109},[],{"trials":3856,"activeCount":109},[],{"trials":3858,"activeCount":109},[],{"intervention":3562,"totalTrials":149,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3862,"activeCount":109},[],{"trials":3864,"activeCount":109},[],{"trials":3866,"activeCount":109},[3867],{"nctId":3552,"briefTitle":3553,"status":169,"phases":3868,"primaryCompletion":3555,"completion":3555,"start":3556,"enrollment":1191,"conditions":3869,"interventions":3870},[89,90],[3558,3559],[3561,3562,3536],{"trials":3872,"activeCount":109},[],{"trials":3874,"activeCount":109},[],{"trials":3876,"activeCount":109},[],{"intervention":3878,"totalTrials":149,"cells":3879},"Definity",{"EARLY_PHASE1":3880,"PHASE1":3882,"PHASE2":3884,"PHASE3":3898,"PHASE4":3900,"NA":3902},{"trials":3881,"activeCount":109},[],{"trials":3883,"activeCount":109},[],{"trials":3885,"activeCount":109},[3886],{"nctId":3887,"briefTitle":3888,"status":169,"phases":3889,"primaryCompletion":3890,"completion":3891,"start":3892,"enrollment":3893,"conditions":3894,"interventions":3897},"NCT02672722","Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound",[89,90],"2017-08","2017-10","2016-01",19,[3895,3896],"Healthy","Physiology",[3878],{"trials":3899,"activeCount":109},[],{"trials":3901,"activeCount":109},[],{"trials":3903,"activeCount":109},[],{"intervention":3905,"totalTrials":149,"cells":3906},"Olanzapine",{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3911,"PHASE3":3922,"PHASE4":3924,"NA":3926},{"trials":3908,"activeCount":109},[],{"trials":3910,"activeCount":109},[],{"trials":3912,"activeCount":109},[3913],{"nctId":3914,"briefTitle":3915,"status":118,"phases":3916,"primaryCompletion":3917,"completion":3917,"start":3918,"enrollment":1191,"conditions":3919,"interventions":3920},"NCT00678457","Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial",[90],"2008-05","2007-01",[3025],[3921,3905],"Ondansetron",{"trials":3923,"activeCount":109},[],{"trials":3925,"activeCount":109},[],{"trials":3927,"activeCount":109},[],{"intervention":3432,"totalTrials":149,"cells":3929},{"EARLY_PHASE1":3930,"PHASE1":3932,"PHASE2":3934,"PHASE3":3940,"PHASE4":3942,"NA":3944},{"trials":3931,"activeCount":109},[],{"trials":3933,"activeCount":109},[],{"trials":3935,"activeCount":109},[3936],{"nctId":3424,"briefTitle":3425,"status":118,"phases":3937,"primaryCompletion":3427,"start":3428,"enrollment":854,"conditions":3938,"interventions":3939},[90],[3430,3417],[3405,3432,3389],{"trials":3941,"activeCount":109},[],{"trials":3943,"activeCount":109},[],{"trials":3945,"activeCount":109},[],{"intervention":3947,"totalTrials":149,"cells":3948},"Dupilumab",{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3953,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3950,"activeCount":109},[],{"trials":3952,"activeCount":109},[],{"trials":3954,"activeCount":109},[3955],{"nctId":3956,"briefTitle":3957,"status":118,"phases":3958,"primaryCompletion":3959,"completion":3959,"start":3960,"enrollment":1191,"conditions":3961,"interventions":3963},"NCT04920916","Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients",[90],"2023-04-18","2021-05-25",[3962],"COVID-19",[3947],{"trials":3965,"activeCount":109},[],{"trials":3967,"activeCount":109},[],{"trials":3969,"activeCount":109},[],{"intervention":3535,"totalTrials":149,"cells":3971},{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3982,"PHASE4":3984,"NA":3986},{"trials":3973,"activeCount":109},[],{"trials":3975,"activeCount":109},[],{"trials":3977,"activeCount":109},[3978],{"nctId":3529,"briefTitle":3530,"status":118,"phases":3979,"primaryCompletion":875,"start":3487,"enrollment":3532,"conditions":3980,"interventions":3981},[89,90],[3430,3417],[3508,3535,3536],{"trials":3983,"activeCount":109},[],{"trials":3985,"activeCount":109},[],{"trials":3987,"activeCount":109},[],{"intervention":3989,"totalTrials":149,"cells":3990},"human rhinovirus",{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3995,"PHASE3":4007,"PHASE4":4009,"NA":4011},{"trials":3992,"activeCount":109},[],{"trials":3994,"activeCount":109},[],{"trials":3996,"activeCount":109},[3997],{"nctId":3998,"briefTitle":3999,"status":118,"phases":4000,"primaryCompletion":4001,"completion":4001,"start":4002,"enrollment":4003,"conditions":4004,"interventions":4006},"NCT02796001","Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans",[89,90],"2020-05-01","2017-09-25",46,[4005],"Healthy Volunteers",[3989],{"trials":4008,"activeCount":109},[],{"trials":4010,"activeCount":109},[],{"trials":4012,"activeCount":109},[],{"intervention":4014,"totalTrials":149,"cells":4015},"Topiramate",{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4020,"PHASE3":4030,"PHASE4":4032,"NA":4034},{"trials":4017,"activeCount":109},[],{"trials":4019,"activeCount":109},[],{"trials":4021,"activeCount":109},[4022],{"nctId":4023,"briefTitle":4024,"status":118,"phases":4025,"primaryCompletion":2595,"completion":2595,"start":4026,"enrollment":2007,"conditions":4027,"interventions":4029},"NCT00300742","Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals",[90],"2006-03",[3025,4028],"Binge Eating",[4014],{"trials":4031,"activeCount":109},[],{"trials":4033,"activeCount":109},[],{"trials":4035,"activeCount":109},[],{"intervention":4037,"totalTrials":149,"cells":4038},"omalizumab",{"EARLY_PHASE1":4039,"PHASE1":4041,"PHASE2":4043,"PHASE3":4054,"PHASE4":4056,"NA":4058},{"trials":4040,"activeCount":109},[],{"trials":4042,"activeCount":109},[],{"trials":4044,"activeCount":109},[4045],{"nctId":4046,"briefTitle":4047,"status":118,"phases":4048,"primaryCompletion":4049,"completion":4049,"start":4050,"enrollment":2553,"conditions":4051,"interventions":4052},"NCT02388997","Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus",[90],"2017-05-04","2013-02-01",[252],[4037,4053],"Rhinovirus",{"trials":4055,"activeCount":109},[],{"trials":4057,"activeCount":109},[],{"trials":4059,"activeCount":109},[],{"intervention":4061,"totalTrials":149,"cells":4062},"Melphalan",{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4067,"PHASE3":4077,"PHASE4":4079,"NA":4081},{"trials":4064,"activeCount":109},[],{"trials":4066,"activeCount":109},[],{"trials":4068,"activeCount":109},[4069],{"nctId":4070,"briefTitle":4071,"status":850,"phases":4072,"primaryCompletion":853,"start":3184,"enrollment":149,"conditions":4073,"interventions":4075},"NCT01617213","Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma",[90],[4074],"Multiple Myeloma",[4061,4076],"Lenalidomide",{"trials":4078,"activeCount":109},[],{"trials":4080,"activeCount":109},[],{"trials":4082,"activeCount":109},[],{"intervention":4076,"totalTrials":149,"cells":4084},{"EARLY_PHASE1":4085,"PHASE1":4087,"PHASE2":4089,"PHASE3":4095,"PHASE4":4097,"NA":4099},{"trials":4086,"activeCount":109},[],{"trials":4088,"activeCount":109},[],{"trials":4090,"activeCount":109},[4091],{"nctId":4070,"briefTitle":4071,"status":850,"phases":4092,"primaryCompletion":853,"start":3184,"enrollment":149,"conditions":4093,"interventions":4094},[90],[4074],[4061,4076],{"trials":4096,"activeCount":109},[],{"trials":4098,"activeCount":109},[],{"trials":4100,"activeCount":109},[],{"intervention":4102,"totalTrials":149,"cells":4103},"bortezomib",{"EARLY_PHASE1":4104,"PHASE1":4106,"PHASE2":4108,"PHASE3":4117,"PHASE4":4119,"NA":4121},{"trials":4105,"activeCount":109},[],{"trials":4107,"activeCount":109},[],{"trials":4109,"activeCount":109},[4110],{"nctId":4111,"briefTitle":4112,"status":850,"phases":4113,"enrollment":4003,"conditions":4114,"interventions":4115},"NCT00265928","Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",[90],[3629],[4102,4116],"rituximab",{"trials":4118,"activeCount":109},[],{"trials":4120,"activeCount":109},[],{"trials":4122,"activeCount":109},[],{"intervention":4116,"totalTrials":149,"cells":4124},{"EARLY_PHASE1":4125,"PHASE1":4127,"PHASE2":4129,"PHASE3":4135,"PHASE4":4137,"NA":4139},{"trials":4126,"activeCount":109},[],{"trials":4128,"activeCount":109},[],{"trials":4130,"activeCount":109},[4131],{"nctId":4111,"briefTitle":4112,"status":850,"phases":4132,"enrollment":4003,"conditions":4133,"interventions":4134},[90],[3629],[4102,4116],{"trials":4136,"activeCount":109},[],{"trials":4138,"activeCount":109},[],{"trials":4140,"activeCount":109},[],{"intervention":4142,"totalTrials":149,"cells":4143},"Zibotentan",{"EARLY_PHASE1":4144,"PHASE1":4146,"PHASE2":4148,"PHASE3":4158,"PHASE4":4160,"NA":4162},{"trials":4145,"activeCount":109},[],{"trials":4147,"activeCount":109},[],{"trials":4149,"activeCount":109},[4150],{"nctId":4151,"briefTitle":4152,"status":118,"phases":4153,"primaryCompletion":2552,"completion":2552,"start":4154,"enrollment":2553,"conditions":4155,"interventions":4157},"NCT01890135","Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication",[90],"2013-06",[2804,4156],"Intermittent Claudication",[4142],{"trials":4159,"activeCount":109},[],{"trials":4161,"activeCount":109},[],{"trials":4163,"activeCount":109},[],{"intervention":4165,"totalTrials":149,"cells":4166},"Orally active growth hormone secretagogue",{"EARLY_PHASE1":4167,"PHASE1":4169,"PHASE2":4171,"PHASE3":4182,"PHASE4":4184,"NA":4186},{"trials":4168,"activeCount":109},[],{"trials":4170,"activeCount":109},[],{"trials":4172,"activeCount":109},[4173],{"nctId":4174,"briefTitle":4175,"status":118,"phases":4176,"completion":3400,"start":4177,"enrollment":4178,"conditions":4179,"interventions":4181},"NCT00474279","Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults",[89,90],"1998-07",72,[4180],"Aging",[4165],{"trials":4183,"activeCount":109},[],{"trials":4185,"activeCount":109},[],{"trials":4187,"activeCount":109},[],{"intervention":901,"totalTrials":149,"cells":4189},{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4194,"PHASE3":4200,"PHASE4":4202,"NA":4204},{"trials":4191,"activeCount":109},[],{"trials":4193,"activeCount":109},[],{"trials":4195,"activeCount":109},[4196],{"nctId":893,"briefTitle":894,"status":104,"phases":4197,"primaryCompletion":896,"completion":896,"start":897,"enrollment":109,"conditions":4198,"interventions":4199},[90],[30,899],[901,902,815,903,904],{"trials":4201,"activeCount":109},[],{"trials":4203,"activeCount":109},[],{"trials":4205,"activeCount":109},[],{"intervention":902,"totalTrials":149,"cells":4207},{"EARLY_PHASE1":4208,"PHASE1":4210,"PHASE2":4212,"PHASE3":4218,"PHASE4":4220,"NA":4222},{"trials":4209,"activeCount":109},[],{"trials":4211,"activeCount":109},[],{"trials":4213,"activeCount":109},[4214],{"nctId":893,"briefTitle":894,"status":104,"phases":4215,"primaryCompletion":896,"completion":896,"start":897,"enrollment":109,"conditions":4216,"interventions":4217},[90],[30,899],[901,902,815,903,904],{"trials":4219,"activeCount":109},[],{"trials":4221,"activeCount":109},[],{"trials":4223,"activeCount":109},[],{"intervention":903,"totalTrials":149,"cells":4225},{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4230,"PHASE3":4236,"PHASE4":4238,"NA":4240},{"trials":4227,"activeCount":109},[],{"trials":4229,"activeCount":109},[],{"trials":4231,"activeCount":109},[4232],{"nctId":893,"briefTitle":894,"status":104,"phases":4233,"primaryCompletion":896,"completion":896,"start":897,"enrollment":109,"conditions":4234,"interventions":4235},[90],[30,899],[901,902,815,903,904],{"trials":4237,"activeCount":109},[],{"trials":4239,"activeCount":109},[],{"trials":4241,"activeCount":109},[],{"intervention":4243,"totalTrials":149,"cells":4244},"Donepezil",{"EARLY_PHASE1":4245,"PHASE1":4247,"PHASE2":4249,"PHASE3":4261,"PHASE4":4263,"NA":4265},{"trials":4246,"activeCount":109},[],{"trials":4248,"activeCount":109},[],{"trials":4250,"activeCount":109},[4251],{"nctId":4252,"briefTitle":4253,"status":118,"phases":4254,"primaryCompletion":4255,"completion":4256,"start":4257,"enrollment":2252,"conditions":4258,"interventions":4260},"NCT06903910","Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease",[90],"2025-06-30","2026-01-31","2024-11-01",[4259],"Parkinson Disease",[4243],{"trials":4262,"activeCount":109},[],{"trials":4264,"activeCount":109},[],{"trials":4266,"activeCount":109},[],{"intervention":4268,"totalTrials":149,"cells":4269},"Dovitinib",{"EARLY_PHASE1":4270,"PHASE1":4272,"PHASE2":4274,"PHASE3":4285,"PHASE4":4287,"NA":4289},{"trials":4271,"activeCount":109},[],{"trials":4273,"activeCount":109},[],{"trials":4275,"activeCount":109},[4276],{"nctId":4277,"briefTitle":4278,"status":118,"phases":4279,"primaryCompletion":4280,"completion":3438,"start":4281,"enrollment":545,"conditions":4282,"interventions":4284},"NCT01524692","Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma",[90],"2014-01","2012-03",[4283],"Adenoid Cystic Carcinoma",[4268],{"trials":4286,"activeCount":109},[],{"trials":4288,"activeCount":109},[],{"trials":4290,"activeCount":109},[],{"intervention":4292,"totalTrials":149,"cells":4293},"Bexarotene",{"EARLY_PHASE1":4294,"PHASE1":4296,"PHASE2":4298,"PHASE3":4308,"PHASE4":4310,"NA":4312},{"trials":4295,"activeCount":109},[],{"trials":4297,"activeCount":109},[],{"trials":4299,"activeCount":109},[4300],{"nctId":4301,"briefTitle":4302,"status":169,"phases":4303,"primaryCompletion":2855,"completion":2855,"start":4304,"enrollment":2252,"conditions":4305,"interventions":4307},"NCT00845351","Preoperative Bexarotene Treatment for Cushing's Disease",[89,90],"2008-11",[4306],"Cushing's Disease",[4292],{"trials":4309,"activeCount":109},[],{"trials":4311,"activeCount":109},[],{"trials":4313,"activeCount":109},[],{"intervention":4315,"totalTrials":149,"cells":4316},"Fludarabine",{"EARLY_PHASE1":4317,"PHASE1":4319,"PHASE2":4321,"PHASE3":4336,"PHASE4":4338,"NA":4340},{"trials":4318,"activeCount":109},[],{"trials":4320,"activeCount":109},[],{"trials":4322,"activeCount":109},[4323],{"nctId":4324,"briefTitle":4325,"status":850,"phases":4326,"primaryCompletion":4327,"completion":4328,"start":4329,"enrollment":2252,"conditions":4330,"interventions":4332},"NCT01622556","Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies",[90],"2014-02","2017-01","2012-01",[4331],"Hematologic Malignancies",[4315,4333,4334,4335],"Busulfan","Thymoglobulin","Umbilical Cord Blood",{"trials":4337,"activeCount":109},[],{"trials":4339,"activeCount":109},[],{"trials":4341,"activeCount":109},[],{"intervention":4333,"totalTrials":149,"cells":4343},{"EARLY_PHASE1":4344,"PHASE1":4346,"PHASE2":4348,"PHASE3":4354,"PHASE4":4356,"NA":4358},{"trials":4345,"activeCount":109},[],{"trials":4347,"activeCount":109},[],{"trials":4349,"activeCount":109},[4350],{"nctId":4324,"briefTitle":4325,"status":850,"phases":4351,"primaryCompletion":4327,"completion":4328,"start":4329,"enrollment":2252,"conditions":4352,"interventions":4353},[90],[4331],[4315,4333,4334,4335],{"trials":4355,"activeCount":109},[],{"trials":4357,"activeCount":109},[],{"trials":4359,"activeCount":109},[],{"intervention":4334,"totalTrials":149,"cells":4361},{"EARLY_PHASE1":4362,"PHASE1":4364,"PHASE2":4366,"PHASE3":4372,"PHASE4":4374,"NA":4376},{"trials":4363,"activeCount":109},[],{"trials":4365,"activeCount":109},[],{"trials":4367,"activeCount":109},[4368],{"nctId":4324,"briefTitle":4325,"status":850,"phases":4369,"primaryCompletion":4327,"completion":4328,"start":4329,"enrollment":2252,"conditions":4370,"interventions":4371},[90],[4331],[4315,4333,4334,4335],{"trials":4373,"activeCount":109},[],{"trials":4375,"activeCount":109},[],{"trials":4377,"activeCount":109},[],{"intervention":4335,"totalTrials":149,"cells":4379},{"EARLY_PHASE1":4380,"PHASE1":4382,"PHASE2":4384,"PHASE3":4390,"PHASE4":4392,"NA":4394},{"trials":4381,"activeCount":109},[],{"trials":4383,"activeCount":109},[],{"trials":4385,"activeCount":109},[4386],{"nctId":4324,"briefTitle":4325,"status":850,"phases":4387,"primaryCompletion":4327,"completion":4328,"start":4329,"enrollment":2252,"conditions":4388,"interventions":4389},[90],[4331],[4315,4333,4334,4335],{"trials":4391,"activeCount":109},[],{"trials":4393,"activeCount":109},[],{"trials":4395,"activeCount":109},[],{"intervention":4397,"totalTrials":149,"cells":4398},"Dulaglutide",{"EARLY_PHASE1":4399,"PHASE1":4401,"PHASE2":4403,"PHASE3":4416,"PHASE4":4418,"NA":4420},{"trials":4400,"activeCount":109},[],{"trials":4402,"activeCount":109},[],{"trials":4404,"activeCount":109},[4405],{"nctId":4406,"briefTitle":4407,"status":3436,"phases":4408,"primaryCompletion":4409,"completion":4410,"start":4411,"enrollment":4412,"conditions":4413,"interventions":4415},"NCT05478707","Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes",[90],"2028-06-30","2028-07-30","2023-10-05",47,[21,4414],"Endothelial Dysfunction",[4397],{"trials":4417,"activeCount":109},[],{"trials":4419,"activeCount":109},[],{"trials":4421,"activeCount":109},[],{"intervention":4423,"totalTrials":149,"cells":4424},"Baclofen",{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4429,"PHASE3":4441,"PHASE4":4443,"NA":4445},{"trials":4426,"activeCount":109},[],{"trials":4428,"activeCount":109},[],{"trials":4430,"activeCount":109},[4431],{"nctId":4432,"briefTitle":4433,"status":118,"phases":4434,"primaryCompletion":4435,"completion":3556,"start":4436,"enrollment":34,"conditions":4437,"interventions":4440},"NCT02298868","Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study",[90],"2013-11","2012-10",[4438,4439],"Muscle Cramps","Cirrhosis",[4423],{"trials":4442,"activeCount":109},[],{"trials":4444,"activeCount":109},[],{"trials":4446,"activeCount":109},[],{"intervention":2922,"totalTrials":149,"cells":4448},{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4453,"PHASE3":4459,"PHASE4":4461,"NA":4463},{"trials":4450,"activeCount":109},[],{"trials":4452,"activeCount":109},[],{"trials":4454,"activeCount":109},[4455],{"nctId":2912,"briefTitle":2913,"status":118,"phases":4456,"primaryCompletion":2915,"completion":2916,"start":2917,"enrollment":2918,"conditions":4457,"interventions":4458},[90],[2903,2920],[2903,2922],{"trials":4460,"activeCount":109},[],{"trials":4462,"activeCount":109},[],{"trials":4464,"activeCount":109},[],{"intervention":4466,"totalTrials":149,"cells":4467},"Oral 2-Deoxy-D-Glucose",{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4472,"PHASE3":4483,"PHASE4":4485,"NA":4487},{"trials":4469,"activeCount":109},[],{"trials":4471,"activeCount":109},[],{"trials":4473,"activeCount":109},[4474],{"nctId":4475,"briefTitle":4476,"status":118,"phases":4477,"primaryCompletion":4478,"completion":4478,"start":4479,"enrollment":37,"conditions":4480,"interventions":4482},"NCT05605301","Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy",[90],"2024-02-05","2022-09-02",[4481],"Epilepsy; Seizure",[4466],{"trials":4484,"activeCount":109},[],{"trials":4486,"activeCount":109},[],{"trials":4488,"activeCount":109},[],{"intervention":4490,"totalTrials":149,"cells":4491},"low-dose IL-2",{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4509,"PHASE4":4511,"NA":4513},{"trials":4493,"activeCount":109},[],{"trials":4495,"activeCount":109},[],{"trials":4497,"activeCount":109},[4498],{"nctId":4499,"briefTitle":4500,"status":118,"phases":4501,"primaryCompletion":4502,"completion":4503,"start":4504,"enrollment":2997,"conditions":4505,"interventions":4507},"NCT00928902","Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma",[90],"2001-04","2005-03","1999-11",[4506],"Melanoma",[4490,4508],"melanoma vaccine",{"trials":4510,"activeCount":109},[],{"trials":4512,"activeCount":109},[],{"trials":4514,"activeCount":109},[],{"intervention":4508,"totalTrials":149,"cells":4516},{"EARLY_PHASE1":4517,"PHASE1":4519,"PHASE2":4521,"PHASE3":4527,"PHASE4":4529,"NA":4531},{"trials":4518,"activeCount":109},[],{"trials":4520,"activeCount":109},[],{"trials":4522,"activeCount":109},[4523],{"nctId":4499,"briefTitle":4500,"status":118,"phases":4524,"primaryCompletion":4502,"completion":4503,"start":4504,"enrollment":2997,"conditions":4525,"interventions":4526},[90],[4506],[4490,4508],{"trials":4528,"activeCount":109},[],{"trials":4530,"activeCount":109},[],{"trials":4532,"activeCount":109},[],{"intervention":4534,"totalTrials":149,"cells":4535},"High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma",{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4540,"PHASE3":4555,"PHASE4":4557,"NA":4559},{"trials":4537,"activeCount":109},[],{"trials":4539,"activeCount":109},[],{"trials":4541,"activeCount":109},[4542],{"nctId":4543,"briefTitle":4544,"status":118,"phases":4545,"primaryCompletion":4546,"completion":4546,"start":4547,"enrollment":4548,"conditions":4549,"interventions":4554},"NCT04374565","Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia",[90],"2021-03-05","2020-05-05",29,[4550,4551,4552,4553],"Corona Virus Infection","SARS-CoV 2","SARS Pneumonia","Pneumonia",[4534],{"trials":4556,"activeCount":109},[],{"trials":4558,"activeCount":109},[],{"trials":4560,"activeCount":109},[],{"intervention":4562,"totalTrials":149,"cells":4563},"Cetuximab",{"EARLY_PHASE1":4564,"PHASE1":4566,"PHASE2":4568,"PHASE3":4578,"PHASE4":4580,"NA":4582},{"trials":4565,"activeCount":109},[],{"trials":4567,"activeCount":109},[],{"trials":4569,"activeCount":109},[4570],{"nctId":4571,"briefTitle":4572,"status":169,"phases":4573,"primaryCompletion":4574,"start":3399,"enrollment":394,"conditions":4575,"interventions":4577},"NCT00292955","Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma",[90],"2012-02",[4576],"Cancer of the Cervix",[4562],{"trials":4579,"activeCount":109},[],{"trials":4581,"activeCount":109},[],{"trials":4583,"activeCount":109},[],{"intervention":4585,"totalTrials":149,"cells":4586},"SLAMF7 FPBMC",{"EARLY_PHASE1":4587,"PHASE1":4589,"PHASE2":4591,"PHASE3":4601,"PHASE4":4603,"NA":4605},{"trials":4588,"activeCount":109},[],{"trials":4590,"activeCount":109},[],{"trials":4592,"activeCount":109},[4593],{"nctId":4594,"briefTitle":4595,"status":104,"phases":4596,"primaryCompletion":4597,"completion":4597,"start":4598,"enrollment":109,"conditions":4599,"interventions":4600},"NCT04864522","Phase I\u002FII Study of SLAMF7 FPBMC\u002FCS-1 FPBMC in Relapsed\u002FRefractory Multiple Myeloma",[89,90],"2023-11","2023-08",[4074],[4585],{"trials":4602,"activeCount":109},[],{"trials":4604,"activeCount":109},[],{"trials":4606,"activeCount":109},[],{"intervention":4608,"totalTrials":154,"cells":4609},"BEET IT - Concentrate Beet root juice",{"EARLY_PHASE1":4610,"PHASE1":4612,"PHASE2":4633,"PHASE3":4635,"PHASE4":4637,"NA":4639},{"trials":4611,"activeCount":109},[],{"trials":4613,"activeCount":109},[4614,4624],{"nctId":4615,"briefTitle":4616,"status":118,"phases":4617,"primaryCompletion":4618,"completion":4618,"start":4619,"enrollment":624,"conditions":4620,"interventions":4623},"NCT05221905","Effects of Inorganic Nitrate and Intensity of Exercise on Cardiovascular Health in Post-Menopausal Females",[89],"2023-04-01","2021-11-01",[4621,4622],"Vascular Dilation","Arterial Stiffness",[4608,4608],{"nctId":4625,"briefTitle":4626,"status":169,"phases":4627,"primaryCompletion":2060,"completion":2060,"start":4628,"enrollment":4629,"conditions":4630,"interventions":4632},"NCT05036213","The Effects of Oral Inorganic Nitrate Supplementation on Lower Limb Perfusion During Exercise in Patients With PAD",[89],"2020-02-01",28,[2804,4631],"Peripheral Vascular Diseases",[4608,4608],{"trials":4634,"activeCount":109},[],{"trials":4636,"activeCount":109},[],{"trials":4638,"activeCount":109},[],{"trials":4640,"activeCount":109},[],{"intervention":4642,"totalTrials":154,"cells":4643},"oral micronized progesterone suspension",{"EARLY_PHASE1":4644,"PHASE1":4646,"PHASE2":4667,"PHASE3":4669,"PHASE4":4671,"NA":4673},{"trials":4645,"activeCount":109},[],{"trials":4647,"activeCount":109},[4648,4658],{"nctId":4649,"briefTitle":4650,"status":118,"phases":4651,"primaryCompletion":4652,"completion":4652,"start":4653,"enrollment":4654,"conditions":4655,"interventions":4657},"NCT00594217","Determining How Quickly Progesterone Slows LH Pulse Frequency",[89],"2020-01-18","2007-11-29",85,[4656,2078],"Normal",[4642],{"nctId":4659,"briefTitle":4660,"status":850,"phases":4661,"primaryCompletion":4662,"completion":4662,"start":4663,"enrollment":31,"conditions":4664,"interventions":4666},"NCT01602679","Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006)",[89],"2015-07-31","2012-05",[4665],"Female Reproductive Physiology",[4642],{"trials":4668,"activeCount":109},[],{"trials":4670,"activeCount":109},[],{"trials":4672,"activeCount":109},[],{"trials":4674,"activeCount":109},[],{"intervention":4676,"totalTrials":149,"cells":4677},"standardized herbal formula, Sho-saiko-to",{"EARLY_PHASE1":4678,"PHASE1":4680,"PHASE2":4689,"PHASE3":4691,"PHASE4":4693,"NA":4695},{"trials":4679,"activeCount":109},[],{"trials":4681,"activeCount":109},[4682],{"nctId":4683,"briefTitle":4684,"status":104,"phases":4685,"enrollment":109,"conditions":4686,"interventions":4688},"NCT00633230","Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C",[89],[4687],"Hepatitis C Virus",[4676],{"trials":4690,"activeCount":109},[],{"trials":4692,"activeCount":109},[],{"trials":4694,"activeCount":109},[],{"trials":4696,"activeCount":109},[],{"intervention":4698,"totalTrials":149,"cells":4699},"Ribociclib",{"EARLY_PHASE1":4700,"PHASE1":4702,"PHASE2":4715,"PHASE3":4717,"PHASE4":4719,"NA":4721},{"trials":4701,"activeCount":109},[],{"trials":4703,"activeCount":109},[4704],{"nctId":4705,"briefTitle":4706,"status":169,"phases":4707,"primaryCompletion":4708,"completion":4709,"start":4710,"enrollment":97,"conditions":4711,"interventions":4714},"NCT02345824","Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma",[89],"2019-09","2020-01","2016-03",[4712,4713],"Glioblastoma","Glioma",[4698],{"trials":4716,"activeCount":109},[],{"trials":4718,"activeCount":109},[],{"trials":4720,"activeCount":109},[],{"trials":4722,"activeCount":109},[],{"intervention":3522,"totalTrials":149,"cells":4724},{"EARLY_PHASE1":4725,"PHASE1":4727,"PHASE2":4733,"PHASE3":4735,"PHASE4":4737,"NA":4739},{"trials":4726,"activeCount":109},[],{"trials":4728,"activeCount":109},[4729],{"nctId":3515,"briefTitle":3516,"status":118,"phases":4730,"primaryCompletion":3518,"start":3519,"enrollment":22,"conditions":4731,"interventions":4732},[89],[3417],[3522,3508,3523,3524,3525],{"trials":4734,"activeCount":109},[],{"trials":4736,"activeCount":109},[],{"trials":4738,"activeCount":109},[],{"trials":4740,"activeCount":109},[],{"intervention":3523,"totalTrials":149,"cells":4742},{"EARLY_PHASE1":4743,"PHASE1":4745,"PHASE2":4751,"PHASE3":4753,"PHASE4":4755,"NA":4757},{"trials":4744,"activeCount":109},[],{"trials":4746,"activeCount":109},[4747],{"nctId":3515,"briefTitle":3516,"status":118,"phases":4748,"primaryCompletion":3518,"start":3519,"enrollment":22,"conditions":4749,"interventions":4750},[89],[3417],[3522,3508,3523,3524,3525],{"trials":4752,"activeCount":109},[],{"trials":4754,"activeCount":109},[],{"trials":4756,"activeCount":109},[],{"trials":4758,"activeCount":109},[],{"intervention":3524,"totalTrials":149,"cells":4760},{"EARLY_PHASE1":4761,"PHASE1":4763,"PHASE2":4769,"PHASE3":4771,"PHASE4":4773,"NA":4775},{"trials":4762,"activeCount":109},[],{"trials":4764,"activeCount":109},[4765],{"nctId":3515,"briefTitle":3516,"status":118,"phases":4766,"primaryCompletion":3518,"start":3519,"enrollment":22,"conditions":4767,"interventions":4768},[89],[3417],[3522,3508,3523,3524,3525],{"trials":4770,"activeCount":109},[],{"trials":4772,"activeCount":109},[],{"trials":4774,"activeCount":109},[],{"trials":4776,"activeCount":109},[],{"intervention":3525,"totalTrials":149,"cells":4778},{"EARLY_PHASE1":4779,"PHASE1":4781,"PHASE2":4787,"PHASE3":4789,"PHASE4":4791,"NA":4793},{"trials":4780,"activeCount":109},[],{"trials":4782,"activeCount":109},[4783],{"nctId":3515,"briefTitle":3516,"status":118,"phases":4784,"primaryCompletion":3518,"start":3519,"enrollment":22,"conditions":4785,"interventions":4786},[89],[3417],[3522,3508,3523,3524,3525],{"trials":4788,"activeCount":109},[],{"trials":4790,"activeCount":109},[],{"trials":4792,"activeCount":109},[],{"trials":4794,"activeCount":109},[],{"intervention":524,"totalTrials":149,"cells":4796},{"EARLY_PHASE1":4797,"PHASE1":4799,"PHASE2":4805,"PHASE3":4807,"PHASE4":4809,"NA":4811},{"trials":4798,"activeCount":109},[],{"trials":4800,"activeCount":109},[4801],{"nctId":515,"briefTitle":516,"status":118,"phases":4802,"start":518,"enrollment":519,"conditions":4803,"interventions":4804},[89],[521],[523,524],{"trials":4806,"activeCount":109},[],{"trials":4808,"activeCount":109},[],{"trials":4810,"activeCount":109},[],{"trials":4812,"activeCount":109},[],{"intervention":4814,"totalTrials":149,"cells":4815},"Propranolol Oral",{"EARLY_PHASE1":4816,"PHASE1":4818,"PHASE2":4830,"PHASE3":4832,"PHASE4":4834,"NA":4836},{"trials":4817,"activeCount":109},[],{"trials":4819,"activeCount":109},[4820],{"nctId":4821,"briefTitle":4822,"status":169,"phases":4823,"primaryCompletion":4824,"completion":4824,"start":4825,"enrollment":4826,"conditions":4827,"interventions":4829},"NCT03523650","Oral Propanolol for Surgically Inaccessible Cavernous Malformations",[89],"2019-01","2018-02-07",346,[4828],"Cavernous Malformations,Cerebral and\u002For Spinal",[4814],{"trials":4831,"activeCount":109},[],{"trials":4833,"activeCount":109},[],{"trials":4835,"activeCount":109},[],{"trials":4837,"activeCount":109},[],{"intervention":4839,"totalTrials":149,"cells":4840},"fenoldopam",{"EARLY_PHASE1":4841,"PHASE1":4843,"PHASE2":4854,"PHASE3":4856,"PHASE4":4858,"NA":4860},{"trials":4842,"activeCount":109},[],{"trials":4844,"activeCount":109},[4845],{"nctId":4846,"briefTitle":4847,"status":169,"phases":4848,"primaryCompletion":4849,"completion":4154,"start":2759,"enrollment":4850,"conditions":4851,"interventions":4853},"NCT00592150","Effect of Gene Variants on Dopamine Receptor Natriuretic Responses",[89],"2008-03",44,[4852],"Hypertension",[4839],{"trials":4855,"activeCount":109},[],{"trials":4857,"activeCount":109},[],{"trials":4859,"activeCount":109},[],{"trials":4861,"activeCount":109},[],{"intervention":4863,"totalTrials":149,"cells":4864},"Salmonella typhi polysaccharide vaccine",{"EARLY_PHASE1":4865,"PHASE1":4867,"PHASE2":4877,"PHASE3":4879,"PHASE4":4881,"NA":4883},{"trials":4866,"activeCount":109},[],{"trials":4868,"activeCount":109},[4869],{"nctId":4870,"briefTitle":4871,"status":118,"phases":4872,"primaryCompletion":62,"completion":62,"start":4873,"enrollment":735,"conditions":4874,"interventions":4876},"NCT03968211","Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency",[89],"2019-07-01",[4875],"Immune Deficiency",[4863],{"trials":4878,"activeCount":109},[],{"trials":4880,"activeCount":109},[],{"trials":4882,"activeCount":109},[],{"trials":4884,"activeCount":109},[],{"intervention":4886,"totalTrials":149,"cells":4887},"Active Aprepitant",{"EARLY_PHASE1":4888,"PHASE1":4890,"PHASE2":4904,"PHASE3":4906,"PHASE4":4908,"NA":4910},{"trials":4889,"activeCount":109},[],{"trials":4891,"activeCount":109},[4892],{"nctId":4893,"briefTitle":4894,"status":118,"phases":4895,"primaryCompletion":4329,"completion":3184,"start":4896,"enrollment":4897,"conditions":4898,"interventions":4903},"NCT01204723","Medications Development for the Treatment of Cannabis Related Disorders",[89],"2009-08",63,[4899,4900,4901,3026,4902],"Nicotine Withdrawal","Marijuana Dependence","Cannabis Dependence","Cannabis Abuse",[4886],{"trials":4905,"activeCount":109},[],{"trials":4907,"activeCount":109},[],{"trials":4909,"activeCount":109},[],{"trials":4911,"activeCount":109},[],{"intervention":4913,"totalTrials":149,"cells":4914},"EGFR BATs with TMZ following SOC RT\u002FTMZ",{"EARLY_PHASE1":4915,"PHASE1":4917,"PHASE2":4930,"PHASE3":4932,"PHASE4":4934,"NA":4936},{"trials":4916,"activeCount":109},[],{"trials":4918,"activeCount":109},[4919],{"nctId":4920,"briefTitle":4921,"status":118,"phases":4922,"primaryCompletion":4923,"completion":2801,"start":4924,"enrollment":4925,"conditions":4926,"interventions":4928},"NCT03344250","Phase I EGFR BATs in Newly Diagnosed Glioblastoma",[89],"2021-12-08","2018-03-01",16,[4712,4927],"Glioblastoma Multiforme",[4913,4929],"Weekly EGFR BATs following SOC RT\u002FTMZ",{"trials":4931,"activeCount":109},[],{"trials":4933,"activeCount":109},[],{"trials":4935,"activeCount":109},[],{"trials":4937,"activeCount":109},[],{"intervention":4929,"totalTrials":149,"cells":4939},{"EARLY_PHASE1":4940,"PHASE1":4942,"PHASE2":4948,"PHASE3":4950,"PHASE4":4952,"NA":4954},{"trials":4941,"activeCount":109},[],{"trials":4943,"activeCount":109},[4944],{"nctId":4920,"briefTitle":4921,"status":118,"phases":4945,"primaryCompletion":4923,"completion":2801,"start":4924,"enrollment":4925,"conditions":4946,"interventions":4947},[89],[4712,4927],[4913,4929],{"trials":4949,"activeCount":109},[],{"trials":4951,"activeCount":109},[],{"trials":4953,"activeCount":109},[],{"trials":4955,"activeCount":109},[],{"intervention":4957,"totalTrials":149,"cells":4958},"HER2 BATs",{"EARLY_PHASE1":4959,"PHASE1":4961,"PHASE2":4972,"PHASE3":4974,"PHASE4":4976,"NA":4978},{"trials":4960,"activeCount":109},[],{"trials":4962,"activeCount":109},[4963],{"nctId":4964,"briefTitle":4965,"status":850,"phases":4966,"primaryCompletion":4967,"completion":4967,"start":4968,"enrollment":97,"conditions":4969,"interventions":4971},"NCT03661424","BATs in Patients With Breast Cancer and Leptomeningeal Metastases",[89],"2021-12-14","2019-02-26",[652,4970],"Leptomeningeal Metastases",[4957],{"trials":4973,"activeCount":109},[],{"trials":4975,"activeCount":109},[],{"trials":4977,"activeCount":109},[],{"trials":4979,"activeCount":109},[],{"intervention":4981,"totalTrials":149,"cells":4982},"Active Comparator: Atomoxetine, Placebo",{"EARLY_PHASE1":4983,"PHASE1":4985,"PHASE2":4997,"PHASE3":4999,"PHASE4":5001,"NA":5003},{"trials":4984,"activeCount":109},[],{"trials":4986,"activeCount":109},[4987],{"nctId":4988,"briefTitle":4989,"status":850,"phases":4990,"primaryCompletion":4574,"completion":3184,"start":4991,"enrollment":4992,"conditions":4993,"interventions":4996},"NCT01343628","A Gene by Medication Interaction to the Acute Effects of Alcohol",[89],"2008-01",43,[4994,4995],"Alcohol-induced Cue-craving","Alcohol Sensitivity",[4981],{"trials":4998,"activeCount":109},[],{"trials":5000,"activeCount":109},[],{"trials":5002,"activeCount":109},[],{"trials":5004,"activeCount":109},[],{"intervention":3406,"totalTrials":149,"cells":5006},{"EARLY_PHASE1":5007,"PHASE1":5009,"PHASE2":5015,"PHASE3":5017,"PHASE4":5019,"NA":5021},{"trials":5008,"activeCount":109},[],{"trials":5010,"activeCount":109},[5011],{"nctId":3396,"briefTitle":3397,"status":118,"phases":5012,"primaryCompletion":3399,"completion":2759,"start":3400,"enrollment":37,"conditions":5013,"interventions":5014},[89],[3402,3403],[3405,3406,3389,3407],{"trials":5016,"activeCount":109},[],{"trials":5018,"activeCount":109},[],{"trials":5020,"activeCount":109},[],{"trials":5022,"activeCount":109},[],{"intervention":3407,"totalTrials":149,"cells":5024},{"EARLY_PHASE1":5025,"PHASE1":5027,"PHASE2":5033,"PHASE3":5035,"PHASE4":5037,"NA":5039},{"trials":5026,"activeCount":109},[],{"trials":5028,"activeCount":109},[5029],{"nctId":3396,"briefTitle":3397,"status":118,"phases":5030,"primaryCompletion":3399,"completion":2759,"start":3400,"enrollment":37,"conditions":5031,"interventions":5032},[89],[3402,3403],[3405,3406,3389,3407],{"trials":5034,"activeCount":109},[],{"trials":5036,"activeCount":109},[],{"trials":5038,"activeCount":109},[],{"trials":5040,"activeCount":109},[],{"intervention":5042,"totalTrials":149,"cells":5043},"Hyperpolarized He3",{"EARLY_PHASE1":5044,"PHASE1":5046,"PHASE2":5057,"PHASE3":5059,"PHASE4":5061,"NA":5063},{"trials":5045,"activeCount":109},[],{"trials":5047,"activeCount":109},[5048],{"nctId":5049,"briefTitle":5050,"status":169,"phases":5051,"primaryCompletion":5052,"completion":5053,"start":5054,"enrollment":624,"conditions":5055,"interventions":5056},"NCT02995590","Assessing Deformable Image Registration in the Lung Using Hyperpolarized-gas MRI",[89],"2019-12-15","2021-12-15","2016-07-01",[4005],[5042],{"trials":5058,"activeCount":109},[],{"trials":5060,"activeCount":109},[],{"trials":5062,"activeCount":109},[],{"trials":5064,"activeCount":109},[],{"intervention":5066,"totalTrials":149,"cells":5067},"triamcinolone acetonide extended-release injectable suspension",{"EARLY_PHASE1":5068,"PHASE1":5070,"PHASE2":5083,"PHASE3":5085,"PHASE4":5087,"NA":5089},{"trials":5069,"activeCount":109},[],{"trials":5071,"activeCount":109},[5072],{"nctId":5073,"briefTitle":5074,"status":850,"phases":5075,"primaryCompletion":5076,"completion":5076,"start":5077,"enrollment":3532,"conditions":5078,"interventions":5082},"NCT04831255","ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis",[89],"2023-08-31","2019-06-21",[5079,5080,5081],"Adhesive Capsulitis","Frozen Shoulder","Adhesive Capsulitis of Shoulder",[5066],{"trials":5084,"activeCount":109},[],{"trials":5086,"activeCount":109},[],{"trials":5088,"activeCount":109},[],{"trials":5090,"activeCount":109},[],{"intervention":536,"totalTrials":149,"cells":5092},{"EARLY_PHASE1":5093,"PHASE1":5095,"PHASE2":5101,"PHASE3":5103,"PHASE4":5105,"NA":5107},{"trials":5094,"activeCount":109},[],{"trials":5096,"activeCount":109},[5097],{"nctId":526,"briefTitle":527,"status":118,"phases":5098,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":5099,"interventions":5100},[89],[534,30],[536,507],{"trials":5102,"activeCount":109},[],{"trials":5104,"activeCount":109},[],{"trials":5106,"activeCount":109},[],{"trials":5108,"activeCount":109},[],{"intervention":5110,"totalTrials":149,"cells":5111},"synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine",{"EARLY_PHASE1":5112,"PHASE1":5114,"PHASE2":5124,"PHASE3":5126,"PHASE4":5128,"NA":5130},{"trials":5113,"activeCount":109},[],{"trials":5115,"activeCount":109},[5116],{"nctId":5117,"briefTitle":5118,"status":118,"phases":5119,"primaryCompletion":2759,"completion":5120,"start":5121,"enrollment":31,"conditions":5122,"interventions":5123},"NCT00304096","Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer",[89],"2008-04","2005-12",[30],[5110],{"trials":5125,"activeCount":109},[],{"trials":5127,"activeCount":109},[],{"trials":5129,"activeCount":109},[],{"trials":5131,"activeCount":109},[],{"intervention":5133,"totalTrials":149,"cells":5134},"Velcade and Vorinostat",{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5149,"PHASE3":5151,"PHASE4":5153,"NA":5155},{"trials":5136,"activeCount":109},[],{"trials":5138,"activeCount":109},[5139],{"nctId":5140,"briefTitle":5141,"status":118,"phases":5142,"primaryCompletion":5143,"completion":5144,"start":2856,"enrollment":5145,"conditions":5146,"interventions":5148},"NCT00731952","Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer",[89],"2012-12","2014-03",21,[5147],"Non Small Cell Lung Cancer",[5133],{"trials":5150,"activeCount":109},[],{"trials":5152,"activeCount":109},[],{"trials":5154,"activeCount":109},[],{"trials":5156,"activeCount":109},[],{"intervention":5158,"totalTrials":149,"cells":5159},"concentrated beet root juice",{"EARLY_PHASE1":5160,"PHASE1":5162,"PHASE2":5172,"PHASE3":5174,"PHASE4":5176,"NA":5178},{"trials":5161,"activeCount":109},[],{"trials":5163,"activeCount":109},[5164],{"nctId":5165,"briefTitle":5166,"status":118,"phases":5167,"primaryCompletion":5168,"completion":5168,"start":5169,"enrollment":545,"conditions":5170,"interventions":5171},"NCT04588740","Inorganic Nitrate: Sex Differences in Muscle Contractile Function and Efficiency",[89],"2023-12-30","2020-01-20",[3895],[5158],{"trials":5173,"activeCount":109},[],{"trials":5175,"activeCount":109},[],{"trials":5177,"activeCount":109},[],{"trials":5179,"activeCount":109},[],{"intervention":5181,"totalTrials":149,"cells":5182},"Nivolumab",{"EARLY_PHASE1":5183,"PHASE1":5185,"PHASE2":5196,"PHASE3":5198,"PHASE4":5200,"NA":5202},{"trials":5184,"activeCount":109},[],{"trials":5186,"activeCount":109},[5187],{"nctId":5188,"briefTitle":5189,"status":850,"phases":5190,"primaryCompletion":5191,"completion":5191,"start":5192,"enrollment":508,"conditions":5193,"interventions":5194},"NCT02648633","Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma",[89],"2017-02-21","2016-05-24",[4712],[5181,5195],"Valproate",{"trials":5197,"activeCount":109},[],{"trials":5199,"activeCount":109},[],{"trials":5201,"activeCount":109},[],{"trials":5203,"activeCount":109},[],{"intervention":5195,"totalTrials":149,"cells":5205},{"EARLY_PHASE1":5206,"PHASE1":5208,"PHASE2":5214,"PHASE3":5216,"PHASE4":5218,"NA":5220},{"trials":5207,"activeCount":109},[],{"trials":5209,"activeCount":109},[5210],{"nctId":5188,"briefTitle":5189,"status":850,"phases":5211,"primaryCompletion":5191,"completion":5191,"start":5192,"enrollment":508,"conditions":5212,"interventions":5213},[89],[4712],[5181,5195],{"trials":5215,"activeCount":109},[],{"trials":5217,"activeCount":109},[],{"trials":5219,"activeCount":109},[],{"trials":5221,"activeCount":109},[],{"intervention":5223,"totalTrials":149,"cells":5224},"MELITAC 12.1",{"EARLY_PHASE1":5225,"PHASE1":5227,"PHASE2":5237,"PHASE3":5239,"PHASE4":5241,"NA":5243},{"trials":5226,"activeCount":109},[],{"trials":5228,"activeCount":109},[5229],{"nctId":5230,"briefTitle":5231,"status":118,"phases":5232,"primaryCompletion":3255,"completion":3255,"start":5233,"enrollment":508,"conditions":5234,"interventions":5235},"NCT01264731","Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma",[89],"2011-01",[4506],[5223,5236],"Imiquimod",{"trials":5238,"activeCount":109},[],{"trials":5240,"activeCount":109},[],{"trials":5242,"activeCount":109},[],{"trials":5244,"activeCount":109},[],{"intervention":5236,"totalTrials":149,"cells":5246},{"EARLY_PHASE1":5247,"PHASE1":5249,"PHASE2":5255,"PHASE3":5257,"PHASE4":5259,"NA":5261},{"trials":5248,"activeCount":109},[],{"trials":5250,"activeCount":109},[5251],{"nctId":5230,"briefTitle":5231,"status":118,"phases":5252,"primaryCompletion":3255,"completion":3255,"start":5233,"enrollment":508,"conditions":5253,"interventions":5254},[89],[4506],[5223,5236],{"trials":5256,"activeCount":109},[],{"trials":5258,"activeCount":109},[],{"trials":5260,"activeCount":109},[],{"trials":5262,"activeCount":109},[],{"intervention":5264,"totalTrials":154,"cells":5265},"Hydrocortisone",{"EARLY_PHASE1":5266,"PHASE1":5285,"PHASE2":5287,"PHASE3":5289,"PHASE4":5291,"NA":5293},{"trials":5267,"activeCount":109},[5268,5276],{"nctId":5269,"briefTitle":5270,"status":104,"phases":5271,"primaryCompletion":5272,"completion":5272,"start":5273,"enrollment":109,"conditions":5274,"interventions":5275},"NCT01422707","Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess",[88],"2018-07-17","2018-01-19",[36,27,18],[5264],{"nctId":5277,"briefTitle":5278,"status":104,"phases":5279,"primaryCompletion":5272,"completion":5272,"start":2484,"enrollment":109,"conditions":5280,"interventions":5281},"NCT01422733","Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction",[88],[36,27,18],[5264,5282,5283,5284],"dexamethasone","Cosyntropin","rhCG",{"trials":5286,"activeCount":109},[],{"trials":5288,"activeCount":109},[],{"trials":5290,"activeCount":109},[],{"trials":5292,"activeCount":109},[],{"trials":5294,"activeCount":109},[],{"intervention":5296,"totalTrials":149,"cells":5297},"PTP-01",{"EARLY_PHASE1":5298,"PHASE1":5307,"PHASE2":5309,"PHASE3":5311,"PHASE4":5313,"NA":5315},{"trials":5299,"activeCount":109},[5300],{"nctId":5301,"briefTitle":5302,"status":850,"phases":5303,"primaryCompletion":3892,"completion":3892,"start":4435,"enrollment":97,"conditions":5304,"interventions":5306},"NCT01962909","Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer",[88],[5305],"Pancreatic Ductal Adenocarcinoma",[5296],{"trials":5308,"activeCount":109},[],{"trials":5310,"activeCount":109},[],{"trials":5312,"activeCount":109},[],{"trials":5314,"activeCount":109},[],{"trials":5316,"activeCount":109},[],{"intervention":5318,"totalTrials":149,"cells":5319},"Leuprolide",{"EARLY_PHASE1":5320,"PHASE1":5328,"PHASE2":5330,"PHASE3":5332,"PHASE4":5334,"NA":5336},{"trials":5321,"activeCount":109},[5322],{"nctId":5323,"briefTitle":5324,"status":104,"phases":5325,"primaryCompletion":5272,"completion":5272,"start":2484,"enrollment":109,"conditions":5326,"interventions":5327},"NCT01422096","Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess",[88],[36,27,18],[5318],{"trials":5329,"activeCount":109},[],{"trials":5331,"activeCount":109},[],{"trials":5333,"activeCount":109},[],{"trials":5335,"activeCount":109},[],{"trials":5337,"activeCount":109},[],{"intervention":5339,"totalTrials":149,"cells":5340},"Xenon129 MRI imaging",{"EARLY_PHASE1":5341,"PHASE1":5354,"PHASE2":5356,"PHASE3":5358,"PHASE4":5360,"NA":5362},{"trials":5342,"activeCount":109},[5343],{"nctId":5344,"briefTitle":5345,"status":118,"phases":5346,"primaryCompletion":5347,"completion":5347,"start":5348,"enrollment":394,"conditions":5349,"interventions":5351},"NCT02826343","New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)",[88],"2018-06-15","2016-05-01",[5350],"Pulmonary Disease, Chronic Obstructive",[5339,5352,5353],"Gadolinium MRI","Advair (250mcg\u002F50mcg) one puff twice a day",{"trials":5355,"activeCount":109},[],{"trials":5357,"activeCount":109},[],{"trials":5359,"activeCount":109},[],{"trials":5361,"activeCount":109},[],{"trials":5363,"activeCount":109},[],{"intervention":5352,"totalTrials":149,"cells":5365},{"EARLY_PHASE1":5366,"PHASE1":5372,"PHASE2":5374,"PHASE3":5376,"PHASE4":5378,"NA":5380},{"trials":5367,"activeCount":109},[5368],{"nctId":5344,"briefTitle":5345,"status":118,"phases":5369,"primaryCompletion":5347,"completion":5347,"start":5348,"enrollment":394,"conditions":5370,"interventions":5371},[88],[5350],[5339,5352,5353],{"trials":5373,"activeCount":109},[],{"trials":5375,"activeCount":109},[],{"trials":5377,"activeCount":109},[],{"trials":5379,"activeCount":109},[],{"trials":5381,"activeCount":109},[],{"intervention":5353,"totalTrials":149,"cells":5383},{"EARLY_PHASE1":5384,"PHASE1":5390,"PHASE2":5392,"PHASE3":5394,"PHASE4":5396,"NA":5398},{"trials":5385,"activeCount":109},[5386],{"nctId":5344,"briefTitle":5345,"status":118,"phases":5387,"primaryCompletion":5347,"completion":5347,"start":5348,"enrollment":394,"conditions":5388,"interventions":5389},[88],[5350],[5339,5352,5353],{"trials":5391,"activeCount":109},[],{"trials":5393,"activeCount":109},[],{"trials":5395,"activeCount":109},[],{"trials":5397,"activeCount":109},[],{"trials":5399,"activeCount":109},[],{"intervention":113,"totalTrials":149,"cells":5401},{"EARLY_PHASE1":5402,"PHASE1":5408,"PHASE2":5410,"PHASE3":5412,"PHASE4":5414,"NA":5416},{"trials":5403,"activeCount":109},[5404],{"nctId":102,"briefTitle":103,"status":104,"phases":5405,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":5406,"interventions":5407},[88],[24,111],[113,96,114],{"trials":5409,"activeCount":109},[],{"trials":5411,"activeCount":109},[],{"trials":5413,"activeCount":109},[],{"trials":5415,"activeCount":109},[],{"trials":5417,"activeCount":109},[],{"intervention":114,"totalTrials":149,"cells":5419},{"EARLY_PHASE1":5420,"PHASE1":5426,"PHASE2":5428,"PHASE3":5430,"PHASE4":5432,"NA":5434},{"trials":5421,"activeCount":109},[5422],{"nctId":102,"briefTitle":103,"status":104,"phases":5423,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":5424,"interventions":5425},[88],[24,111],[113,96,114],{"trials":5427,"activeCount":109},[],{"trials":5429,"activeCount":109},[],{"trials":5431,"activeCount":109},[],{"trials":5433,"activeCount":109},[],{"trials":5435,"activeCount":109},[],{"intervention":5437,"totalTrials":149,"cells":5438},"ACTH",{"EARLY_PHASE1":5439,"PHASE1":5449,"PHASE2":5451,"PHASE3":5453,"PHASE4":5455,"NA":5457},{"trials":5440,"activeCount":109},[5441],{"nctId":5442,"briefTitle":5443,"status":169,"phases":5444,"primaryCompletion":2102,"completion":141,"start":5445,"enrollment":5446,"conditions":5447,"interventions":5448},"NCT03905603","Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS",[88],"2019-10-08",144,[18],[5437,5284],{"trials":5450,"activeCount":109},[],{"trials":5452,"activeCount":109},[],{"trials":5454,"activeCount":109},[],{"trials":5456,"activeCount":109},[],{"trials":5458,"activeCount":109},[],{"intervention":5460,"totalTrials":149,"cells":5461},"aminophylline",{"EARLY_PHASE1":5462,"PHASE1":5473,"PHASE2":5475,"PHASE3":5477,"PHASE4":5479,"NA":5481},{"trials":5463,"activeCount":109},[5464],{"nctId":5465,"briefTitle":5466,"status":118,"phases":5467,"primaryCompletion":5468,"completion":5468,"start":5469,"enrollment":97,"conditions":5470,"interventions":5472},"NCT01240824","Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer",[88],"2011-02","2010-07",[5471],"Bladder Cancer",[5460],{"trials":5474,"activeCount":109},[],{"trials":5476,"activeCount":109},[],{"trials":5478,"activeCount":109},[],{"trials":5480,"activeCount":109},[],{"trials":5482,"activeCount":109},[],{"intervention":5484,"totalTrials":149,"cells":5485},"Glembatumumab Vedotin",{"EARLY_PHASE1":5486,"PHASE1":5496,"PHASE2":5498,"PHASE3":5500,"PHASE4":5502,"NA":5504},{"trials":5487,"activeCount":109},[5488],{"nctId":5489,"briefTitle":5490,"status":104,"phases":5491,"primaryCompletion":5492,"completion":5492,"start":5492,"enrollment":109,"conditions":5493,"interventions":5495},"NCT03473691","Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer",[88],"2018-05-01",[5494],"Triple Negative Breast Cancer",[5484],{"trials":5497,"activeCount":109},[],{"trials":5499,"activeCount":109},[],{"trials":5501,"activeCount":109},[],{"trials":5503,"activeCount":109},[],{"trials":5505,"activeCount":109},[],{"intervention":5507,"totalTrials":149,"cells":5508},"Oral combined hormonal contraceptives",{"EARLY_PHASE1":5509,"PHASE1":5519,"PHASE2":5521,"PHASE3":5523,"PHASE4":5525,"NA":5527},{"trials":5510,"activeCount":109},[5511],{"nctId":5512,"briefTitle":5513,"status":104,"phases":5514,"primaryCompletion":5515,"completion":5515,"start":5516,"enrollment":109,"conditions":5517,"interventions":5518},"NCT03905941","Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age",[88],"2024-11-25","2021-08-23",[18],[502,5507],{"trials":5520,"activeCount":109},[],{"trials":5522,"activeCount":109},[],{"trials":5524,"activeCount":109},[],{"trials":5526,"activeCount":109},[],{"trials":5528,"activeCount":109},[],{"intervention":5530,"totalTrials":149,"cells":5531},"Empagliflozin 25 MG",{"EARLY_PHASE1":5532,"PHASE1":5542,"PHASE2":5544,"PHASE3":5546,"PHASE4":5548,"NA":5550},{"trials":5533,"activeCount":109},[5534],{"nctId":5535,"briefTitle":5536,"status":169,"phases":5537,"primaryCompletion":5538,"completion":5539,"start":4628,"enrollment":760,"conditions":5540,"interventions":5541},"NCT04203927","Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes",[88],"2023-10-30","2023-11-30",[176,124],[5530],{"trials":5543,"activeCount":109},[],{"trials":5545,"activeCount":109},[],{"trials":5547,"activeCount":109},[],{"trials":5549,"activeCount":109},[],{"trials":5551,"activeCount":109},[],{"intervention":5553,"totalTrials":149,"cells":5554},"Dasatinib",{"EARLY_PHASE1":5555,"PHASE1":5564,"PHASE2":5566,"PHASE3":5568,"PHASE4":5570,"NA":5572},{"trials":5556,"activeCount":109},[5557],{"nctId":5558,"briefTitle":5559,"status":118,"phases":5560,"primaryCompletion":2709,"completion":3438,"start":4329,"enrollment":31,"conditions":5561,"interventions":5563},"NCT01482728","Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer",[88],[5562],"Endometrial Cancer",[5553,5553],{"trials":5565,"activeCount":109},[],{"trials":5567,"activeCount":109},[],{"trials":5569,"activeCount":109},[],{"trials":5571,"activeCount":109},[],{"trials":5573,"activeCount":109},[],{"intervention":126,"totalTrials":149,"cells":5575},{"EARLY_PHASE1":5576,"PHASE1":5582,"PHASE2":5584,"PHASE3":5586,"PHASE4":5588,"NA":5590},{"trials":5577,"activeCount":109},[5578],{"nctId":116,"briefTitle":117,"status":118,"phases":5579,"primaryCompletion":120,"completion":120,"start":121,"enrollment":25,"conditions":5580,"interventions":5581},[88],[123,124],[126,96,127],{"trials":5583,"activeCount":109},[],{"trials":5585,"activeCount":109},[],{"trials":5587,"activeCount":109},[],{"trials":5589,"activeCount":109},[],{"trials":5591,"activeCount":109},[],{"intervention":127,"totalTrials":149,"cells":5593},{"EARLY_PHASE1":5594,"PHASE1":5600,"PHASE2":5602,"PHASE3":5604,"PHASE4":5606,"NA":5608},{"trials":5595,"activeCount":109},[5596],{"nctId":116,"briefTitle":117,"status":118,"phases":5597,"primaryCompletion":120,"completion":120,"start":121,"enrollment":25,"conditions":5598,"interventions":5599},[88],[123,124],[126,96,127],{"trials":5601,"activeCount":109},[],{"trials":5603,"activeCount":109},[],{"trials":5605,"activeCount":109},[],{"trials":5607,"activeCount":109},[],{"trials":5609,"activeCount":109},[],{"intervention":2081,"totalTrials":149,"cells":5611},{"EARLY_PHASE1":5612,"PHASE1":5618,"PHASE2":5620,"PHASE3":5622,"PHASE4":5624,"NA":5626},{"trials":5613,"activeCount":109},[5614],{"nctId":2073,"briefTitle":2074,"status":169,"phases":5615,"primaryCompletion":1509,"completion":1509,"start":2076,"enrollment":34,"conditions":5616,"interventions":5617},[88],[2078,18],[2020,2080,2081],{"trials":5619,"activeCount":109},[],{"trials":5621,"activeCount":109},[],{"trials":5623,"activeCount":109},[],{"trials":5625,"activeCount":109},[],{"trials":5627,"activeCount":109},[],{"intervention":5629,"totalTrials":149,"cells":5630},"Growth Hormone Replacement",{"EARLY_PHASE1":5631,"PHASE1":5642,"PHASE2":5644,"PHASE3":5646,"PHASE4":5648,"NA":5650},{"trials":5632,"activeCount":109},[5633],{"nctId":5634,"briefTitle":5635,"status":118,"phases":5636,"primaryCompletion":5637,"completion":5637,"start":5638,"enrollment":2441,"conditions":5639,"interventions":5641},"NCT00929045","Growth Hormone and Insulin Growth Factor 1 Deficiencies in Children\u002FAdolescents Following Traumatic Brain Injury: The Impact on Growth and Neuropsychological Development",[88],"2010-12","2007-07",[5640],"Traumatic Brain Injury",[5629],{"trials":5643,"activeCount":109},[],{"trials":5645,"activeCount":109},[],{"trials":5647,"activeCount":109},[],{"trials":5649,"activeCount":109},[],{"trials":5651,"activeCount":109},[],{"intervention":5653,"totalTrials":2252,"cells":5654},"Progesterone",{"EARLY_PHASE1":5655,"PHASE1":5657,"PHASE2":5676,"PHASE3":5678,"PHASE4":5680,"NA":5682},{"trials":5656,"activeCount":109},[],{"trials":5658,"activeCount":109},[5659,5667],{"nctId":5660,"briefTitle":5661,"status":169,"phases":5662,"primaryCompletion":2060,"completion":2060,"start":5663,"enrollment":1191,"conditions":5664,"interventions":5666},"NCT01428089","Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone",[89],"2011-03-11",[18,33,5665],"Normal Puberty",[5653],{"nctId":5668,"briefTitle":5669,"status":118,"phases":5670,"primaryCompletion":5671,"completion":5671,"start":5672,"enrollment":28,"conditions":5673,"interventions":5675},"NCT01773772","Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls",[89],"2009-06-08","2005-02-08",[5674],"Female Puberty",[5653],{"trials":5677,"activeCount":109},[],{"trials":5679,"activeCount":109},[],{"trials":5681,"activeCount":109},[],{"trials":5683,"activeCount":109},[5684,5693,5702,5711],{"nctId":5685,"briefTitle":5686,"status":850,"phases":5687,"primaryCompletion":5688,"completion":5688,"start":5689,"enrollment":97,"conditions":5690,"interventions":5691},"NCT01428245","Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition",[93],"2013-05-14","2011-04-22",[36,18],[5653,5692],"Estrace",{"nctId":5694,"briefTitle":5695,"status":169,"phases":5696,"primaryCompletion":322,"completion":322,"start":5697,"enrollment":174,"conditions":5698,"interventions":5700},"NCT01425541","Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition",[93],"2000-04",[36,5699],"Polycystic Ovary Syndrome (PCOS)",[5701,5653],"estrace",{"nctId":5703,"briefTitle":5704,"status":118,"phases":5705,"primaryCompletion":5706,"completion":5706,"start":5707,"enrollment":5708,"conditions":5709,"interventions":5710},"NCT01427595","Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone",[93],"2015-01-17","2009-02-18",25,[18,33],[502,5653,5701],{"nctId":5712,"briefTitle":5713,"status":850,"phases":5714,"primaryCompletion":3890,"completion":3890,"start":5715,"enrollment":508,"conditions":5716,"interventions":5717},"NCT01428193","Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone",[93],"2006-09",[18,33],[2080,5653,5701],{"intervention":5701,"totalTrials":508,"cells":5719},{"EARLY_PHASE1":5720,"PHASE1":5722,"PHASE2":5724,"PHASE3":5726,"PHASE4":5728,"NA":5730},{"trials":5721,"activeCount":109},[],{"trials":5723,"activeCount":109},[],{"trials":5725,"activeCount":109},[],{"trials":5727,"activeCount":109},[],{"trials":5729,"activeCount":109},[],{"trials":5731,"activeCount":109},[5732,5736,5740,5744],{"nctId":5685,"briefTitle":5686,"status":850,"phases":5733,"primaryCompletion":5688,"completion":5688,"start":5689,"enrollment":97,"conditions":5734,"interventions":5735},[93],[36,18],[5653,5692],{"nctId":5694,"briefTitle":5695,"status":169,"phases":5737,"primaryCompletion":322,"completion":322,"start":5697,"enrollment":174,"conditions":5738,"interventions":5739},[93],[36,5699],[5701,5653],{"nctId":5703,"briefTitle":5704,"status":118,"phases":5741,"primaryCompletion":5706,"completion":5706,"start":5707,"enrollment":5708,"conditions":5742,"interventions":5743},[93],[18,33],[502,5653,5701],{"nctId":5712,"briefTitle":5713,"status":850,"phases":5745,"primaryCompletion":3890,"completion":3890,"start":5715,"enrollment":508,"conditions":5746,"interventions":5747},[93],[18,33],[2080,5653,5701],{"intervention":4053,"totalTrials":508,"cells":5749},{"EARLY_PHASE1":5750,"PHASE1":5752,"PHASE2":5754,"PHASE3":5770,"PHASE4":5772,"NA":5774},{"trials":5751,"activeCount":109},[],{"trials":5753,"activeCount":109},[],{"trials":5755,"activeCount":109},[5756,5766],{"nctId":5757,"briefTitle":5758,"status":118,"phases":5759,"primaryCompletion":5760,"completion":5760,"start":5761,"enrollment":5762,"conditions":5763,"interventions":5765},"NCT02910401","Clinical Response to Rhinovirus Challenge",[90],"2022-09-21","2016-09",38,[252,5764],"Allergic Rhinitis",[4053],{"nctId":4046,"briefTitle":4047,"status":118,"phases":5767,"primaryCompletion":4049,"completion":4049,"start":4050,"enrollment":2553,"conditions":5768,"interventions":5769},[90],[252],[4037,4053],{"trials":5771,"activeCount":109},[],{"trials":5773,"activeCount":109},[],{"trials":5775,"activeCount":109},[5776,5784],{"nctId":5777,"briefTitle":5778,"status":118,"phases":5779,"primaryCompletion":2552,"completion":2552,"start":543,"enrollment":5780,"conditions":5781,"interventions":5783},"NCT01669603","Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)",[93],789,[5782],"Common Cold",[4053],{"nctId":5785,"briefTitle":5786,"status":118,"phases":5787,"primaryCompletion":5788,"completion":5789,"start":5790,"enrollment":5791,"conditions":5792,"interventions":5793},"NCT02111772","Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic",[93],"2017-04-20","2017-04-27","2013-09-01",26,[252],[4053],{"intervention":3921,"totalTrials":508,"cells":5795},{"EARLY_PHASE1":5796,"PHASE1":5798,"PHASE2":5800,"PHASE3":5814,"PHASE4":5828,"NA":5830},{"trials":5797,"activeCount":109},[],{"trials":5799,"activeCount":109},[],{"trials":5801,"activeCount":109},[5802,5806],{"nctId":3914,"briefTitle":3915,"status":118,"phases":5803,"primaryCompletion":3917,"completion":3917,"start":3918,"enrollment":1191,"conditions":5804,"interventions":5805},[90],[3025],[3921,3905],{"nctId":5807,"briefTitle":5808,"status":118,"phases":5809,"primaryCompletion":5810,"completion":5810,"start":2595,"enrollment":865,"conditions":5811,"interventions":5813},"NCT00689572","New Medication Treatment for Stimulant Dependence",[90],"2013-12",[5812],"Cocaine Dependence",[3921],{"trials":5815,"activeCount":109},[5816],{"nctId":5817,"briefTitle":5818,"status":118,"phases":5819,"primaryCompletion":5820,"completion":5820,"start":5821,"enrollment":5822,"conditions":5823,"interventions":5826},"NCT01414777","Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients",[90,91],"2011-06","2009-11",68,[5824,5825],"Hypotension","Pregnancy",[5827],"ondansetron",{"trials":5829,"activeCount":109},[],{"trials":5831,"activeCount":109},[5832],{"nctId":5833,"briefTitle":5834,"status":169,"phases":5835,"primaryCompletion":5469,"completion":5637,"start":5836,"enrollment":31,"conditions":5837,"interventions":5839},"NCT00599573","Pharmacotherapy for HIV+ Stimulant Dependent Individuals",[93],"2007-10",[5838,5812],"HIV Infections",[5827],{"intervention":502,"totalTrials":508,"cells":5841},{"EARLY_PHASE1":5842,"PHASE1":5855,"PHASE2":5857,"PHASE3":5859,"PHASE4":5861,"NA":5863},{"trials":5843,"activeCount":109},[5844,5848],{"nctId":5512,"briefTitle":5513,"status":104,"phases":5845,"primaryCompletion":5515,"completion":5515,"start":5516,"enrollment":109,"conditions":5846,"interventions":5847},[88],[18],[502,5507],{"nctId":5849,"briefTitle":5850,"status":169,"phases":5851,"primaryCompletion":2060,"completion":2060,"start":5852,"enrollment":439,"conditions":5853,"interventions":5854},"NCT01422746","Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess",[88],"2017-03-20",[27,36,18],[502],{"trials":5856,"activeCount":109},[],{"trials":5858,"activeCount":109},[],{"trials":5860,"activeCount":109},[],{"trials":5862,"activeCount":109},[],{"trials":5864,"activeCount":109},[5865,5874],{"nctId":5866,"briefTitle":5867,"status":118,"phases":5868,"primaryCompletion":3120,"completion":3120,"start":5869,"enrollment":3893,"conditions":5870,"interventions":5871},"NCT02633488","Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome",[93],"2014-06",[186,124],[5872,5873],"Placebos","metformin",{"nctId":5703,"briefTitle":5704,"status":118,"phases":5875,"primaryCompletion":5706,"completion":5706,"start":5707,"enrollment":5708,"conditions":5876,"interventions":5877},[93],[18,33],[502,5653,5701],{"intervention":5879,"totalTrials":508,"cells":5880},"Dexamethasone",{"EARLY_PHASE1":5881,"PHASE1":5887,"PHASE2":5889,"PHASE3":5891,"PHASE4":5900,"NA":5902},{"trials":5882,"activeCount":109},[5883],{"nctId":5277,"briefTitle":5278,"status":104,"phases":5884,"primaryCompletion":5272,"completion":5272,"start":2484,"enrollment":109,"conditions":5885,"interventions":5886},[88],[36,27,18],[5264,5282,5283,5284],{"trials":5888,"activeCount":109},[],{"trials":5890,"activeCount":109},[],{"trials":5892,"activeCount":109},[5893],{"nctId":5894,"briefTitle":5895,"status":850,"phases":5896,"primaryCompletion":3253,"completion":3253,"start":5144,"enrollment":34,"conditions":5897,"interventions":5899},"NCT02111785","Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma",[90,91],[5898],"Chronic Subdural Hematoma",[5879],{"trials":5901,"activeCount":109},[],{"trials":5903,"activeCount":109},[5904,5911],{"nctId":5905,"briefTitle":5906,"status":169,"phases":5907,"primaryCompletion":172,"completion":172,"start":5908,"enrollment":184,"conditions":5909,"interventions":5910},"NCT01421810","Ovarian Contribution to Androgen Production in Adolescent Girls",[93],"2011-03-10",[18,27,33],[5879,5284],{"nctId":5912,"briefTitle":5913,"status":169,"phases":5914,"primaryCompletion":5915,"completion":2060,"start":5916,"enrollment":5917,"conditions":5918,"interventions":5919},"NCT01421797","Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation",[93],"2024-08-27","2006-10-10",84,[36,18,27],[5879,5920],"Cortrosyn",{"intervention":5284,"totalTrials":97,"cells":5922},{"EARLY_PHASE1":5923,"PHASE1":5933,"PHASE2":5935,"PHASE3":5937,"PHASE4":5939,"NA":5941},{"trials":5924,"activeCount":109},[5925,5929],{"nctId":5442,"briefTitle":5443,"status":169,"phases":5926,"primaryCompletion":2102,"completion":141,"start":5445,"enrollment":5446,"conditions":5927,"interventions":5928},[88],[18],[5437,5284],{"nctId":5277,"briefTitle":5278,"status":104,"phases":5930,"primaryCompletion":5272,"completion":5272,"start":2484,"enrollment":109,"conditions":5931,"interventions":5932},[88],[36,27,18],[5264,5282,5283,5284],{"trials":5934,"activeCount":109},[],{"trials":5936,"activeCount":109},[],{"trials":5938,"activeCount":109},[],{"trials":5940,"activeCount":109},[],{"trials":5942,"activeCount":109},[5943],{"nctId":5905,"briefTitle":5906,"status":169,"phases":5944,"primaryCompletion":172,"completion":172,"start":5908,"enrollment":184,"conditions":5945,"interventions":5946},[93],[18,27,33],[5879,5284],{"intervention":5283,"totalTrials":97,"cells":5948},{"EARLY_PHASE1":5949,"PHASE1":5955,"PHASE2":5957,"PHASE3":5959,"PHASE4":5972,"NA":5974},{"trials":5950,"activeCount":109},[5951],{"nctId":5277,"briefTitle":5278,"status":104,"phases":5952,"primaryCompletion":5272,"completion":5272,"start":2484,"enrollment":109,"conditions":5953,"interventions":5954},[88],[36,27,18],[5264,5282,5283,5284],{"trials":5956,"activeCount":109},[],{"trials":5958,"activeCount":109},[],{"trials":5960,"activeCount":109},[5961],{"nctId":5962,"briefTitle":5963,"status":118,"phases":5964,"primaryCompletion":5965,"completion":5965,"start":5966,"enrollment":299,"conditions":5967,"interventions":5971},"NCT03368066","Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?",[91],"2019-03-12","2018-01-29",[5968,4439,5969,5970],"Adrenal Insufficiency","Spur Cell Anemia","Lecithin Acyltransferase Deficiency",[5283],{"trials":5973,"activeCount":109},[],{"trials":5975,"activeCount":109},[5976],{"nctId":5977,"briefTitle":5978,"status":118,"phases":5979,"primaryCompletion":5980,"completion":5981,"start":5982,"enrollment":5983,"conditions":5984,"interventions":5985},"NCT04642391","Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis",[],"2023-06-30","2024-06-30","2021-08-02",76,[4439,5968],[5283],{"intervention":2080,"totalTrials":97,"cells":5987},{"EARLY_PHASE1":5988,"PHASE1":5994,"PHASE2":6005,"PHASE3":6007,"PHASE4":6009,"NA":6011},{"trials":5989,"activeCount":109},[5990],{"nctId":2073,"briefTitle":2074,"status":169,"phases":5991,"primaryCompletion":1509,"completion":1509,"start":2076,"enrollment":34,"conditions":5992,"interventions":5993},[88],[2078,18],[2020,2080,2081],{"trials":5995,"activeCount":109},[5996],{"nctId":5997,"briefTitle":5998,"status":169,"phases":5999,"primaryCompletion":6000,"completion":6001,"start":6002,"enrollment":4178,"conditions":6003,"interventions":6004},"NCT00930228","Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome",[89],"2024-05","2024-08","2009-01",[18],[2080],{"trials":6006,"activeCount":109},[],{"trials":6008,"activeCount":109},[],{"trials":6010,"activeCount":109},[],{"trials":6012,"activeCount":109},[6013],{"nctId":5712,"briefTitle":5713,"status":850,"phases":6014,"primaryCompletion":3890,"completion":3890,"start":5715,"enrollment":508,"conditions":6015,"interventions":6016},[93],[18,33],[2080,5653,5701],{"intervention":6018,"totalTrials":154,"cells":6019},"Povidone-Iodine",{"EARLY_PHASE1":6020,"PHASE1":6022,"PHASE2":6024,"PHASE3":6026,"PHASE4":6028,"NA":6030},{"trials":6021,"activeCount":109},[],{"trials":6023,"activeCount":109},[],{"trials":6025,"activeCount":109},[],{"trials":6027,"activeCount":109},[],{"trials":6029,"activeCount":109},[],{"trials":6031,"activeCount":109},[6032,6045],{"nctId":6033,"briefTitle":6034,"status":118,"phases":6035,"primaryCompletion":6036,"completion":6037,"start":6038,"enrollment":6039,"conditions":6040,"interventions":6042},"NCT01886001","Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections",[93],"2013-05","2013-07","2012-11",53,[6041],"Colonization",[6018,6043,6044],"Chlorhexidine","Pluronic",{"nctId":6046,"briefTitle":6047,"status":169,"phases":6048,"primaryCompletion":6049,"completion":6050,"start":6037,"enrollment":299,"conditions":6051,"interventions":6054},"NCT01893060","Umbilical Cord Care for the Prevention of Colonization",[93],"2014-05","2014-07",[6052,6053],"Line Insertion Site","Central Line-associated Bloodstream Infection (CLABSI)",[6018,6055,6056],"Chlorhexidine gluconate","Pluronic Cream",{"intervention":6058,"totalTrials":154,"cells":6059},"Saline",{"EARLY_PHASE1":6060,"PHASE1":6062,"PHASE2":6064,"PHASE3":6066,"PHASE4":6068,"NA":6070},{"trials":6061,"activeCount":109},[],{"trials":6063,"activeCount":109},[],{"trials":6065,"activeCount":109},[],{"trials":6067,"activeCount":109},[],{"trials":6069,"activeCount":109},[],{"trials":6071,"activeCount":109},[6072,6081],{"nctId":6073,"briefTitle":6074,"status":118,"phases":6075,"primaryCompletion":2595,"start":3400,"enrollment":4548,"conditions":6076,"interventions":6077},"NCT00912574","Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38",[93],[4506],[6078,6079,6080,6058],"GM-CSF-in-adjuvant","Montanide ISA-51","GM-CSF and Montanide ISA-51",{"nctId":6082,"briefTitle":6083,"status":169,"phases":6084,"primaryCompletion":6050,"completion":6050,"start":5143,"enrollment":2252,"conditions":6085,"interventions":6086},"NCT01795235","Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones",[93],[3895],[6058,6087,6088],"Glucagon","Atenolol",{"intervention":6090,"totalTrials":154,"cells":6091},"Normal saline",{"EARLY_PHASE1":6092,"PHASE1":6094,"PHASE2":6096,"PHASE3":6098,"PHASE4":6100,"NA":6102},{"trials":6093,"activeCount":109},[],{"trials":6095,"activeCount":109},[],{"trials":6097,"activeCount":109},[],{"trials":6099,"activeCount":109},[],{"trials":6101,"activeCount":109},[],{"trials":6103,"activeCount":109},[6104,6112],{"nctId":6105,"briefTitle":6106,"status":169,"phases":6107,"primaryCompletion":6108,"completion":6108,"start":2825,"enrollment":439,"conditions":6109,"interventions":6111},"NCT02413125","Comparison of Nasal Saline Irrigation Bottle Contamination Between Two Solutions",[93],"2015-06",[6110],"Sinusitis",[6090],{"nctId":6113,"briefTitle":6114,"status":118,"phases":6115,"primaryCompletion":6116,"completion":6117,"start":2528,"enrollment":1242,"conditions":6118,"interventions":6120},"NCT04508504","PENG Block for Arthroscopic Hip Surgery",[93],"2022-02-01","2022-02-08",[2668,6119],"Hip Arthroscopy",[6121,6122],"Ropivacaine 0.5% Injectable Solution","Normal Saline",{"intervention":6124,"totalTrials":154,"cells":6125},"MK-0677",{"EARLY_PHASE1":6126,"PHASE1":6128,"PHASE2":6130,"PHASE3":6140,"PHASE4":6142,"NA":6144},{"trials":6127,"activeCount":109},[],{"trials":6129,"activeCount":109},[],{"trials":6131,"activeCount":109},[6132],{"nctId":6133,"briefTitle":6134,"status":104,"phases":6135,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":109,"conditions":6136,"interventions":6139},"NCT01343641","Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4\u002F5 Subjects",[90],[6137,6138],"Chronic Kidney Disease","Kidney Disease",[6124],{"trials":6141,"activeCount":109},[],{"trials":6143,"activeCount":109},[],{"trials":6145,"activeCount":109},[6146],{"nctId":6147,"briefTitle":6148,"status":118,"phases":6149,"primaryCompletion":6002,"completion":6150,"start":6151,"enrollment":2736,"conditions":6152,"interventions":6153},"NCT00395291","Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients",[93],"2010-05","2006-08",[6137,3832],[6124],{"intervention":6155,"totalTrials":149,"cells":6156},"Contrast Enhanced Voiding Urosonography with Urodynamic Testing",{"EARLY_PHASE1":6157,"PHASE1":6159,"PHASE2":6161,"PHASE3":6163,"PHASE4":6165,"NA":6167},{"trials":6158,"activeCount":109},[],{"trials":6160,"activeCount":109},[],{"trials":6162,"activeCount":109},[],{"trials":6164,"activeCount":109},[],{"trials":6166,"activeCount":109},[],{"trials":6168,"activeCount":109},[6169],{"nctId":6170,"briefTitle":6171,"status":169,"phases":6172,"primaryCompletion":6173,"completion":6173,"start":6174,"enrollment":6175,"conditions":6176,"interventions":6183},"NCT04738539","Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies",[],"2022-03-02","2021-03-02",105,[6177,6178,6179,6180,6181,6182],"Myelomeningocele","Neurogenic Bladder","Tethered Cord Syndrome","Bladder, Neurogenic","Urologic Diseases","Neurologic Dysfunction",[6155],{"intervention":6185,"totalTrials":149,"cells":6186},"Mirtazapine",{"EARLY_PHASE1":6187,"PHASE1":6189,"PHASE2":6191,"PHASE3":6193,"PHASE4":6195,"NA":6197},{"trials":6188,"activeCount":109},[],{"trials":6190,"activeCount":109},[],{"trials":6192,"activeCount":109},[],{"trials":6194,"activeCount":109},[],{"trials":6196,"activeCount":109},[],{"trials":6198,"activeCount":109},[6199],{"nctId":6200,"briefTitle":6201,"status":104,"phases":6202,"primaryCompletion":6203,"completion":5469,"start":6204,"enrollment":109,"conditions":6205,"interventions":6207},"NCT00600145","Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward",[93],"2009-12","2007-09",[6206],"Amphetamine Dependence",[6185],{"intervention":6209,"totalTrials":149,"cells":6210},"DNA, RNA testing",{"EARLY_PHASE1":6211,"PHASE1":6213,"PHASE2":6215,"PHASE3":6217,"PHASE4":6219,"NA":6221},{"trials":6212,"activeCount":109},[],{"trials":6214,"activeCount":109},[],{"trials":6216,"activeCount":109},[],{"trials":6218,"activeCount":109},[],{"trials":6220,"activeCount":109},[],{"trials":6222,"activeCount":109},[6223],{"nctId":6224,"briefTitle":6225,"status":169,"phases":6226,"primaryCompletion":6227,"start":6228,"enrollment":6229,"conditions":6230,"interventions":6233},"NCT02869464","UVA Brain and Aortic Aneurysm Study",[],"2017-04","2014-04",360,[6231,6232],"Intracranial Aneurysm","Abdominal Aortic Aneurysm",[6209],{"intervention":6235,"totalTrials":149,"cells":6236},"BOLUS",{"EARLY_PHASE1":6237,"PHASE1":6239,"PHASE2":6241,"PHASE3":6243,"PHASE4":6245,"NA":6247},{"trials":6238,"activeCount":109},[],{"trials":6240,"activeCount":109},[],{"trials":6242,"activeCount":109},[],{"trials":6244,"activeCount":109},[],{"trials":6246,"activeCount":109},[],{"trials":6248,"activeCount":109},[6249],{"nctId":6250,"briefTitle":6251,"status":118,"phases":6252,"primaryCompletion":2552,"completion":2552,"start":3556,"enrollment":439,"conditions":6253,"interventions":6255},"NCT02058979","Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery",[93],[6254],"Plasma Concentration of Antibiotics",[6235,6256],"CONTINUOUS",{"intervention":6256,"totalTrials":149,"cells":6258},{"EARLY_PHASE1":6259,"PHASE1":6261,"PHASE2":6263,"PHASE3":6265,"PHASE4":6267,"NA":6269},{"trials":6260,"activeCount":109},[],{"trials":6262,"activeCount":109},[],{"trials":6264,"activeCount":109},[],{"trials":6266,"activeCount":109},[],{"trials":6268,"activeCount":109},[],{"trials":6270,"activeCount":109},[6271],{"nctId":6250,"briefTitle":6251,"status":118,"phases":6272,"primaryCompletion":2552,"completion":2552,"start":3556,"enrollment":439,"conditions":6273,"interventions":6274},[93],[6254],[6235,6256],{"intervention":6276,"totalTrials":149,"cells":6277},"Pharmacological",{"EARLY_PHASE1":6278,"PHASE1":6280,"PHASE2":6282,"PHASE3":6284,"PHASE4":6286,"NA":6288},{"trials":6279,"activeCount":109},[],{"trials":6281,"activeCount":109},[],{"trials":6283,"activeCount":109},[],{"trials":6285,"activeCount":109},[],{"trials":6287,"activeCount":109},[],{"trials":6289,"activeCount":109},[6290],{"nctId":6291,"briefTitle":6292,"status":118,"phases":6293,"primaryCompletion":6294,"completion":6294,"start":5761,"enrollment":6295,"conditions":6296,"interventions":6297},"NCT02905656","Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit",[93],"2020-06-16",903,[2290],[6276],{"intervention":6299,"totalTrials":149,"cells":6300},"GIA",{"EARLY_PHASE1":6301,"PHASE1":6303,"PHASE2":6305,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6302,"activeCount":109},[],{"trials":6304,"activeCount":109},[],{"trials":6306,"activeCount":109},[],{"trials":6308,"activeCount":109},[],{"trials":6310,"activeCount":109},[],{"trials":6312,"activeCount":109},[6313],{"nctId":6314,"briefTitle":6315,"status":169,"phases":6316,"primaryCompletion":6317,"completion":6318,"start":6319,"enrollment":439,"conditions":6320,"interventions":6322},"NCT04142333","GIA in Cascade Testing",[93],"2021-08-09","2022-12-01","2020-12-18",[6321],"Genetic Predisposition",[6299],{"intervention":6043,"totalTrials":149,"cells":6324},{"EARLY_PHASE1":6325,"PHASE1":6327,"PHASE2":6329,"PHASE3":6331,"PHASE4":6333,"NA":6335},{"trials":6326,"activeCount":109},[],{"trials":6328,"activeCount":109},[],{"trials":6330,"activeCount":109},[],{"trials":6332,"activeCount":109},[],{"trials":6334,"activeCount":109},[],{"trials":6336,"activeCount":109},[6337],{"nctId":6033,"briefTitle":6034,"status":118,"phases":6338,"primaryCompletion":6036,"completion":6037,"start":6038,"enrollment":6039,"conditions":6339,"interventions":6340},[93],[6041],[6018,6043,6044],{"intervention":6044,"totalTrials":149,"cells":6342},{"EARLY_PHASE1":6343,"PHASE1":6345,"PHASE2":6347,"PHASE3":6349,"PHASE4":6351,"NA":6353},{"trials":6344,"activeCount":109},[],{"trials":6346,"activeCount":109},[],{"trials":6348,"activeCount":109},[],{"trials":6350,"activeCount":109},[],{"trials":6352,"activeCount":109},[],{"trials":6354,"activeCount":109},[6355],{"nctId":6033,"briefTitle":6034,"status":118,"phases":6356,"primaryCompletion":6036,"completion":6037,"start":6038,"enrollment":6039,"conditions":6357,"interventions":6358},[93],[6041],[6018,6043,6044],{"intervention":6360,"totalTrials":149,"cells":6361},"ACEI or ARB",{"EARLY_PHASE1":6362,"PHASE1":6364,"PHASE2":6366,"PHASE3":6368,"PHASE4":6370,"NA":6372},{"trials":6363,"activeCount":109},[],{"trials":6365,"activeCount":109},[],{"trials":6367,"activeCount":109},[],{"trials":6369,"activeCount":109},[],{"trials":6371,"activeCount":109},[],{"trials":6373,"activeCount":109},[6374],{"nctId":6375,"briefTitle":6376,"status":850,"phases":6377,"primaryCompletion":3829,"completion":3829,"start":6378,"enrollment":2252,"conditions":6379,"interventions":6381},"NCT01101269","Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease",[93],"2010-02",[6380],"Type 2 Diabetes",[6360,6382],"Lisinopril",{"intervention":6382,"totalTrials":149,"cells":6384},{"EARLY_PHASE1":6385,"PHASE1":6387,"PHASE2":6389,"PHASE3":6391,"PHASE4":6393,"NA":6395},{"trials":6386,"activeCount":109},[],{"trials":6388,"activeCount":109},[],{"trials":6390,"activeCount":109},[],{"trials":6392,"activeCount":109},[],{"trials":6394,"activeCount":109},[],{"trials":6396,"activeCount":109},[6397],{"nctId":6375,"briefTitle":6376,"status":850,"phases":6398,"primaryCompletion":3829,"completion":3829,"start":6378,"enrollment":2252,"conditions":6399,"interventions":6400},[93],[6380],[6360,6382],{"intervention":6402,"totalTrials":149,"cells":6403},"sodium hyaluronate",{"EARLY_PHASE1":6404,"PHASE1":6406,"PHASE2":6408,"PHASE3":6410,"PHASE4":6412,"NA":6414},{"trials":6405,"activeCount":109},[],{"trials":6407,"activeCount":109},[],{"trials":6409,"activeCount":109},[],{"trials":6411,"activeCount":109},[],{"trials":6413,"activeCount":109},[],{"trials":6415,"activeCount":109},[6416],{"nctId":6417,"briefTitle":6418,"status":118,"phases":6419,"completion":2125,"start":2759,"enrollment":760,"conditions":6420,"interventions":6422},"NCT00570648","A Prospective Study of the Effect of Topical Sodium Hyaluronate Immediately Post-PKP on Time to Reepithelialization",[93],[6421],"Corneal Transplantation",[6402],{"intervention":6424,"totalTrials":149,"cells":6425},"Simvastatin",{"EARLY_PHASE1":6426,"PHASE1":6428,"PHASE2":6430,"PHASE3":6432,"PHASE4":6434,"NA":6436},{"trials":6427,"activeCount":109},[],{"trials":6429,"activeCount":109},[],{"trials":6431,"activeCount":109},[],{"trials":6433,"activeCount":109},[],{"trials":6435,"activeCount":109},[],{"trials":6437,"activeCount":109},[6438],{"nctId":6439,"briefTitle":6440,"status":118,"phases":6441,"primaryCompletion":6442,"completion":6442,"start":6443,"enrollment":4654,"conditions":6444,"interventions":6446},"NCT00587678","Comprehensive Magnetic Resonance of Peripheral Arterial Disease",[93],"2009-10","2006-01",[6445],"Peripheral Artery Disease",[6424,6447,6448],"Ezetimibe","Simvastatin\u002FEzetimibe",{"intervention":6447,"totalTrials":149,"cells":6450},{"EARLY_PHASE1":6451,"PHASE1":6453,"PHASE2":6455,"PHASE3":6457,"PHASE4":6459,"NA":6461},{"trials":6452,"activeCount":109},[],{"trials":6454,"activeCount":109},[],{"trials":6456,"activeCount":109},[],{"trials":6458,"activeCount":109},[],{"trials":6460,"activeCount":109},[],{"trials":6462,"activeCount":109},[6463],{"nctId":6439,"briefTitle":6440,"status":118,"phases":6464,"primaryCompletion":6442,"completion":6442,"start":6443,"enrollment":4654,"conditions":6465,"interventions":6466},[93],[6445],[6424,6447,6448],{"intervention":6448,"totalTrials":149,"cells":6468},{"EARLY_PHASE1":6469,"PHASE1":6471,"PHASE2":6473,"PHASE3":6475,"PHASE4":6477,"NA":6479},{"trials":6470,"activeCount":109},[],{"trials":6472,"activeCount":109},[],{"trials":6474,"activeCount":109},[],{"trials":6476,"activeCount":109},[],{"trials":6478,"activeCount":109},[],{"trials":6480,"activeCount":109},[6481],{"nctId":6439,"briefTitle":6440,"status":118,"phases":6482,"primaryCompletion":6442,"completion":6442,"start":6443,"enrollment":4654,"conditions":6483,"interventions":6484},[93],[6445],[6424,6447,6448],{"intervention":6486,"totalTrials":149,"cells":6487},"SUPREP Bowel Prep Kit",{"EARLY_PHASE1":6488,"PHASE1":6490,"PHASE2":6492,"PHASE3":6494,"PHASE4":6496,"NA":6498},{"trials":6489,"activeCount":109},[],{"trials":6491,"activeCount":109},[],{"trials":6493,"activeCount":109},[],{"trials":6495,"activeCount":109},[],{"trials":6497,"activeCount":109},[],{"trials":6499,"activeCount":109},[6500],{"nctId":6501,"briefTitle":6502,"status":169,"phases":6503,"primaryCompletion":6504,"completion":6505,"start":6506,"enrollment":6507,"conditions":6508,"interventions":6512},"NCT04504292","Pilot Study to Assess Tolerability and Feasibility of Oral Sulfate Solution (SUPREP) in Hospitalized Patients",[93],"2021-05-30","2021-07-30","2020-08-01",124,[6509,6510,6511],"Inpatient Colonoscopy","Oral Sulfate Solution","Polyethelene Glycol",[6486,6513],"Golytely Oral Product",{"intervention":6513,"totalTrials":149,"cells":6515},{"EARLY_PHASE1":6516,"PHASE1":6518,"PHASE2":6520,"PHASE3":6522,"PHASE4":6524,"NA":6526},{"trials":6517,"activeCount":109},[],{"trials":6519,"activeCount":109},[],{"trials":6521,"activeCount":109},[],{"trials":6523,"activeCount":109},[],{"trials":6525,"activeCount":109},[],{"trials":6527,"activeCount":109},[6528],{"nctId":6501,"briefTitle":6502,"status":169,"phases":6529,"primaryCompletion":6504,"completion":6505,"start":6506,"enrollment":6507,"conditions":6530,"interventions":6531},[93],[6509,6510,6511],[6486,6513],{"intervention":6533,"totalTrials":149,"cells":6534},"Definity microbubbles",{"EARLY_PHASE1":6535,"PHASE1":6537,"PHASE2":6539,"PHASE3":6541,"PHASE4":6543,"NA":6545},{"trials":6536,"activeCount":109},[],{"trials":6538,"activeCount":109},[],{"trials":6540,"activeCount":109},[],{"trials":6542,"activeCount":109},[],{"trials":6544,"activeCount":109},[],{"trials":6546,"activeCount":109},[6547],{"nctId":6548,"briefTitle":6549,"status":118,"phases":6550,"primaryCompletion":4435,"completion":4435,"start":2440,"enrollment":1116,"conditions":6551,"interventions":6552},"NCT01337947","The Impact of Fitness on Vascular Dysfunction in Adolescents With Type 1 Diabetes",[],[24],[6533],{"intervention":5872,"totalTrials":149,"cells":6554},{"EARLY_PHASE1":6555,"PHASE1":6557,"PHASE2":6559,"PHASE3":6561,"PHASE4":6563,"NA":6565},{"trials":6556,"activeCount":109},[],{"trials":6558,"activeCount":109},[],{"trials":6560,"activeCount":109},[],{"trials":6562,"activeCount":109},[],{"trials":6564,"activeCount":109},[],{"trials":6566,"activeCount":109},[6567],{"nctId":5866,"briefTitle":5867,"status":118,"phases":6568,"primaryCompletion":3120,"completion":3120,"start":5869,"enrollment":3893,"conditions":6569,"interventions":6570},[93],[186,124],[5872,5873],{"intervention":6572,"totalTrials":149,"cells":6573},"Definity ultrasound contrast agent",{"EARLY_PHASE1":6574,"PHASE1":6576,"PHASE2":6578,"PHASE3":6580,"PHASE4":6582,"NA":6584},{"trials":6575,"activeCount":109},[],{"trials":6577,"activeCount":109},[],{"trials":6579,"activeCount":109},[],{"trials":6581,"activeCount":109},[],{"trials":6583,"activeCount":109},[],{"trials":6585,"activeCount":109},[6586],{"nctId":6587,"briefTitle":6588,"status":169,"phases":6589,"primaryCompletion":3438,"start":6590,"enrollment":5708,"conditions":6591,"interventions":6593},"NCT02147470","Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study",[93],"2013-02",[6592],"Liver Cirrhosis and Acute Kidney Injury",[6572],{"intervention":6595,"totalTrials":149,"cells":6596},"Erythromycin",{"EARLY_PHASE1":6597,"PHASE1":6599,"PHASE2":6601,"PHASE3":6603,"PHASE4":6605,"NA":6607},{"trials":6598,"activeCount":109},[],{"trials":6600,"activeCount":109},[],{"trials":6602,"activeCount":109},[],{"trials":6604,"activeCount":109},[],{"trials":6606,"activeCount":109},[],{"trials":6608,"activeCount":109},[6609],{"nctId":6610,"briefTitle":6611,"status":169,"phases":6612,"primaryCompletion":5144,"completion":5869,"start":6613,"enrollment":1191,"conditions":6614,"interventions":6618},"NCT01825473","Study of Erythromycin in GER-Associated Apnea of the Newborn",[93],"2012-09",[6615,6616,6617],"Gastroesophageal Reflux","Apnea","Bradycardia",[6595],{"intervention":6620,"totalTrials":149,"cells":6621},"Gadolinium contrast dye",{"EARLY_PHASE1":6622,"PHASE1":6624,"PHASE2":6626,"PHASE3":6628,"PHASE4":6630,"NA":6632},{"trials":6623,"activeCount":109},[],{"trials":6625,"activeCount":109},[],{"trials":6627,"activeCount":109},[],{"trials":6629,"activeCount":109},[],{"trials":6631,"activeCount":109},[],{"trials":6633,"activeCount":109},[6634],{"nctId":6635,"briefTitle":6636,"status":169,"phases":6637,"primaryCompletion":3253,"completion":3253,"start":3230,"enrollment":174,"conditions":6638,"interventions":6640},"NCT02512796","In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes",[],[6639],"Gadolinium Toxicity",[6620],{"intervention":6642,"totalTrials":149,"cells":6643},"Bovine gelatin",{"EARLY_PHASE1":6644,"PHASE1":6646,"PHASE2":6648,"PHASE3":6650,"PHASE4":6652,"NA":6654},{"trials":6645,"activeCount":109},[],{"trials":6647,"activeCount":109},[],{"trials":6649,"activeCount":109},[],{"trials":6651,"activeCount":109},[],{"trials":6653,"activeCount":109},[],{"trials":6655,"activeCount":109},[6656],{"nctId":6657,"briefTitle":6658,"status":104,"phases":6659,"primaryCompletion":6150,"completion":6150,"start":3689,"enrollment":2883,"conditions":6660,"interventions":6662},"NCT00963196","Study of Supplementation of Antidepressants With Fish Oil to Improve Time to Clinical Response",[93],[6661],"Major Depressive Disorder",[6642],{"intervention":6664,"totalTrials":149,"cells":6665},"Contrast Enhanced Ultrasonography",{"EARLY_PHASE1":6666,"PHASE1":6668,"PHASE2":6670,"PHASE3":6672,"PHASE4":6674,"NA":6676},{"trials":6667,"activeCount":109},[],{"trials":6669,"activeCount":109},[],{"trials":6671,"activeCount":109},[],{"trials":6673,"activeCount":109},[],{"trials":6675,"activeCount":109},[],{"trials":6677,"activeCount":109},[6678],{"nctId":6679,"briefTitle":6680,"status":104,"phases":6681,"primaryCompletion":6682,"completion":6682,"start":6683,"enrollment":109,"conditions":6684,"interventions":6686},"NCT01426724","Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease",[93],"2013-08","2011-09",[6137,6685],"Secondary Hyperparathyroidism",[6664],{"intervention":6688,"totalTrials":149,"cells":6689},"modafinil",{"EARLY_PHASE1":6690,"PHASE1":6692,"PHASE2":6694,"PHASE3":6696,"PHASE4":6698,"NA":6700},{"trials":6691,"activeCount":109},[],{"trials":6693,"activeCount":109},[],{"trials":6695,"activeCount":109},[],{"trials":6697,"activeCount":109},[],{"trials":6699,"activeCount":109},[],{"trials":6701,"activeCount":109},[6702],{"nctId":6703,"briefTitle":6704,"status":169,"phases":6705,"start":6706,"conditions":6707,"interventions":6712},"NCT00112515","Modafinil in Treating Fatigue in Patients With Cancer",[93],"2004-02",[6708,6709,6710,6711],"Cognitive\u002FFunctional Effects","Depression","Fatigue","Unspecified Adult Solid Tumor, Protocol Specific",[6688],{"intervention":6078,"totalTrials":149,"cells":6714},{"EARLY_PHASE1":6715,"PHASE1":6717,"PHASE2":6719,"PHASE3":6721,"PHASE4":6723,"NA":6725},{"trials":6716,"activeCount":109},[],{"trials":6718,"activeCount":109},[],{"trials":6720,"activeCount":109},[],{"trials":6722,"activeCount":109},[],{"trials":6724,"activeCount":109},[],{"trials":6726,"activeCount":109},[6727],{"nctId":6073,"briefTitle":6074,"status":118,"phases":6728,"primaryCompletion":2595,"start":3400,"enrollment":4548,"conditions":6729,"interventions":6730},[93],[4506],[6078,6079,6080,6058],{"intervention":6079,"totalTrials":149,"cells":6732},{"EARLY_PHASE1":6733,"PHASE1":6735,"PHASE2":6737,"PHASE3":6739,"PHASE4":6741,"NA":6743},{"trials":6734,"activeCount":109},[],{"trials":6736,"activeCount":109},[],{"trials":6738,"activeCount":109},[],{"trials":6740,"activeCount":109},[],{"trials":6742,"activeCount":109},[],{"trials":6744,"activeCount":109},[6745],{"nctId":6073,"briefTitle":6074,"status":118,"phases":6746,"primaryCompletion":2595,"start":3400,"enrollment":4548,"conditions":6747,"interventions":6748},[93],[4506],[6078,6079,6080,6058],{"intervention":6080,"totalTrials":149,"cells":6750},{"EARLY_PHASE1":6751,"PHASE1":6753,"PHASE2":6755,"PHASE3":6757,"PHASE4":6759,"NA":6761},{"trials":6752,"activeCount":109},[],{"trials":6754,"activeCount":109},[],{"trials":6756,"activeCount":109},[],{"trials":6758,"activeCount":109},[],{"trials":6760,"activeCount":109},[],{"trials":6762,"activeCount":109},[6763],{"nctId":6073,"briefTitle":6074,"status":118,"phases":6764,"primaryCompletion":2595,"start":3400,"enrollment":4548,"conditions":6765,"interventions":6766},[93],[4506],[6078,6079,6080,6058],{"intervention":6768,"totalTrials":149,"cells":6769},"Closed loop with pramlintide",{"EARLY_PHASE1":6770,"PHASE1":6772,"PHASE2":6774,"PHASE3":6776,"PHASE4":6778,"NA":6780},{"trials":6771,"activeCount":109},[],{"trials":6773,"activeCount":109},[],{"trials":6775,"activeCount":109},[],{"trials":6777,"activeCount":109},[],{"trials":6779,"activeCount":109},[],{"trials":6781,"activeCount":109},[6782],{"nctId":6783,"briefTitle":6784,"status":850,"phases":6785,"primaryCompletion":4574,"completion":4574,"start":5468,"enrollment":154,"conditions":6786,"interventions":6787},"NCT01434862","Pramlintide Combined With Model Predictive Control Algorithm",[93],[15],[6768,6788],"Open loop with pramlintide",{"intervention":6788,"totalTrials":149,"cells":6790},{"EARLY_PHASE1":6791,"PHASE1":6793,"PHASE2":6795,"PHASE3":6797,"PHASE4":6799,"NA":6801},{"trials":6792,"activeCount":109},[],{"trials":6794,"activeCount":109},[],{"trials":6796,"activeCount":109},[],{"trials":6798,"activeCount":109},[],{"trials":6800,"activeCount":109},[],{"trials":6802,"activeCount":109},[6803],{"nctId":6783,"briefTitle":6784,"status":850,"phases":6804,"primaryCompletion":4574,"completion":4574,"start":5468,"enrollment":154,"conditions":6805,"interventions":6806},[93],[15],[6768,6788],{"intervention":6808,"totalTrials":149,"cells":6809},"sirolimus",{"EARLY_PHASE1":6810,"PHASE1":6812,"PHASE2":6814,"PHASE3":6816,"PHASE4":6818,"NA":6820},{"trials":6811,"activeCount":109},[],{"trials":6813,"activeCount":109},[],{"trials":6815,"activeCount":109},[],{"trials":6817,"activeCount":109},[],{"trials":6819,"activeCount":109},[],{"trials":6821,"activeCount":109},[6822],{"nctId":6823,"briefTitle":6824,"status":118,"phases":6825,"primaryCompletion":4710,"completion":4710,"start":2439,"enrollment":1116,"conditions":6826,"interventions":6829},"NCT01462006","Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)",[93],[2254,6827,6828],"Diffuse Parenchymal Lung Disease","Interstitial Lung Disease",[6808],{"intervention":6831,"totalTrials":149,"cells":6832},"hyperpolarized helium-3 gas with MRI of the chest",{"EARLY_PHASE1":6833,"PHASE1":6835,"PHASE2":6837,"PHASE3":6839,"PHASE4":6841,"NA":6843},{"trials":6834,"activeCount":109},[],{"trials":6836,"activeCount":109},[],{"trials":6838,"activeCount":109},[],{"trials":6840,"activeCount":109},[],{"trials":6842,"activeCount":109},[],{"trials":6844,"activeCount":109},[6845],{"nctId":6846,"briefTitle":6847,"status":118,"phases":6848,"primaryCompletion":6849,"completion":6849,"start":6850,"enrollment":624,"conditions":6851,"interventions":6854},"NCT02154568","Study of Airflow in the Lungs Using Helium MRI",[93],"2026-02-26","2013-11-07",[6852,3895,6853],"COPD","Constrictive Bronchitis",[6831],{"intervention":6856,"totalTrials":149,"cells":6857},"perflutren",{"EARLY_PHASE1":6858,"PHASE1":6860,"PHASE2":6862,"PHASE3":6864,"PHASE4":6866,"NA":6868},{"trials":6859,"activeCount":109},[],{"trials":6861,"activeCount":109},[],{"trials":6863,"activeCount":109},[],{"trials":6865,"activeCount":109},[],{"trials":6867,"activeCount":109},[],{"trials":6869,"activeCount":109},[6870],{"nctId":6871,"briefTitle":6872,"status":169,"phases":6873,"primaryCompletion":4327,"start":4574,"enrollment":348,"conditions":6874,"interventions":6876},"NCT01544036","Monitoring Renal Blood Flow With Contrast Enhanced Ultrasound During Coronary Angiogram",[93],[6875],"Contrast Induced Acute Kidney Injury",[6856],{"intervention":6878,"totalTrials":149,"cells":6879},"lovaza",{"EARLY_PHASE1":6880,"PHASE1":6882,"PHASE2":6884,"PHASE3":6886,"PHASE4":6888,"NA":6890},{"trials":6881,"activeCount":109},[],{"trials":6883,"activeCount":109},[],{"trials":6885,"activeCount":109},[],{"trials":6887,"activeCount":109},[],{"trials":6889,"activeCount":109},[],{"trials":6891,"activeCount":109},[6892],{"nctId":6893,"briefTitle":6894,"status":104,"phases":6895,"primaryCompletion":6203,"completion":6378,"start":6204,"enrollment":109,"conditions":6896,"interventions":6897},"NCT00569686","Lovaza Therapy of Peripheral Arterial Disease",[93],[6445],[6878],{"intervention":6899,"totalTrials":149,"cells":6900},"Endoscopic injection of 99mTc-sulfur colloid",{"EARLY_PHASE1":6901,"PHASE1":6903,"PHASE2":6905,"PHASE3":6907,"PHASE4":6909,"NA":6911},{"trials":6902,"activeCount":109},[],{"trials":6904,"activeCount":109},[],{"trials":6906,"activeCount":109},[],{"trials":6908,"activeCount":109},[],{"trials":6910,"activeCount":109},[],{"trials":6912,"activeCount":109},[6913],{"nctId":6914,"briefTitle":6915,"status":104,"phases":6916,"primaryCompletion":6917,"start":6036,"enrollment":109,"conditions":6918,"interventions":6920},"NCT02112240","Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients",[93],"2017-02",[6919],"Rectal Cancer",[6899],{"intervention":6922,"totalTrials":149,"cells":6923},"Methylphenidate Transdermal System",{"EARLY_PHASE1":6924,"PHASE1":6926,"PHASE2":6928,"PHASE3":6930,"PHASE4":6932,"NA":6934},{"trials":6925,"activeCount":109},[],{"trials":6927,"activeCount":109},[],{"trials":6929,"activeCount":109},[],{"trials":6931,"activeCount":109},[],{"trials":6933,"activeCount":109},[],{"trials":6935,"activeCount":109},[6936],{"nctId":6937,"briefTitle":6938,"status":169,"phases":6939,"primaryCompletion":6940,"completion":6940,"start":5638,"enrollment":28,"conditions":6941,"interventions":6943},"NCT00572026","Enhancing ADHD Driving Performance With Stimulant Medication",[93],"2009-07",[6942],"Attention Deficit Hyperactivity Disorder",[6922],{"intervention":5920,"totalTrials":149,"cells":6945},{"EARLY_PHASE1":6946,"PHASE1":6948,"PHASE2":6950,"PHASE3":6952,"PHASE4":6954,"NA":6956},{"trials":6947,"activeCount":109},[],{"trials":6949,"activeCount":109},[],{"trials":6951,"activeCount":109},[],{"trials":6953,"activeCount":109},[],{"trials":6955,"activeCount":109},[],{"trials":6957,"activeCount":109},[6958],{"nctId":5912,"briefTitle":5913,"status":169,"phases":6959,"primaryCompletion":5915,"completion":2060,"start":5916,"enrollment":5917,"conditions":6960,"interventions":6961},[93],[36,18,27],[5879,5920],{"intervention":6963,"totalTrials":149,"cells":6964},"Hyperpolarized Helium-3 MRI of the chest",{"EARLY_PHASE1":6965,"PHASE1":6967,"PHASE2":6969,"PHASE3":6971,"PHASE4":6973,"NA":6975},{"trials":6966,"activeCount":109},[],{"trials":6968,"activeCount":109},[],{"trials":6970,"activeCount":109},[],{"trials":6972,"activeCount":109},[],{"trials":6974,"activeCount":109},[],{"trials":6976,"activeCount":109},[6977],{"nctId":6978,"briefTitle":6979,"status":118,"phases":6980,"primaryCompletion":6981,"completion":6982,"start":6983,"enrollment":557,"conditions":6984,"interventions":6987},"NCT02163681","MRI for Non-Invasive Imaging in Neonates and Children",[93],"2018-06-30","2018-07-30","2011-01-01",[3895,6985,252,6986],"Cystic Fibrosis (CF)","Bronchopulmonary Dysplasia (BPD)",[6963],{"intervention":6121,"totalTrials":149,"cells":6989},{"EARLY_PHASE1":6990,"PHASE1":6992,"PHASE2":6994,"PHASE3":6996,"PHASE4":6998,"NA":7000},{"trials":6991,"activeCount":109},[],{"trials":6993,"activeCount":109},[],{"trials":6995,"activeCount":109},[],{"trials":6997,"activeCount":109},[],{"trials":6999,"activeCount":109},[],{"trials":7001,"activeCount":109},[7002],{"nctId":6113,"briefTitle":6114,"status":118,"phases":7003,"primaryCompletion":6116,"completion":6117,"start":2528,"enrollment":1242,"conditions":7004,"interventions":7005},[93],[2668,6119],[6121,6122],{"intervention":7007,"totalTrials":149,"cells":7008},"Pravastatin",{"EARLY_PHASE1":7009,"PHASE1":7011,"PHASE2":7013,"PHASE3":7015,"PHASE4":7017,"NA":7019},{"trials":7010,"activeCount":109},[],{"trials":7012,"activeCount":109},[],{"trials":7014,"activeCount":109},[],{"trials":7016,"activeCount":109},[],{"trials":7018,"activeCount":109},[],{"trials":7020,"activeCount":109},[7021],{"nctId":7022,"briefTitle":7023,"status":169,"phases":7024,"primaryCompletion":2855,"completion":2855,"start":7025,"enrollment":1191,"conditions":7026,"interventions":7028},"NCT00599625","Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study",[93],"2004-10",[7027],"Crohn's Disease",[7007],{"intervention":7030,"totalTrials":149,"cells":7031},"CeVUS",{"EARLY_PHASE1":7032,"PHASE1":7034,"PHASE2":7036,"PHASE3":7038,"PHASE4":7040,"NA":7042},{"trials":7033,"activeCount":109},[],{"trials":7035,"activeCount":109},[],{"trials":7037,"activeCount":109},[],{"trials":7039,"activeCount":109},[],{"trials":7041,"activeCount":109},[],{"trials":7043,"activeCount":109},[7044],{"nctId":7045,"briefTitle":7046,"status":118,"phases":7047,"primaryCompletion":7048,"completion":7048,"start":7049,"enrollment":5708,"conditions":7050,"interventions":7051},"NCT04170413","Feasibility of Using Contrast Enhanced Voiding Urosonography (CeVUS) During Urodynamic Studies",[],"2020-11-02","2020-01-01",[6178],[7030],{"intervention":7053,"totalTrials":149,"cells":7054},"Bifidobacterium animalis subsp. lactis Bl-04",{"EARLY_PHASE1":7055,"PHASE1":7057,"PHASE2":7059,"PHASE3":7061,"PHASE4":7063,"NA":7065},{"trials":7056,"activeCount":109},[],{"trials":7058,"activeCount":109},[],{"trials":7060,"activeCount":109},[],{"trials":7062,"activeCount":109},[],{"trials":7064,"activeCount":109},[],{"trials":7066,"activeCount":109},[7067],{"nctId":7068,"briefTitle":7069,"status":118,"phases":7070,"primaryCompletion":7071,"completion":7071,"start":7072,"enrollment":7073,"conditions":7074,"interventions":7075},"NCT02679807","Effect of Probiotic on Rhinovirus Induced Colds",[93],"2018-04","2016-02",380,[5782],[7053],{"intervention":6087,"totalTrials":149,"cells":7077},{"EARLY_PHASE1":7078,"PHASE1":7080,"PHASE2":7082,"PHASE3":7084,"PHASE4":7086,"NA":7088},{"trials":7079,"activeCount":109},[],{"trials":7081,"activeCount":109},[],{"trials":7083,"activeCount":109},[],{"trials":7085,"activeCount":109},[],{"trials":7087,"activeCount":109},[],{"trials":7089,"activeCount":109},[7090],{"nctId":6082,"briefTitle":6083,"status":169,"phases":7091,"primaryCompletion":6050,"completion":6050,"start":5143,"enrollment":2252,"conditions":7092,"interventions":7093},[93],[3895],[6058,6087,6088],{"intervention":6088,"totalTrials":149,"cells":7095},{"EARLY_PHASE1":7096,"PHASE1":7098,"PHASE2":7100,"PHASE3":7102,"PHASE4":7104,"NA":7106},{"trials":7097,"activeCount":109},[],{"trials":7099,"activeCount":109},[],{"trials":7101,"activeCount":109},[],{"trials":7103,"activeCount":109},[],{"trials":7105,"activeCount":109},[],{"trials":7107,"activeCount":109},[7108],{"nctId":6082,"briefTitle":6083,"status":169,"phases":7109,"primaryCompletion":6050,"completion":6050,"start":5143,"enrollment":2252,"conditions":7110,"interventions":7111},[93],[3895],[6058,6087,6088],{"intervention":7113,"totalTrials":149,"cells":7114},"Riboflavin 400mg daily",{"EARLY_PHASE1":7115,"PHASE1":7117,"PHASE2":7119,"PHASE3":7121,"PHASE4":7123,"NA":7125},{"trials":7116,"activeCount":109},[],{"trials":7118,"activeCount":109},[],{"trials":7120,"activeCount":109},[],{"trials":7122,"activeCount":109},[],{"trials":7124,"activeCount":109},[],{"trials":7126,"activeCount":109},[7127],{"nctId":7128,"briefTitle":7129,"status":118,"phases":7130,"primaryCompletion":2053,"completion":2053,"start":7131,"enrollment":7132,"conditions":7133,"interventions":7135},"NCT02235337","The Impact of Riboflavin on the Severity and Duration of Sports Related Concussion",[93],"2014-09",248,[7134],"Sports Related Concussion",[7113],{"intervention":7137,"totalTrials":149,"cells":7138},"Nicotine patch",{"EARLY_PHASE1":7139,"PHASE1":7141,"PHASE2":7143,"PHASE3":7145,"PHASE4":7147,"NA":7149},{"trials":7140,"activeCount":109},[],{"trials":7142,"activeCount":109},[],{"trials":7144,"activeCount":109},[],{"trials":7146,"activeCount":109},[],{"trials":7148,"activeCount":109},[],{"trials":7150,"activeCount":109},[7151],{"nctId":7152,"briefTitle":7153,"status":118,"phases":7154,"primaryCompletion":7155,"completion":7156,"start":7157,"enrollment":624,"conditions":7158,"interventions":7159},"NCT05649241","QuitAid Pilot Feasibility Trial",[93],"2022-06-27","2022-10-19","2021-08-31",[2290],[7137,7160],"Nicotine gum",{"intervention":7160,"totalTrials":149,"cells":7162},{"EARLY_PHASE1":7163,"PHASE1":7165,"PHASE2":7167,"PHASE3":7169,"PHASE4":7171,"NA":7173},{"trials":7164,"activeCount":109},[],{"trials":7166,"activeCount":109},[],{"trials":7168,"activeCount":109},[],{"trials":7170,"activeCount":109},[],{"trials":7172,"activeCount":109},[],{"trials":7174,"activeCount":109},[7175],{"nctId":7152,"briefTitle":7153,"status":118,"phases":7176,"primaryCompletion":7155,"completion":7156,"start":7157,"enrollment":624,"conditions":7177,"interventions":7178},[93],[2290],[7137,7160],{"intervention":7180,"totalTrials":149,"cells":7181},"General anesthetic",{"EARLY_PHASE1":7182,"PHASE1":7184,"PHASE2":7186,"PHASE3":7188,"PHASE4":7190,"NA":7192},{"trials":7183,"activeCount":109},[],{"trials":7185,"activeCount":109},[],{"trials":7187,"activeCount":109},[],{"trials":7189,"activeCount":109},[],{"trials":7191,"activeCount":109},[],{"trials":7193,"activeCount":109},[7194],{"nctId":7195,"briefTitle":7196,"status":118,"phases":7197,"primaryCompletion":7198,"completion":7198,"start":7199,"enrollment":7200,"conditions":7201,"interventions":7205},"NCT05917691","Impact of Functional Status on 30-day Resource Utilization and Organ System Complications Following Bariatric Surgery",[],"2019-12-31","2015-01-01",65627,[7202,7203,7204],"Dependence","Perioperative\u002FPostoperative Complications","Frailty",[7180],{"intervention":6055,"totalTrials":149,"cells":7207},{"EARLY_PHASE1":7208,"PHASE1":7210,"PHASE2":7212,"PHASE3":7214,"PHASE4":7216,"NA":7218},{"trials":7209,"activeCount":109},[],{"trials":7211,"activeCount":109},[],{"trials":7213,"activeCount":109},[],{"trials":7215,"activeCount":109},[],{"trials":7217,"activeCount":109},[],{"trials":7219,"activeCount":109},[7220],{"nctId":6046,"briefTitle":6047,"status":169,"phases":7221,"primaryCompletion":6049,"completion":6050,"start":6037,"enrollment":299,"conditions":7222,"interventions":7223},[93],[6052,6053],[6018,6055,6056],{"intervention":6056,"totalTrials":149,"cells":7225},{"EARLY_PHASE1":7226,"PHASE1":7228,"PHASE2":7230,"PHASE3":7232,"PHASE4":7234,"NA":7236},{"trials":7227,"activeCount":109},[],{"trials":7229,"activeCount":109},[],{"trials":7231,"activeCount":109},[],{"trials":7233,"activeCount":109},[],{"trials":7235,"activeCount":109},[],{"trials":7237,"activeCount":109},[7238],{"nctId":6046,"briefTitle":6047,"status":169,"phases":7239,"primaryCompletion":6049,"completion":6050,"start":6037,"enrollment":299,"conditions":7240,"interventions":7241},[93],[6052,6053],[6018,6055,6056],{"intervention":7243,"totalTrials":149,"cells":7244},"letrozole",{"EARLY_PHASE1":7245,"PHASE1":7247,"PHASE2":7249,"PHASE3":7251,"PHASE4":7253,"NA":7255},{"trials":7246,"activeCount":109},[],{"trials":7248,"activeCount":109},[],{"trials":7250,"activeCount":109},[],{"trials":7252,"activeCount":109},[],{"trials":7254,"activeCount":109},[],{"trials":7256,"activeCount":109},[7257],{"nctId":7258,"briefTitle":7259,"status":118,"phases":7260,"completion":2759,"start":7261,"conditions":7262,"interventions":7264},"NCT00114270","Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density",[93],"2004-05",[30,7263],"Osteoporosis",[7243,7265],"zoledronic acid",{"intervention":7265,"totalTrials":149,"cells":7267},{"EARLY_PHASE1":7268,"PHASE1":7270,"PHASE2":7272,"PHASE3":7274,"PHASE4":7276,"NA":7278},{"trials":7269,"activeCount":109},[],{"trials":7271,"activeCount":109},[],{"trials":7273,"activeCount":109},[],{"trials":7275,"activeCount":109},[],{"trials":7277,"activeCount":109},[],{"trials":7279,"activeCount":109},[7280],{"nctId":7258,"briefTitle":7259,"status":118,"phases":7281,"completion":2759,"start":7261,"conditions":7282,"interventions":7283},[93],[30,7263],[7243,7265],{"intervention":7285,"totalTrials":149,"cells":7286},"Progress, Pain",{"EARLY_PHASE1":7287,"PHASE1":7289,"PHASE2":7291,"PHASE3":7293,"PHASE4":7295,"NA":7297},{"trials":7288,"activeCount":109},[],{"trials":7290,"activeCount":109},[],{"trials":7292,"activeCount":109},[],{"trials":7294,"activeCount":109},[],{"trials":7296,"activeCount":109},[],{"trials":7298,"activeCount":109},[7299],{"nctId":7300,"briefTitle":7301,"status":169,"phases":7302,"primaryCompletion":2552,"completion":7303,"start":6049,"enrollment":7304,"conditions":7305,"interventions":7307},"NCT02178878","Genetic and Demographic Factors That Influence the Pain and Progress of Labor",[],"2016-12",800,[7306],"Rapid Progress of Labor",[7285],{"intervention":7309,"totalTrials":149,"cells":7310},"perflutren lipid microspheres",{"EARLY_PHASE1":7311,"PHASE1":7313,"PHASE2":7315,"PHASE3":7317,"PHASE4":7319,"NA":7321},{"trials":7312,"activeCount":109},[],{"trials":7314,"activeCount":109},[],{"trials":7316,"activeCount":109},[],{"trials":7318,"activeCount":109},[],{"trials":7320,"activeCount":109},[],{"trials":7322,"activeCount":109},[7323],{"nctId":7324,"briefTitle":7325,"status":169,"phases":7326,"completion":6203,"start":2856,"enrollment":439,"conditions":7327,"interventions":7329},"NCT00631553","Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound",[93],[7328],"Kidney",[7309]]